

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
25 March 2004 (25.03.2004)

PCT

(10) International Publication Number  
**WO 2004/024761 A1**

(51) International Patent Classification<sup>7</sup>: C07K 14/505,  
17/10, C08B 31/00, C07K 17/06, C12N 15/12, A61K  
38/18, C07K 14/55, 14/54, 14/56, 14/565, 14/53

38527 Meine (DE). FRANK, Ronald [DE/DE]; Heeg-  
blick 1, 38527 Meine-Grassel (DE). EICHNER, Wolfram  
[DE/DE]; An der Landwehr 30, 35510 Butzbach (DE).

(21) International Application Number:  
PCT/EP2003/008858

(74) Agent: WICHMANN, Hendrik; Isenbruck Bösl  
Hörschler Wichmann Huhn, Postfach 860880, 81635  
München (DE).

(22) International Filing Date: 8 August 2003 (08.08.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
02020425.1 11 September 2002 (11.09.2002) EP  
60/409,781 11 September 2002 (11.09.2002) US

(71) Applicant (for all designated States except US): FRESE-  
NIUS KABI DEUTSCHLAND GMBH [DE/DE]; Kabi  
Strategic Business Center, 61346 Bad Homburg v.d.H.  
(DE).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,  
SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,  
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,  
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (for US only): CONRADT, Har-  
ald, S. [DE/DE]; Museumstr. 6, 38100 Braunschweig  
(DE). GRABENHORST, Eckart [DE/DE]; Pappel-  
berg 57, 38104 Braunschweig (DE). NIMITZ, Manfred  
[DE/DE]; Heimstättenweg 29a, 38300 Wolfenbüttel (DE).  
ZANDER, Norbert [DE/DE]; Zellbergshaideweg 45,

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

WO 2004/024761 A1

(54) Title: HASYLATED POLYPEPTIDES, ESPECIALLY HASYLATED ERYTHROPOIETIN

(57) Abstract: The present invention relates to hydroxyalkylstarch (HAS)-polypeptide-conjugate (HAS-polypeptide) comprising one or more HAS molecules, wherein each HAS is conjugated to the polypeptide via a carbohydrate moiety or a thioether as well as to methods for the production thereof. In a preferred embodiment, the polypeptide is erythropoietin (EPO).

F38171PC

**HASylated polypeptides, especially HASylated erythropoietin**

- 5 The present invention relates to polypeptides, especially erythropoietin conjugated to hydroxyalkylstarch (HAS), especially to hydroxyethylstarch.

The application of polypeptides, especially enzymes or cytokines, to the circulatory system in order to obtain a particular physiological effect is a well-known  
10 tool in modern medicine.

Erythropoietin (EPO) is a glycoprotein hormone necessary for the maturation of erythroid progenitor cells into erythrocytes. In human adults, it is produced in the kidney. EPO is essential in regulating the level of red blood cells in the circulation. Conditions marked by low levels of tissue oxygen provoke an increased biosynthesis of EPO, which in turn stimulates erythropoiesis. A loss of kidney function as it is seen in chronic renal failure, for example, typically results in decreased biosynthesis of EPO and a concomitant reduction in red blood cells.  
15

- 20 Erythropoietin is an acid glycoprotein hormone of approximately 34,000 Da. Human erythropoietin is a 166 amino acid polypeptide that exists naturally as a monomer (Lin et al., 1985, PNAS 82, 7580-7584, EP 148 605 B2, EP 411 678 B2). The identification, cloning and expression of genes encoding erythropoietin are described, e.g., in U.S. Patent 4,703,008. The purification of recombinant  
25 erythropoietin from cell culture medium that supported the growth of mammalian cells containing recombinant erythropoietin plasmids, for example, is described in U.S. Patent 4,667,016.

- 2 -

It is generally believed in this technical field that the biological activity of EPO in vivo mainly depends on the degree of sialic acids bound to EPO (see e.g. EP 428 267 B1). Theoretically, 14 molecules of sialic acid can be bound to one molecule EPO at the terminal ends of the carbohydrate side chains linked to N- and O-glycosylation sites. Highly sophisticated purification steps are necessary to obtain highly sialylated EPO preparations.

For further detailed information on erythropoietin see Krantz, Erythropoietin, 1991, Blood, 77(3):419-34 (Review) and Cerami, Beyond erythropoiesis: novel applications for recombinant human erythropoietin, 2001, Semin Hematol., (3 Suppl 7):33-9 (Review).

A well-known problem with the application of polypeptides and enzymes is that these proteins often exhibit an unsatisfactory stability. Especially, erythropoietin has a relatively short plasma half live (Spivak and Hogans, 1989, Blood 73, 90; McMahon et al., 1990, Blood 76, 1718). This means that therapeutic plasma levels are rapidly lost and repeated intravenous administrations must be carried out. Furthermore, in certain circumstances an immune response against the peptides is observed.

It is generally accepted that the stability of polypeptides can be improved and the immune response against these polypeptides is reduced when the polypeptides are coupled to polymeric molecules. WO 94/28024 discloses that physiologically active polypeptides modified with polyethyleneglycol (PEG) exhibit reduced immunogenicity and antigenicity and circulate in the bloodstream considerably longer than unconjugated proteins, i.e. have a longer clearance rate.

However, PEG-drug conjugates exhibit several disadvantages, e.g. they do not exhibit a natural structure which can be recognized by elements of in vivo degradation pathways. Therefore, apart from PEG-conjugates, other conjugates and protein polymerates have been produced. A plurality of methods for the cross-

- 3 -

linking of different proteins and macromolecules such as polymerase have been described in the literature (see e.g. Wong, Chemistry of protein conjugation and cross-linking, 1993, CRCs, Inc.).

5 Hydroxyethylstarch (HES) is a derivative of naturally occurring amylopectine and is degraded by  $\alpha$ -Amylase in the body. The preparation of HES-protein-conjugates is described in the state of the art (see, e.g., HES-hemoglobin-conjugates in DE 26 16 086 or DE 26 46 854).

10 DE 26 46 854 discloses methods for the conjugation of hemoglobin to HES. In these methods, HES is reacted with sodiumperiodate, which results in the production of dialdehydes which are linked to hemoglobin. In contrast to this, DE 26 16 086 discloses the conjugation of hemoglobin to HES according to a procedure wherein first a cross-linking agent (e.g. bromocyanide) is bound to HES and subse-  
15 quently hemoglobin is linked to the intermediate product.

HES is a substituted derivative of the carbohydrate polymer amylopectine, which is present in corn starch at a concentration of up to 95 % per weight. HES exhibits advantageous biological properties and is used as a blood volume replacement  
20 agent and in hemodilution therapy in the clinics (Sommermeyer et al., 1987, Krankenhauspharmazie, 8(8), 271-278; and Weidler et al., 1991, Arzneimittel-Forschung/Drug Res., 41, 494-498).

Amylopectine consists of glucose moieties, wherein in the main chain  $\alpha$ -1,4-glycosidic bonds are present and at the branching sites  $\alpha$ -1,6-glycosidic bonds are  
25 found. The physical-chemical properties of this molecule are mainly determined by the type of glycosidic bonds. Due to the nicked  $\alpha$ -1,4-glycosidic bond, helical structures with about six glucose-monomers per turn are produced.

30 The physical-chemical as well as the biochemical properties of the polymer can be modified via substitution. The introduction of a hydroxyethyl group can be

- 4 -

achieved via alkaline hydroxyethylation. By adapting the reaction conditions it is possible to exploit the different reactivity of the respective hydroxy group in the unsubstituted glucose monomer with respect to a hydroxyethylation. Owing to this fact, the skilled person is able to influence the substitution pattern to a limited extent.

Consequently, HES is mainly characterized by the molecular weight distribution and the degree of substitution. There are two possibilities of describing the substitution degree:

10

1. The substitution degree can be described relative to the portion of substituted glucose monomers with respect to all glucose moieties (DS).
2. The substitution degree can be described as the "molar substitution" (MS), wherein the number of hydroxyethyl groups per glucose moiety are described.

15

HES solutions are present as polydisperse compositions, wherein each molecule differs from the other with respect to the polymerisation degree, the number and pattern of branching sites and the substitution pattern. HES is therefore a mixture of compounds with different molecular weight. Consequently, a particular HES solution is determined by average molecular weight with the help of statistical means. In this context,  $M_n$  is calculated as the arithmetic mean depending on the number of molecules. Alternatively,  $M_w$ , the weight mean, represents a unit which depends on the mass of the HES.

20

25

The HES-drug conjugates disclosed in the art suffer from the disadvantage that HES is not conjugated site-specifically to the drug. Consequently, the conjugation results in a very heterogenous product having many components that may be inactive due to the destruction of the 3-dimensional structure during the conjugation step.

30

- 5 -

In summary, there is still a need for further improved polypeptides with improved stability and/or bioactivity. This applies especially to erythropoietin where isoforms with a high degree of sialic acids and therefore high activity have to be purified from isoforms with a low degree of sialic acids (see EP 428 267 B1). Therefore, it would be highly advantageous if production methods were available which provide highly active polypeptides without requiring extensive purification. Unfortunately, the production of polypeptides in bacteria or insect cells is often difficult, because the polypeptides are often not produced in a properly folded, native confirmation and lack proper glycosylation.

Consequently, it is an object of the present invention to provide polypeptide derivatives, especially erythropoietin derivatives, having a high biological activity in vivo which can be easily produced and at reduced costs. Furthermore, it is a further object of the present invention to provide a method for the production of polypeptide derivatives which is easy to perform and yields in products with high biological activity. It is a further object of the invention to provide pharmaceutical compositions comprising polypeptide derivatives with high biological activity.

According to one aspect of the present invention, the problem is solved by a hydroxyalkylstarch (HAS)-erythropoietin (EPO)-conjugate (HAS-EPO) comprising one or more HAS molecules, wherein each HAS is conjugated to the EPO via

- a) a carbohydrate moiety; or
- b) a thioether.

The HAS-EPO of the invention has the advantage that it exhibits an improved biological stability when compared to the erythropoietin before conjugation. Furthermore, it exhibits a higher biological activity than standard BRP EPO. This is mainly due to the fact that HAS-EPO is less or even not recognized by the removal systems of the liver and kidney and therefore persists in the circulatory

- 6 -

system for a longer period of time. Furthermore, since the HAS is attached site-specifically, the risk of destroying the *in vivo* biological activity of EPO by conjugation of HAS to EPO is minimized.

- 5 The HAS-EPO of the invention has mainly two components, namely the erythropoietin (EPO)-polypeptide and the hydroxyalkylstarch (HAS) linked thereto.

The EPO can be of any human (see e.g. Inoue, Wada, Takeuchi, 1994, An improved method for the purification of human erythropoietin with high *in vivo* activity from the urine of anemic patients, *Biol Pharm Bull.* 17(2), 180-4; Miyake, Kung, Goldwasser, 1977, Purification of human erythropoietin., *J Biol Chem.*, 252(15), 5558-64) or another mammalian source and can be obtained by purification from naturally occurring sources like human kidney, embryonic human liver or animal, preferably monkey kidney. Furthermore, the expression "erythropoietin" or "EPO" encompasses also an EPO variant wherein one or more amino acids (e.g. 1 to 25, preferably 1 to 10, more preferred 1 to 5, most preferred 1 or 2) have been exchanged by another amino acid and which exhibits erythropoietic activity (see e.g. EP 640 619 B1). The measurement of erythropoietic activity is described in the art (for measurement of activity *in vitro* see e.g. Fibi et al., 1991, *Blood*, 77, 1203 ff; Kitamura et al, 1989, *J. Cell Phys.*, 140, 323-334; for measurement of EPO activity *in vivo* see Ph. Eur. 2001, 911-917; Ph. Eur. 2000, 1316 Erythropoietini solutio concentrata, 780- 785; European Pharmacopoeia (1996/2000); European Pharmacopoeia, 1996, Erythropoietin concentrated solution, *Pharmaeuropa.*, 8, 371-377; Fibi, Hermentin, Pauly, Lauffer, Zettlmeissl., 1995, N- and O-glycosylation muteins of recombinant human erythropoietin secreted from BHK-21 cells, *Blood*, 85(5), 1229-36; (EPO and modified EPO forms were injected into female NMRI mice (equal amounts of protein 50 ng/mouse) at day 1, 2 and 3 blood samples were taken at day 4 and reticulocytes were determined)). Further publications where tests for the measurement of the activity of EPO are Barbone, Aparicio, Anderson, Natarajan, Ritchie, 1994, Reticulocytes measurements as a bioassay for erythropoietin, *J. Pharm. Biomed. Anal.*, 12(4),

- 7 -

- 515-22; Bowen, Culligan, Beguin, Kendall, Villis, 1994, Estimation of effective and total erythropoiesis in myelodysplasia using serum transferrin receptor and erythropoietin concentrations, with automated reticulocyte parameters, *Leukemi*, 8(1), 151-5; Delorme, Lorenzini, Giffin, Martin, Jacobsen, Boone, Elliott, 1992, 5 Role of glycosylation on the secretion and biological activity of erythropoietin, *Biochemistry*, 31(41), 9871-6; Higuchi, Oh-eda, Kuboniwa, Tomonoh, Shimomaka, Ochi, 1992; Role of sugar chains in the expression of the biological activity of human erythropoietin, *J. Biol. Chem.*, 267(11), 7703-9; Yamaguchi, Akai, Kawanishi, Ueda, Masuda, Sasaki, 1991, Effects of site-directed removal of N- 10 glycosylation sites in human erythropoietin on its production and biological properties, *J. Biol. Chem.*, 266(30), 20434-9; Takeuchi, Inoue, Strickland, Kubota, Wada, Shimizu, Hoshi, Kozutsumi, Takasaki, Kobata, 1989, Relationship between sugar chain structure and biological activity of recombinant human erythropoietin produced in Chinese hamster ovary cells, *Proc. Natl. Acad. Sci. USA*, 85(20), 7819-22; Kurtz, Eckardt, 1989, Assay methods for erythropoietin, 15 *Nephron*, 51(1), 11-4 (German); Zucali, Sulkowski, 1985, Purification of human urinary erythropoietin on controlled-pore glass and silicic acid, *Exp. Hematol.*, 13(3), 833-7; Krystal, 1983, Physical and biological characterization of erythroblast enhancing factor (EEF), a late acting erythropoietic stimulator in serum distinct from erythropoietin, *Exp. Hematol.*, 11(1), 18-31. 20

Preferably, the EPO is recombinantly produced. This includes the production in eukaryotic or prokaryotic cells, preferably mammalian, insect, yeast, bacterial cells or in any other cell type which is convenient for the recombinant production 25 of EPO. Furthermore, the EPO may be expressed in transgenic animals (e.g. in body fluids like milk, blood, etc.), in eggs of transgenic birds, especially poultry, preferred chicken, or in transgenic plants.

The recombinant production of a polypeptide is known in the art. In general, this 30 includes the transfection of host cells with an appropriate expression vector, the cultivation of the host cells under conditions which enable the production of the



- 8 -

polypeptide and the purification of the polypeptide from the host cells. For detailed information see e.g. Krystal, Pankratz, Farber, Smart, 1986, Purification of human erythropoietin to homogeneity by a rapid five-step procedure, *Blood*, 67(1), 71-9; Quelle, Caslake, Burkert, Wojchowski, 1989, High-level expression and purification of a recombinant human erythropoietin produced using a baculovirus vector, *Blood*, 74(2), 652-7; EP 640 619 B1 and EP 668 351 B1.

In a preferred embodiment, the EPO has the amino acid sequence of human EPO (see EP 148 605 B2).

10

The EPO may comprise one or more carbohydrate side chains (preferably 1-4, preferably 4) attached to the EPO via N- and/ or O-linked glycosylation, i.e. the EPO is glycosylated. Usually, when EPO is produced in eukaryotic cells, the polypeptide is posttranslationally glycosylated. Consequently, the carbohydrate side chains may have been attached to the EPO during biosynthesis in mammalian, especially human, insect or yeast cells. The structure and properties of glycosylated EPO have been extensively studied in the art (see EP 428 267 B1; EP 640 619 B1; Rush, Derby, Smith, Merry, Rogers, Rohde, Katta, 1995, Microheterogeneity of erythropoietin carbohydrate structure, *Anal Chem.*, 67(8), 1442-52; Takeuchi, Kobata, 1991, Structures and functional roles of the sugar chains of human erythropoietins, *Glycobiology*, 1(4), 337-46 (Review).

15  
20

The HAS may be directly conjugated to the EPO or, alternatively, via a linker molecule. The nature of the linker molecule depends on the way how the HAS is linked to the EPO. Possible functional groups of linkers are described in Table 1 and below. Several linkers are commercially available (e.g. from Pierce, available from Perbio Science Deutschland GmbH, Bonn, Germany)). Some suitable linkers are described in Table 2. The nature of the linker and its purpose are described in detail below in the section concerning the method for the production of HES-EPO.

25  
30

- 9 -

According to a preferred embodiment of the HAS-EPO conjugate of the invention, the HAS is conjugated to the EPO via a carbohydrate moiety.

In the context of the present invention, the term "carbohydrate moiety" refers to hydroxyaldehydes or hydroxyketones as well as to chemical modifications thereof (see Römpp Chemielexikon, Thieme Verlag Stuttgart, Germany, 9<sup>th</sup> edition 1990, Volume 9, pages 2281-2285 and the literature cited therein). Furthermore, it also refers to derivatives of naturally occurring carbohydrate moieties like glucose, galactose, mannose, sialic acid and the like. The term also includes chemically oxidized naturally occurring carbohydrate moieties wherein the ring structure has been opened.

The carbohydrate moiety may be linked directly to the EPO polypeptide backbone. Preferably, the carbohydrate moiety is part of a carbohydrate side chain. In this case, further carbohydrate moieties may be present between the carbohydrate moiety to which HAS is linked and the EPO polypeptide backbone. More preferably, the carbohydrate moiety is the terminal moiety of the carbohydrate side chain.

In a more preferred embodiment, the HAS is conjugated to a galactose residue of the carbohydrate side chains, preferably the terminal galactose residue of the carbohydrate side chain. This galactose residue can be made available for conjugation by removal of terminal sialic acids, followed by oxidation (see below).

In a further more preferred embodiment, the HAS is conjugated to a sialic acid residue of the carbohydrate side chains, preferably the terminal sialic acid residue of the carbohydrate side chain.

Furthermore, the HAS may be conjugated to the EPO via a thioether. As explained in detail below, the S atom can be derived from any SH group attached to the EPO, both naturally or non naturally occurring.

- 10 -

In a preferred embodiment, the S atom may be derived from a SH group which has been introduced in an oxidized carbohydrate moiety of HES, preferably an oxidized carbohydrate moiety which is part of a carbohydrate side chain of EPO (see below).

5

Preferably, the S atom in the thioether is derived from a naturally-occurring cysteine or from an added cysteine. More preferably, the EPO has the amino acid sequence of human EPO and the naturally occurring cysteines are cysteine 29 and/or 33. In a more preferred embodiment, HAS is conjugated to cysteine 29 and  
10 cysteine 33 is replaced by another amino acid. Alternatively, HAS may be conjugated to cysteine 33 and cysteine 29 is replaced by another amino acid.

In the context of the present invention, by the term "added cysteines" it is meant that the polypeptides, preferably EPO, comprise a cysteine residue which is not  
15 present in the wild-type polypeptide.

In the context of this aspect of the invention, the cysteine may be an additional amino acid added at the N- or C-terminal end of EPO.

20 Furthermore, the added cysteine may have been added by replacing a naturally occurring amino acid by a cysteine. Suitable methods are known in the art (see above). Preferably, in the context of this aspect of the invention, the EPO is human EPO and the replaced amino acid residue is serine 126.

25 The second component of the HAS-EPO is hydroxyalkylstarch (HAS).

In the context of the present invention, the term "hydroxyalkylstarch" is used to indicate starch derivatives which have been substituted by hydroxyalkylgroups. In this context, the alkyl group may be substituted. Preferably, the hydroxyalkyl contains 2-10 carbon atoms, more preferably 2-4 carbon atoms. "Hydroxyalkylstarch"  
30 therefore preferably comprises hydroxyethylstarch, hydroxypropylstarch and hy-

- 11 -

droxybutylstarch, wherein hydroxyethylstarch and hydroxypropylstarch are preferred.

The hydroxyalkylgroup(s) of HAS contain at least one OH-group.

5

The expression "hydroxyalkylstarch" also includes derivatives wherein the alkyl group is mono- or polysubstituted. In this context, it is preferred that the alkyl group is substituted with an halogen, especially flourine, or with an aryl group, provided that the HAS remains water soluble. Furthermore, the terminal hydroxy  
10 group of hydroxyalkyl may be esterified or etherified. In addition, the alkyl group of the hydroxyalkylstarch may be linear or branched.

Furthermore, instead of alkyl, also linear or branched substituted or unsubstituted alkene groups may be used.

15

Hydroxyethylstarch (HES) is most preferred for all embodiments of the present invention.

In the context of the present invention, hydroxyethylstarch may have a mean molecular weight (weight mean) of 1-300 kDa, wherein a mean molecular weight of  
20 5-100 kDa is more preferred. Hydroxyethylstarch can further exhibit a molar degree of substitution of 0.1 to 0.8 and a ratio between C<sub>2</sub>:C<sub>6</sub>-substitution in the range of 2-20, with respect to the hydroxyethylgroups.

25 The HAS-EPO may comprise 1-12, preferably 1-9, 1-6 or 1-3, most preferred 1-4 HAS molecules per EPO molecule. The number of HAS-molecules per EPO molecule can be determined by quanatitative carbohydrate compositional analysis using GC-MS after hydrolysis of the product and derivatisation of the resulting monosaccharides (see Chaplin and Kennedy (eds.), 1986, Carbohydrate Analysis:  
30 a practical approach, IRL Press Practical approach series (ISBN 0-947946-44-3),

- 12 -

especially Chapter 1, Monosaccharides, page 1-36; Chapter 2, Oligosaccharides, page 37-53, Chapter 3, Neutral Polysaccharides, page 55-96).

5 The HAS-EPO conjugate of the invention may exhibit essentially the same in-vitro biological activity as recombinant native EPO, since the in-vitro biological activity only measures binding affinity to the EPO receptor. Methods for determining the in-vitro biological activity are known in the art (see above).

10 Furthermore, the HAS-EPO exhibits a greater in vivo activity than the EPO used as a starting material for conjugation (unconjugated EPO). Methods for determining the in vivo biological activity are known in the art (see above). Furthermore, assays for the determination of in vivo and in vitro EPO activity are given in Examples 9 and 10.

15 The HAS-EPO conjugate may exhibit an in vivo activity of 110 to 500 %, preferably 300 to 400 %, or 110 % to 300 %, preferably 110 % to 200 %, more preferred 110 % to 180 % or 110 to 150 %, most preferred 110 % to 140 %, if the in vivo activity of the unconjugated EPO is set as 100 %.

20 Compared to the highly sialylated EPO of Amgen (see EP 428 267 B1), the HAS-EPO exhibits preferably at least 50%, more preferred at least 70 %, even more preferred at least 85 % or at least 95 %, at least 150 %, at least 200 % or at least 300 % of the in vivo activity of the highly sialylated EPO, if the in vivo activity of highly sialylated EPO is set as 100 %. Most preferred, it exhibits at least 95 % of  
25 the in vivo activity of the highly sialylated EPO.

The high in vivo biological activity of the HAS-EPO conjugate of the invention mainly results from the fact that the HAS-EPO conjugate remains longer in the circulation than the unconjugated EPO, because it is less recognized by the removal systems of the liver and because renal clearance is reduced due to the  
30 higher molecular weight. Methods for the determination of the in vivo half life

- 13 -

time of EPO in the circulation are known in the art (Sytkowski, Lunn, Davis, Feldman, Siekman, 1998, Human erythropoietin dimers with markedly enhanced in vivo activity, Proc. Natl. Acad. Sci. USA, 95(3), 1184-8).

5     Consequently, it is a great advantage of the present invention that a HAS-EPO is provided that may be administered less frequently than the EPO preparations commercially available at present. While standard EPO preparations have to be administered at least all 3 days, the HAS-EPO conjugate of the invention is preferable administered twice a week, more preferably once a week.

10     All embodiments disclosed below with respect of the method of the invention to produce a HAS-EPO concerning properties of EPO or HAS apply also to the HAS-EPO conjugate of the invention.

15     Hydroxyalkylstarch is an ether derivative of starch. Besides of said ether derivatives, also other starch derivatives can be used in the context of the present invention. For example, derivatives are useful which comprise esterified hydroxy groups. These derivatives may be e.g. derivatives of unsubstituted mono- or dicarboxylic acids with 2-12 carbon atoms or of substituted derivatives thereof. Especially useful are derivatives of unsubstituted monocarboxylic acids with 2-6  
20     carbon atoms, especially of acetic acid. In this context, acetylstarch, butylstarch or propylstarch are preferred.

25     Furthermore, derivatives of unsubstituted dicarboxylic acids with 2-6 carbon atoms are preferred.

30     In the case of derivatives of dicarboxylic acids, it is useful that the second carboxy group of the dicarboxylic acid is also esterified. Furthermore, derivatives of monoalkyl esters of dicarboxylic acids are also suitable in the context of the present invention.

- 14 -

For the substituted mono- or dicarboxylic acids, the substitute groups may be preferably the same as mentioned above for substituted alkyl residues.

Techniques for the esterification of starch are known in the art (see e.g. Klemm D. et al, Comprehensive Cellulose Chemistry Vol. 2, 1998, Wiley-VCH, Weinheim, New York, especially chapter 4.4, Esterification of Cellulose (ISBN 3-527-29489-9)).

In a further aspect, the present invention relates to a method for the production of a hydroxyalkylstarch (HAS)-erythropoietin (EPO)-conjugate (HAS-EPO), comprising the steps of:

- a) providing EPO being capable of reacting with modified HAS,
- b) providing modified HAS being capable of reacting with the EPO of step a), and
- c) reacting the EPO of step a) with the HAS of step b), whereby an HAS-EPO is produced comprising one or more HAS molecules, wherein each HAS is conjugated to the EPO via
  - i) a carbohydrate moiety; or
  - ii) a thioether.

The method of the invention has the advantage that a HAS-EPO conjugate is produced which exhibits a high biological activity. Furthermore, the method of the invention has the advantage that an effective EPO derivative can be produced at reduced costs since the method does not comprise extensive and time consuming purification steps resulting in low final yield, e.g. it is not necessary to purify away undersialylated EPO forms which are known to exhibit low or no in-vivo biological activity. Especially Example 20 demonstrates that a HES-EPO produced with few modifications steps exhibits a 3-fold activity over standard BRP EPO.

- 15 -

Accordingly, in the first step of the method of the invention, an EPO is provided which is capable of reacting with modified HAS.

As used in the present invention, the term "providing" has to be interpreted in the way that after the respective step a molecule (in step a) EPO, in step b) HAS) with the desired properties is available.

In the case of step a), this includes the purification of EPO from natural sources as well as the recombinant production in host cells or organisms, and, if necessary, the modification of the EPO so obtained.

With respect to the EPO being the starting material of the present invention, the same applies as for the erythropoietin being part of the HAS-EPO conjugate of the invention. In this context, the preferred embodiments disclosed above apply also for the method of the invention.

Consequently, in a preferred embodiment, the EPO has the amino acid sequence of human EPO.

Preferably, the EPO is recombinantly produced. This includes the production in eukaryotic or prokaryotic cells, preferably mammalian, insect, yeast, bacterial cells or in any other cell type which is convenient for the recombinant production of EPO. Furthermore, the EPO may be expressed in transgenic animals (e.g. in body fluids like milk, blood, etc.), in eggs of transgenic birds, especially poultry, preferred chicken, or in transgenic plants.

The recombinant production of a polypeptide is known in the art. In general, this includes the transfection of host cells with an appropriate expression vector, the cultivation of the host cells under conditions which enable the production of the polypeptide and the purification of the polypeptide from the host cells (Krystal, Pankratz, Farber, Smart, 1986, Purification of human erythropoietin to homogene-



- 16 -

ity by a rapid five-step procedure, Blood, 67(1), 71-9; Quelle, Caslake, Burkert, Wojchowski, 1989, High-level expression and purification of a recombinant human erythropoietin produced using a baculovirus vector, Blood, 74(2), 652-7; EP 640 619 B1 and EP 668 351 B1).

5

The EPO may comprise one or more carbohydrate side chains attached to the EPO via N- and/ or O-linked glycosylation, i.e. the EPO is glycosylated. Unusually, when EPO is produced in eukaryotic cells, the polypeptide is posttranslationally glycosylated. Consequently, the carbohydrate side chains may have been attached  
10 to the EPO during production in mammalian, especially human, insect or yeast cells, which may be cells of a transgenic animal (see above), either extracted from the animal or still in the animal.

These carbohydrate side chains may have been chemically or enzymatically modified after the expression in the appropriate cells, e.g. by removing or adding one  
15 or more carbohydrate moieties (see e.g. Dittmar, Conradt, Hauser, Hofer, Lindmaier, 1989, Advances in Protein design; Bloecker, Collins, Schmidt, and Schomburg eds., GBF-Monographs, 12, 231-246, VCH Publishers, Weinheim, New York, Cambridge)

20

It is the object of the method of the invention to provide an HAS-EPO comprising one or more HAS molecules where the HAS is conjugated to the EPO via a carbohydrate moiety (i) or via a thioether (ii). Consequently, the EPO provided in step a) should have the properties that a conjugation via a carbohydrate moiety  
25 and/ or via a thioether is possible. Therefore the EPO after step a) may preferably contain either

(1) at least one reactive group linked, either directly or via a linker molecule, to sulfide groups or carbohydrate moieties, which is capable to react with HES or  
30 modified HES,

- 17 -

(2) at least one carbohydrate moiety to which modified HAS can be conjugated, and/or

(3) at least one free SH-group.

5 With respect to possibility (1) above, the EPO of step a) is preferably obtainable by conjugating an appropriate linker molecule to the SH-group(s) or carbohydrate moieties of EPO. An example for such a modified EPO is provided in Example 4, 2.1. It is important to ensure that the addition of the linker molecule does not damage the EPO. However, this is known to the person skilled in the art.

10

With respect to possibility (2) above, in a preferred embodiment, the modified HAS is conjugated to the EPO via a carbohydrate moiety.

15

The carbohydrate moiety may be linked directly to the EPO polypeptide backbone. Preferably, the carbohydrate moiety is part of a carbohydrate side chain. In this case, further carbohydrate moieties may be present between the carbohydrate moiety to which HAS is linked and the EPO polypeptide backbone. More preferably, the carbohydrate moiety is the terminal moiety of the carbohydrate side chain.

20 Consequently, in a preferred embodiment, the modified HAS is attached (via a linker or not, see below) to carbohydrate chains linked to N- and/ or O-glycosylation sites of EPO.

25 However, it is also included within the present invention that the EPO contains (a) further carbohydrate moiety(ies) to which the modified HAS is conjugated. Techniques for attaching carbohydrate moieties to polypeptides, either enzymatically or by genetic engineering, followed by expression in appropriate cells, are known in the art (Berger, Greber, Mosbach, 1986, Galactosyltransferase-dependent sialylation of complex and endo-N-acetylglucosaminidase H-treated core N-glycans in  
30 vitro, FEBS Lett., 203(1), 64-8; Dittmar, Conradt, Hauser, Hofer, Lindenmaier, 1989, Advances in Protein design; Bloecker, Collins, Schmidt, and Schomburg

eds., GBF-Monographs, 12, 231-246, VCH Publishers, Weinheim, New York, Cambridge).

5 In a preferred embodiment of the method of the invention, the carbohydrate moiety is oxidized in order to be able to react with the modified HAS. This oxidation can be performed either chemically or enzymatically.

Methods for the chemical oxidation of carbohydrate moieties of polypeptides are known in the art and include the treatment with periodate (Chamow et al., 1992, J. Biol. Chem., 267, 15916-15922).

10 By chemically oxidizing, it is principally possible to oxidize any carbohydrate moiety, being terminally positioned or not. However, by choosing mild conditions (1 mM periodate, 0 °C in contrast to harsh conditions: 10 mM periodate 1h at room temperature), it is possible to preferably oxidize the terminal carbohydrate moiety, e.g. sialic acid or galactose, of a carbohydrate side chain.

Alternatively, the carbohydrate moiety may be oxidized enzymatically. Enzymes for the oxidation of the individual carbohydrate moieties are known in the art, e.g. in the case of galactose the enzyme is galactose oxidase.

20 If it is intended to oxidize terminal galactose moieties, it will be eventually necessary to remove terminal sialic acids (partially or completely) if the EPO has been produced in cells capable of attaching sialic acids to carbohydrate chains, e.g. in mammalian cells or in cells which have been genetically modified to be capable of attaching sialic acids to carbohydrate chains. Chemical or enzymatic methods for the removal of sialic acids are known in the art (Chaplin and Kennedy (eds.), 1996, Carbohydrate Analysis: a practical approach, especially Chapter 5 Montreuil, Glycoproteins, pages 175-177; IRL Press Practical approach series (ISBN 0-947946-44-3)).

- 19 -

However, it is also included within the present invention that the carbohydrate moiety to which the modified HAS is to be attached is attached to the EPO within step a). In the case it is desired to attach galactose, this can be achieved by the means of galactosyltransferase. The methods are known in the art (Berger, Greber,  
5 Mosbach, 1986, Galactosyltransferase-dependent sialylation of complex and endo-N-acetylglucosaminidase H-treated core N-glycans in vitro, FEBS Lett., 203(1), 64-8).

In a most preferred embodiment, in step a) the EPO is modified by oxidizing at  
10 least one terminal saccharide unit, preferably galactose, of the one or more carbohydrate side chains of the EPO, preferably after partial or complete (enzymatic and/or chemical) removal of the terminal sialic acid, if necessary (see above).

Consequently, preferably the modified HAS is conjugated to the oxidized terminal  
15 saccharide unit of the carbohydrate chain, preferably galactose.

Furthermore, the modified HAS may be preferably conjugated to a terminal sialic acid, which is preferably oxidized in step a) of the method of the invention.

20 In a further preferred embodiment (see point (3) above), the EPO comprises at least one free SH-group.

According to a preferred embodiment, this SH group may be linked to a preferably oxidized carbohydrate moiety, e.g. by using a hydroxylamine derivative, e.g.  
25 2-(aminooxy)ethylmercaptan hydrochloride (Bauer L. et al., 1965, J. Org. Chem., 30, 949) or by using a hydrazide derivative, e.g. thioglycolic acid hydrazide (Whitesides et al., 1977, J. Org. Chem., 42, 332.) The methods for conjugating these molecules to the oxidized carbohydrate moiety of EPO may be analogous to those described in Example Protocols 8 and 9.

30

- 20 -

According to a further preferred embodiment, the free SH-group is part of a naturally-occurring cysteine or of an added cysteine.

Mammalian EPO has several cysteines which normally form disulfide bonds.  
5 However, by replacing at least one of the cysteines by another amino acid (e.g. by recombinant means), it is possible to obtain an EPO where at least one of the naturally occurring cysteines comprises a free SH-group. Methods for the replacement of amino acids are known in the art (Elliott, Lorenzini, Chang, Barzilay, Delorme, 1997, Mapping of the active site of recombinant human erythropoietin, Blood,  
10 89(2), 493-502; Boissel, Lee, Presnell, Cohen, Bunn, 1993, Erythropoietin structure-function relationships. Mutant proteins that test a model of tertiary structure, J Biol Chem., 268(21), 15983-93)).

Preferably, the EPO has the amino acid sequence of human EPO and the naturally  
15 occurring cysteines are cysteine 29 and/ or 33.

Accordingly, in a preferred embodiment, cysteine 33 is replaced by another amino acid and in step c) the modified HAS is conjugated to cysteine 29.

20 In a further preferred embodiment, cysteine 29 is replaced by another amino acid and in step c) the modified HAS is conjugated to cysteine 33.

In the context of the present invention, by the term "added cysteines" it is meant that the polypeptides, preferably EPO, comprise a cysteine residue which is not  
25 present in the wild type polypeptide. This can be achieved by adding (e.g. by recombinant means) a cysteine residue either at the N- or at the C-terminus of the polypeptide or by replacing (e.g. by recombinant means) a naturally-occurring amino acid by cysteine. The respective methods are known to the person skilled in the art (see above).

30

- 21 -

Preferably, the added cysteine has been added by replacing a naturally occurring amino acid by a cysteine.

In a preferred embodiment, the EPO is human EPO and the replaced amino acid residue is serine 126.

Preferably, the modified HAS is conjugated in step c) to the added cysteine.

In step b) of the method of the invention, modified HAS is provided which is capable of reacting with the EPO of step a).

In this context, the HAS may be preferably modified at its reducing end. This has the advantage that the chemical reaction can be controlled easily and that the skilled person can be sure which group of HAS is modified during the reaction. Since only one group is introduced into the HAS, crosslinking between different EPO molecules by multifunctional HAS molecules and other side reactions can be prevented.

Accordingly, the modified HAS may be capable of reacting either with

- (1) at least one group linked, either directly or via a linker molecule, to sulfide groups or carbohydrate moieties of EPO,
- (2) at least one carbohydrate moiety, which is preferably oxidized, and /or
- (3) at least one free SH-group.

With respect to point (1) above, the modification of HAS will depend on the group linked to EPO. The underlying mechanism are known in the art. An example is given in Example 4, 2.1.

With respect to points (2) and (3) above, several methods are known in the art to modify HAS. The basic principle underlying these methods is that either a reac-

- 22 -

tive group of HAS is modified in order to be capable of reacting with the carbohydrate moiety or SH-group or a linker molecule is conjugated to HAS which contains a reactive group being capable of reacting with the carbohydrate moiety or SH-group.

5

In case of point (2), the modified HAS may be capable of reacting with oxidized carbohydrate moieties, preferably a terminal saccharide residue, more preferably galactose, or a terminal sialic acid.

- 10 Several ways are known to modify HAS such that it is capable of reacting with an oxidized, preferably terminal saccharide residue. As mentioned above, this modification may be introduced regioselectively at the reducing end of the HES-chain. In this case, in a first step, the aldehyde group is oxidized to a lactone. The modifications include, but are not limited to the addition of hydrazide, amino (also hydroxylamino), semicarbazide or thiol functions to HAS, either directly or via a linker. These techniques are explained in further detail in Examples 2-4. Furthermore, the mechanisms per se are known in the art (see e.g. DE 196 28 705 A1; Hpoe et al., 1981, Carbohydrate Res., 91, 39; Fissekis et al., 1960, Journal of Medicinal and Pharmaceutical Chemistry, 2, 47; Frie, 1998, diploma thesis, Fachhochschule Hamburg, DE).
- 15
- 20

- Within the present invention, the addition of a hydrazide or hydroxylamino function is preferred. In this case, by preferably conducting the reaction of step c) of the method of the present invention at a pH of 5.5, it is ensured that the modified HAS reacts selectively with the oxidized carbohydrate moiety of EPO without inter- or intramolecular EPO cross-linking by imine formation of lysin side chains with the oxidized saccharide residue.
- 25

- In the case of point (3), also several ways are known to modify HAS such that it is capable of reacting with a free SH-group. Preferentially, this modification is introduced regioselectively at the reducing end of the HES-chain. The methods in-
- 30

clude, but are not limited to the addition of maleimide, disulfide or halogen acetamide functions to HAS. These techniques are explained in further detail in Examples 2-4.

5 Further details about these techniques can be obtained from Chamov et al., 1992, J. Biol. Chem., 267, 15916; Thorpe et al., 1984, Eur. J. Biochem., 140, 63; Greenfield et al., 1990, Cancer Research, 50, 6600 as well as from the literature cited in Example 2, 1.3.

10 Further possible functions are listed in Table 1, providing a systematic overview over possible linker molecules. Furthermore, the mechanisms per se are known in the art.

Several linker molecules which are useful in the context of the present invention  
15 are known in the art or commercially available (e.g. from Pierce, available from Perbio Science Deutschland GmbH, Bonn, Germany). Examples are given in Table 2.

In step c) of the method of the present invention, the EPO of step a) with the HAS  
20 of step b) is reacted, whereby an HAS-EPO is produced comprising one or more HAS molecules, wherein the HAS is conjugated to the EPO via a carbohydrate moiety or via a thioether.

In principle, the detailed methods how to react the EPO with the modified HAS  
25 depend on the individual modification of the EPO and /or the HAS and are known in the art (see e.g. Rose, 1994, J. Am. Chem. Soc., 116, 30, O'Shannessay and Wichek, 1990, Analytical Biochemistry, 191, 1; Thorpe et al., 1984, Eur. J. Biochem., 140, 63; Chamov et al., 1992, J. Biol. Chem. 267, 15916).

30 For the methods exemplified in the present invention, the details are given in Examples 2-4, especially 4.



Step c) may be performed in a reaction medium comprising at least 10 % per weight H<sub>2</sub>O.

5 The reaction medium in this preferred embodiment of the method of the invention comprises at least 10 % per weight water, preferred at least 50 %, more preferred at least 80 %, e.g. 90 % or up to 100 %. The degree of organic solvents is calculated respectively. Consequently, the reaction takes place in an aqueous phase. The preferred reaction medium is water.

10

One advantage of this embodiment of the method of the invention is, that it is not necessary to use toxicologically critical solvents and that therefore it is not necessary to remove these solvents after the production process, in order to avoid the contamination with the solvent. Furthermore, it is not necessary to perform additional quality controls with respect to residual toxicologically critical solvents. It is preferred to use as organic solvents toxicologically not critical solvents like ethanol or propylenglycol.

20 Another advantage of the method of the invention is that irreversible or reversible structural changes are avoided which are induced by organic solvents. Consequently, polypeptides obtained according to the method of the invention are different from those prepared in organic solvents such as DMSO.

25 Furthermore, it has been surprisingly observed that the conjugation of HAS to drugs in an aqueous solution minimizes or avoids side reactions. Consequently, this embodiment of the method of the invention leads to improved products with great purity.

30 In the context of the present invention, the term "hydroxyalkylstarch" is used to indicate starch derivatives which have been substituted by hydroxyalkylgroups. In this context, the alkyl group may be substituted. Preferably, the hydroxyalkyl con-

- 25 -

tains 2-10 carbon atoms, more preferably 2-4 carbon atoms. "Hydroxyalkylstarch" therefore preferably comprises hydroxyethylstarch, hydroxypropylstarch and hydroxybutylstarch, wherein hydroxyethylstarch and hydroxypropylstarch are preferred.

5

The hydroxyalkylgroup(s) of HAS contain at least one OH-group.

Hydroxyethylstarch (HES) is most preferred for all embodiments of the present invention.

10

The expression "hydroxyalkylstarch" also includes derivatives wherein the alkyl group is mono- or polysubstituted. In this context, it is preferred that the alkyl group is substituted with a halogen, especially fluorine, or with an aryl group, provided that the HAS remains water soluble. Furthermore, the terminal hydroxy group of hydroxyalkyl may be esterified or etherified. In addition, the alkyl group of the hydroxyalkylstarch may be linear or branched.

15

Furthermore, instead of alkyl, also linear or branched substituted or unsubstituted alkylene groups may be used.

20

In the context of the present invention, hydroxyethylstarch may have a mean molecular weight (weight mean) of 1-300 kDa, wherein a mean molecular weight of 5-100 kDa is more preferred. Hydroxyethylstarch may further exhibit a molar degree of substitution of 0.1 to 0.8 and a ratio between C<sub>2</sub>:C<sub>6</sub>-substitution in the range of 2-20, with respect to the hydroxyethylgroups.

25

The HAS-EPO produced by the method of the invention can be purified and characterized as follows:

30

Isolation of the HAS-EPO can be performed by using known procedures for the purification of natural and recombinant EPO (e.g. size exclusion chromatography,

- 26 -

ion-exchange chromatography, RP-HPLC, hydroxyapatite chromatography, hydrophobic interaction chromatography, the procedure described in Example 20.8 or combinations thereof).

- 5 The covalent attachment of HAS to the EPO polypeptide can be verified by carbohydrate compositional analysis after hydrolysis of the modified protein (ratio of hydroxyethylglucose and mannose present on the three N-glycosylation sites of EPO).
- 10 Demonstration of HAS modification at N-linked oligosaccharides of EPO can be accomplished by removal of the HAS modified N-glycans and observation of the predicted shift to higher mobility in SDS-PAGE +/- Western Blotting analysis.

- HAS modification of EPO at cysteine residues can be demonstrated by the failure
- 15 to detect the corresponding proteolytic Cys-peptide in RP-HPLC and MALDI/TOF-MS in the proteolytic fragments of the HAS-modified product (Zhou et al., 1998, Application of capillary electrophoresis, liquid chromatography, electrospray-mass spectrometry and matrix-assisted laserdesorption/ionization - time of flight - mass spectrometry to the characterization of recombinant human erythropoietin. Electrophoresis, 19(13), 2348-55). The isolation
  - 20 of the HAS-containing fraction after proteolytic digestion of the Cys-modified EPO enables the verification in this fraction of the corresponding peptide by conventional amino acid compositional analysis.

- 25 All embodiments disclosed above with respect of the HAS-EPO of the invention concerning properties of EPO or HAS apply also to the method of the invention for preparing a HAS-EPO.

- The invention further relates to a HAS-EPO, obtainable by the method of the invention. Preferably, this HAS-EPO has the features as defined for the above HAS-
- 30 EPO of the invention.

- 27 -

The invention further relates to a HAS-EPO according to the invention for use in a method for treatment of the human or animal body.

- 5 Furthermore, the present invention relates to a pharmaceutical composition comprising the HAS-EPO of the invention. In a preferred embodiment, the pharmaceutical composition comprises further at least one pharmaceutically acceptable diluent, adjuvant and/or carrier useful in erythropoietin therapy.
- 10 The pharmaceutical composition is preferably used for the treatment of anemic disorders or hematopoietic dysfunction disorders or diseases related thereto.

A "therapeutically effective amount" as used herein refers to that amount which provides therapeutic effect for a given condition and administration regimen. The  
15 administration of erythropoietin isoforms is preferably by parenteral routes. The specific route chosen will depend upon the condition being treated. The administration of erythropoietin isoforms is preferably done as part of a formulation containing a suitable carrier, such as human serum albumin, a suitable diluent, such as a buffered saline solution, and/or a suitable adjuvant. The required dosage will be  
20 in amounts sufficient to raise the hematocrit of patients and will vary depending upon the severity of the condition being treated, the method of administration used and the like.

The object of the treatment with the pharmaceutical composition of the invention  
25 is preferably an increase of the hemoglobin value of more than 6.8 mmol/l in the blood. For this, the pharmaceutical composition may be administered in a way that the hemoglobin value increases between 0.6 mmol/l and 1.6 mmol/l per week. If the hemoglobin value exceeds 8.7 mmol/l, the therapy should be preferably interrupted until the hemoglobin value is below 8.1 mmol/l.

- 28 -

The composition of the invention is preferably used in a formulation suitable for subcutaneous or intravenous or parenteral injection. For this, suitable excipients and carriers are e.g. sodium dihydrogen phosphate, disodium hydrogen phosphate, sodium chloride, polysorbate 80, HSA and water for injection. The composition  
5 may be administered three times a week, preferably two times a week, more preferably once a week, and most preferably every two weeks.

Preferably, the pharmaceutical composition is administered in an amount of 0.01-10 µg/kg body weight of the patient, more preferably 0.1 to 5 µg/kg, 0.1 to 1  
10 µg/kg, or 0.2-0.9 µg/kg, most preferably 0.3-0.7 µg/kg, and most preferred 0.4-0.6 µg/kg body weight.

In general, preferably between 10 µg and 200 µg, preferably between 15 µg and 100 µg are administered per dosis.

15

The invention further relates to the use of a HAS-EPO of the invention for the preparation of a medicament for the treatment of anemic disorders or hematopoietic dysfunction disorders or diseases related hereto.

20 According to a further aspect of the present invention, the problem is solved by a hydroxyalkylstarch (HAS)-polypeptide-conjugate (HAS-polypeptide) comprising one or more HAS molecules, wherein each HAS is conjugated to the polypeptide via

- 25       a) a carbohydrate moiety; or  
         b) a thioether.

The HAS-polypeptide of the invention has the advantage that it exhibits an improved biological stability when compared to the polypeptide before conjugation.

30 This is mainly due to the fact that HAS-polypeptide is less or not recognized by the removal systems of the liver and kidney and therefore persists in the circula-

- 29 -

tory system for a longer period of time. Furthermore, since the HAS is attached site-specifically, the risk of destroying the in vivo biological activity of the polypeptide by conjugation of HAS to the polypeptide is minimized.

- 5 The HAS-polypeptide of the invention has mainly two components, namely the polypeptide and the hydroxyalkylstarch (HAS) linked thereto.

The polypeptide can be of any human or animal source. In a preferred embodiment, the polypeptide is of human source.

10

The polypeptide may be a cytokine, especially erythropoietin, an antithrombin (AT) such as AT III, an interleukin, especially interleukin-2, IFN-beta, IFN-alpha, G-CSF, CSF, interleukin-6 and therapeutic antibodies.

- 15 According to a preferred embodiment, the polypeptide is an antithrombin (AT), preferably AT III (Levy JH, Weisinger A, Ziomek CA, Echelard Y, Recombinant Antithrombin: Production and Role in Cardiovascular Disorder, Seminars in Thrombosis and Hemostasis 27, 4 (2001) 405-416; Edmunds T, Van Patten SM, Pollock J, Hanson E, Bernasconi R, Higgins E, Manavalan P, Ziomek C, Meade  
20 H, McPherson J, Cole ES, Transgenically Produced Human Antithrombin: Structural and Functional Comparison to Human Plasma-Derived Antithrombin, Blood 91, 12 (1998) 4661-4671; Minnema MC, Chang ACK, Jansen PM, Lubbers YTP, Pratt BM, Whittaker BG, Taylor FB, Hack CE, Friedman B, Recombinant human antithrombin III improves survival and attenuates inflammatory responses in ba-  
25 boons lethally challenged with *Escherichia coli*, Blood 95, 4 (2000) 1117-1123; Van Patten SM, Hanson EH, Bernasconi R, Zhang K, Manavaln P, Cole ES, McPherson JM, Edmunds T, Oxidation of Methionine Residues in Antithrombin, J. Biol. Chemistry 274, 15 (1999) 10268-10276).

- 30 -

According to another preferred embodiment, the polypeptide is human IFN-beta, in particular IFN-beta 1a (cf. Avonex®, REBIF®) and IFN-beta 1b (cf. BETASERON®).

- 5 A further preferred polypeptide is human G-CSF (granulocyte colony stimulating factor). See, e.g., Nagata et al., The chromosomal gene structure and two mRNAs for human granulocyte colony-stimulating factor, EMBO J. 5: 575-581, 1986; Souza et al., Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells, Science 232 (1986) 61-65; and Herman et al., Characterization, formulation, and stability of Neupogen® (Filgrastim), a re-  
10 combinant human granulocyte-colony stimulating factor, in: Formulation, characterization, and stability of protein drugs, Rodney Pearlman and Y. John Wang, eds., Plenum Press, New York, 1996, 303-328.

- 15 With respect to erythropoietin, all embodiments disclosed above also apply here.

Preferably, the polypeptide is recombinantly produced. This includes the production in eukaryotic or prokaryotic cells, preferably mammalian, insect, yeast, bacterial cells or in any other cell type which is convenient for the recombinant production of the polypeptide. Furthermore, the polypeptide may be expressed in trans-  
20 genic animals (e.g. in body fluids like milk, blood, etc.), in eggs of transgenic birds, especially poultry, preferred chicken, or in transgenic plants.

The recombinant production of a polypeptide is known in the art. In general, this  
25 includes the transfection of host cells with an appropriate expression vector, the cultivation of the host cells under conditions which enable the production of the polypeptide and the purification of the polypeptide from the host cells. For detailed information see e.g. Krystal, Pankratz, Farber, Smart, 1986, Purification of human erythropoietin to homogeneity by a rapid five-step procedure, Blood,  
30 67(1), 71-9; Quelle, Caslake, Burkert, Wojchowski, 1989, High-level expression

and purification of a recombinant human erythropoietin produced using a baculovirus vector, Blood, 74(2), 652-7; EP 640 619 B1 and EP 668 351 B1.

5 The polypeptide may comprise one or more carbohydrate side chains attached to the polypeptide via N- and/ or O-linked glycosylation, i.e. the polypeptide is glycosylated. Usually, when a polypeptide is produced in eukaryotic cells, the polypeptide is posttranslationally glycosylated. Consequently, the carbohydrate side chains may have been attached to the polypeptide during biosynthesis in mammalian, especially human, insect or yeast cells.

10

The HAS may be directly conjugated to the polypeptide or, alternatively, via a linker molecule. The nature of the linker molecule depends on the way how the HAS is linked to the polypeptide. Several linkers are commercially available (e.g. from Pierce, see above). The nature of the linker and its purpose are described in  
15 detail below in the section concerning the method for the production of HES-polypeptide is discussed.

According to a preferred embodiment of the HAS-polypeptide conjugate of the invention, the HAS is conjugated to the polypeptide via a carbohydrate moiety.  
20 Preferably, this applies if the polypeptide is an antithrombin, preferably AT III.

In the context of the present invention, the term "carbohydrate moiety" refers to hydroxyaldehydes or hydroxyketones as well as to chemical modifications thereof (see Römpp Chemielexikon, 1990, Thieme Verlag Stuttgart, Germany, 9<sup>th</sup> edition,  
25 9, 2281-2285 and the literature cited therein). Furthermore, it also refers to derivatives of naturally occurring carbohydrate moieties like glucose, galactose, mannose, sialic acid, and the like. The term also includes chemically oxidized naturally occurring carbohydrate moieties wherein the ring structure has been opened.

30 The carbohydrate moiety may be linked directly to the polypeptide backbone. Preferably, the carbohydrate moiety is part of a carbohydrate side chain. In this



- 32 -

case, further carbohydrate moieties may be present between the carbohydrate moiety to which HAS is linked and the polypeptide backbone. More preferably, the carbohydrate moiety is the terminal moiety of the carbohydrate side chain.

5 In a more preferred embodiment, the HAS is conjugated to a galactose residue of the carbohydrate side chains, preferably the terminal galactose residue of the carbohydrate side chain. This galactose residue can be made available for conjugation by removal of terminal sialic acids, followed by oxidation (see below).

10 In a further more preferred embodiment, the HAS is conjugated to a sialic acid residue of the carbohydrate side chains, preferably the terminal sialic acid residue of the carbohydrate side chain.

Furthermore, the HAS may be conjugated to the polypeptide via a thioether. As  
15 explained in detail below, the S atom can be derived from any SH group attached to the polypeptide, both naturally or non naturally occurring.

In a preferred embodiment, the S atom may be derived from a SH group which has been introduced in an oxidized carbohydrate moiety of HES, preferably an  
20 oxidized carbohydrate moiety which is part of a carbohydrate side chain of the polypeptide (see below).

Preferably, the S atom in the thioether is derived from a naturally-occurring cysteine or from an added cysteine.

25

In the context of the present invention, by the term "added cysteines" it is meant that the polypeptides comprise a cysteine residue which is not present in the wild-type polypeptide.

30 In the context of this aspect of the invention, the cysteine may be an additional amino acid added at the N- or C-terminal end of the polypeptide.

- 33 -

Furthermore, the added cysteine may have been added by replacing a naturally occurring amino acid by a cysteine.

5 The second component of the HAS-polypeptide is HAS.

In the context of the present invention, the term "hydroxyalkylstarch" is used to indicate starch derivatives which have been substituted by hydroxyalkylgroups. In this context, the alkyl group may be substituted. Preferably, the hydroxyalkyl contains 2-10 carbon atoms, more preferably 2-4 carbon atoms. "Hydroxyalkylstarch" therefore preferably comprises hydroxyethylstarch, hydroxypropylstarch and hydroxybutylstarch, wherein hydroxyethylstarch and hydroxypropylstarch are preferred.

15 The hydroxyalkylgroup(s) of HAS contain at least one OH-group.

The expression "hydroxyalkylstarch" also includes derivatives wherein the alkyl group is mono- or polysubstituted. In this context, it is preferred that the alkyl group is substituted with an halogen, especially fluorine, or with an aryl group, provided that the HAS remains water soluble. Furthermore, the terminal hydroxy group of hydroxyalkyl may be esterified or etherified. In addition, the alkyl group of the hydroxyalkylstarch may be linear or branched.

25 Furthermore, instead of alkyl, also linear or branched substituted or unsubstituted alkene groups may be used.

Hydroxyethylstarch (HES) is most preferred for all embodiments of the present invention.

30 In the context of the present invention, hydroxyethylstarch may have a mean molecular weight (weight mean) of 1-300 kDa, wherein a mean molecular weight of

- 34 -

5-100 kDa is more preferred. Hydroxyethylstarch can further exhibit a molar degree of substitution of 0.1 to 0.8 and a ratio between C<sub>2</sub>:C<sub>6</sub>-substitution in the range of 2-20, with respect to the hydroxyethylgroups.

5 The HAS-polypeptide may comprise 1-12, preferably 1-9, 1-6 or 1-3, most preferred 1-4 HAS molecules per polypeptide molecule. The number of HAS-molecules per polypeptide molecule can be determined by quantitative carbohydrate compositional analysis using GC-MS after hydrolysis of the product and derivatisation of the resulting monosaccharides (Chaplin and Kennedy, 1986,  
10 Carbohydrate Analysis (eds.): a practical approach ed., Chapter 1. Monosaccharides page 1-36; Chapter 2. Oligosaccharides page 37-53; Chapter 3. Neutral Polysaccharides; 55-96; IRL Press Practical approach series (ISBN 0-947946-44-3).

15 All embodiments disclosed below with respect of the method of the invention to produce a HAS-polypeptide concerning properties of the polypeptide or HAS apply also to the HAS-polypeptide of the invention. Furthermore, all embodiments disclosed above with respect to HAS-EPO or the preparation thereof which relate to peptides in general or to HAS apply also to the HAS-polypeptide of the invention.  
20

Hydroxyalkylstarch is an ether derivative of starch. Besides of said ether derivatives, also other starch derivatives can be used in the context of the present invention. For example, derivatives are useful which comprise esterified hydroxy  
25 groups. These derivatives may be e.g. derivatives of unsubstituted mono- or dicarboxylic acids with 2-12 carbon atoms or of substituted derivatives thereof. Especially useful are derivatives of unsubstituted monocarboxylic acids with 2-6 carbon atoms, especially of acetic acid. In this context, acetylstarch, butylstarch or propylstarch are preferred.

30

- 35 -

Furthermore, derivatives of unsubstituted dicarboxylic acids with 2-6 carbon atoms are preferred.

In the case of derivatives of dicarboxylic acids, it is useful that the second carboxy group of the dicarboxylic acid is also esterified. Furthermore, derivatives of monoalkyl esters of dicarboxylic acids are also suitable in the context of the present invention.

For the substituted mono- or dicarboxylic acids, the substitute groups may be preferably the same as mentioned above for substituted alkyl residues.

Techniques for the esterification of starch are known in the art (see e.g. Klemm D. et al, Comprehensive Cellulose Chemistry Vol. 2, 1998, Wiley-VCH, Weinheim, New York, especially chapter 4.4, Esterification of Cellulose (ISBN 3-527-29489-9)).

In a further aspect, the present invention relates to a method for the production of a hydroxyalkylstarch (HAS)-polypeptide-conjugate (HAS-polypeptide), comprising the steps of:

- a) providing a polypeptide being capable of reacting with modified HAS,
- b) providing modified HAS being capable of reacting with the polypeptide of step a), and
- c) reacting the polypeptide of step a) with the HAS of step b), whereby an HAS-polypeptide is produced comprising one or more HAS molecules, wherein the HAS is conjugated to the polypeptide via
  - i) a carbohydrate moiety; or
  - ii) a thioether.

The method of the invention has the advantage that a HAS-polypeptide conjugate is produced which exhibits a high biological activity. Furthermore, the method of

- 36 -

the invention has the advantage that an effective polypeptide derivative can be produced at reduced cost since the method does not comprise extensive and time consuming purification steps resulting in low final yield.

- 5 Accordingly, in the first step of the method of the invention, a polypeptide is provided which is capable of reacting with modified HAS.

As used in the present invention, the term "providing" has to be interpreted in the way that after the respective step a molecule (in step a) a polypeptide, in step b)  
10 HAS) with the desired properties is available.

In the case of step a), this includes the purification of the polypeptide from natural sources as well as the recombinant production in host cells or organism, and, if necessary, the modification of the polypeptide so obtained.

15

With respect to the polypeptide being the starting material of the present invention, the same applies as for the erythropoietin being part of the HAS-polypeptide conjugate of the invention. In this context, the preferred embodiments disclosed above apply also for the method of the invention.

20

Preferably, the polypeptide is recombinantly produced. This includes the production in eukaryotic or prokaryotic cells, preferably mammalian, insect, yeast, bacterial cells or in any other cell type which is convenient for the recombinant production of the polypeptide. Furthermore, the polypeptide may be expressed in transgenic animals (e.g. in body fluids like milk, blood, etc.), in eggs of transgenic  
25 birds, especially poultry, preferred chicken, or in transgenic plants.

The recombinant production of a polypeptide is known in the art. In general, this includes the transfection of host cells with an appropriate expression vector, the  
30 cultivation of the host cells under conditions which enable the production of the polypeptide and the purification of the polypeptide from the host cells (Krystal,

- 37 -

Pankratz, Farber, Smart, 1986, Purification of human erythropoietin to homogeneity by a rapid five-step procedure, *Blood*, 67(1), 71-9; Quelle, Caslake, Burkert, Wojchowski, 1989, High-level expression and purification of a recombinant human erythropoietin produced using a baculovirus vector, *Blood*, 74(2), 652-7; EP 640 619 B1 and EP 668 351 B1).

The polypeptide may comprise one or more carbohydrate side chains attached to the polypeptide via N- and/ or O-linked glycosylation, i.e. the polypeptide is glycosylated. Unusually, when the polypeptide is produced in eukaryotic cells, the polypeptide is posttranslationally glycosylated. Consequently, the carbohydrate side chains may have been attached to the polypeptide during production in mammalian, especially human, insect or yeast cells, wherein the cells may be those of a transgenic animal or plant (see above).

These carbohydrate side chains may have been chemically or enzymatically modified after the expression in the appropriate cells, e.g. by removing or adding one or more carbohydrate moieties (see e.g. Dittmar, Conradt, Hauser, Hofer, Lindenmaier, 1989, *Advances in Protein design*; Bloecker, Collins, Schmidt, and Schomburg eds., *GBF-Monographs*, 12, 231-246, VCH Publishers, Weinheim, New York, Cambridge)

It is the object of the method of the invention to provide an HAS-polypeptide comprising one or more HAS molecules wherein the HAS is conjugated to the polypeptide via a carbohydrate moiety (i) or via a thioether (ii). Consequently, the polypeptide provided in step a) should have the properties that a conjugation via a carbohydrate moiety and/ or via a thioether is possible. Therefore the polypeptide after step a) may preferably contain either

(1) at least one reactive group linked, either directly or via a linker molecule, to sulfide groups or carbohydrate moieties, which is capable to react with HES or modified HES,

- 38 -

(2) at least one carbohydrate moiety to which modified HAS can be conjugated, and/or

(3) at least one free SH-group.

5 With respect to possibility (1) above, the polypeptide of step a) is preferably obtainable by conjugating an appropriate linker molecule to the SH-group(s) or carbohydrate moieties of the polypeptide. An example for such a modified polypeptide is provided in Example 4, 2.1. It is important to ensure that the addition of the linker molecule does not damage the polypeptide. However, this is known to the  
10 person skilled in the art.

With respect to possibility (2) above, in a preferred embodiment, the modified HAS is conjugated to the polypeptide via a carbohydrate moiety.

15 The carbohydrate moiety may be linked directly to the polypeptide backbone. Preferably, the carbohydrate moiety is part of a carbohydrate side chain. In this case, further carbohydrate moieties may be present between the carbohydrate moiety to which HAS is linked and the polypeptide backbone. More preferably, the carbohydrate moiety is the terminal moiety of the carbohydrate side chain.

20 Consequently, in a preferred embodiment, the modified HAS is attached (via a linker or not, see below) to carbohydrate chains linked to N- and/ or O-glycosylation sites of the polypeptide.

25 However, it is also included within the present invention that the polypeptide contains (a) further carbohydrate moiety(ies) to which the modified HAS is conjugated. Techniques for attaching carbohydrate moieties to polypeptides, either enzymatically or by genetic engineering, followed by expression in appropriate cells, are known in the art (Berger, Greber, Mosbach, 1986, Galactosyltransferase-dependent sialylation of complex and endo-N-acetylglucosaminidase H-treated  
30 core N-glycans in vitro, FEBS Lett., 203(1), 64-8; Dittmar, Conradt, Hauser,

Hofer, Lindenmaier, 1989, *Advances in Protein design*; Bloecker, Collins, Schmidt, and Schomburg eds., GBF-Monographs, 12, 231-246, VCH Publishers, Weinheim, New York, Cambridge).

- 5 In a preferred embodiment of the method of the invention, the carbohydrate moiety is oxidized in order to be able to react with the modified HAS. This oxidation can be performed either chemically or enzymatically.

Methods for the chemical oxidation of carbohydrate moieties of polypeptides are  
10 known in the art and include the treatment with periodate (Chamow et al., 1992, *J. Biol. Chem.*, 267, 15916-15922).

By chemically oxidizing, it is principally possible to oxidize any carbohydrate moiety, being terminally positioned or not. However, by choosing mild conditions  
15 (1 mM periodate, 0 °C in contrast to harsh conditions: 10 mM periodate 1h at room temperature), it is possible to preferably oxidize the terminal carbohydrate moiety, e.g. sialic acid or galactose, of a carbohydrate side chain.

Alternatively, the carbohydrate moiety may be oxidized enzymatically. Enzymes  
20 for the oxidation of the individual carbohydrate moieties are known in the art, e.g. in the case of galactose the enzyme is galactose oxidase.

If it is intended to oxidize terminal galactose moieties, it will be eventually necessary to remove terminal sialic acids (partially or completely) if the polypeptide  
25 has been produced in cells capable of attaching sialic acids to carbohydrate chains, e.g. in mammalian cells or in cells which have been genetically modified to be capable of attaching sialic acids to carbohydrate chains. Chemical or enzymatic methods for the removal of sialic acids are known in the art (Chaplin and Kennedy (eds.), 1996, *Carbohydrate Analysis: a practical approach*, especially Chapter 5 Montreuil, *Glycoproteins*, pages 175-177; IRL Press Practical approach series (ISBN 0-947946-44-3)).  
30



- 40 -

However, it is also included within the present invention that the carbohydrate moiety to which the modified HAS is to be attached is attached to the polypeptide within step a). In the case it is desired to attach galactose, this can be achieved by the means of galactose transferase. The methods are known in the art (Berger, Greber, Mosbach, 1986, Galactosyltransferase-dependent sialylation of complex and endo-N-acetylglucosaminidase H-treated core N-glycans in vitro, FEBS Lett., 203(1), 64-8).

10 In a most preferred embodiment, in step a) the polypeptide is modified by oxidizing at least one terminal saccharide unit, preferably galactose, of the one or more carbohydrate side chains of the polypeptide, preferably after partial or complete (enzymatic and/ or chemical) removal of the terminal sialic acid, if necessary (see above).

15 Consequently, preferably the modified HAS is conjugated to the oxidized terminal saccharide unit of the carbohydrate chain, preferably galactose.

20 In a further preferred embodiment (see point (3) above), the polypeptide comprises at least one free SH-group.

According to a preferred embodiment, the free SH-group is part of a naturally-occurring cysteine or of an added cysteine.

25 Methods for the replacement of amino acids are known in the art (Elliott, Lorenzini, Chang, Barzilay, Delorme, 1997, Mapping of the active site of recombinant human erythropoietin, Blood, 89(2), 493-502; Boissel, Lee, Presnell, Cohen, Bunn, 1993, Erythropoietin structure-function relationships. Mutant proteins that test a model of tertiary structure, J Biol Chem., 268(21), 15983-93)).

30

- 41 -

In the context of the present invention, by the term "added cysteines" it is meant that the polypeptides comprise a cysteine residue which is not present in the wild type polypeptide. This can be achieved by adding (e.g. by recombinant means) a cysteine residue either at the N- or at the C-terminus of the polypeptide or by replacing (e.g. by recombinant means) a naturally-occurring amino acid by cysteine. The respective methods are known to the person skilled in the art (see above).

Preferably, the added cysteine has been added by replacing a naturally occurring amino acid by a cysteine.

Preferably, the modified HAS is conjugated in step c) to the added cysteine.

In step b) of the method of the invention, modified HAS is provided which is capable of reacting with the polypeptide of step a).

In this context, the HAS may be preferably modified at its reducing end. This has the advantage that the chemical reaction can be controlled easily and that the skilled person can be sure which group of HAS is modified during the reaction. Since only one group is introduced into the HAS, crosslinking between different polypeptide molecules by multifunctional HAS molecules and other side reactions can be prevented.

Accordingly, the modified HAS may be capable of reacting either with

- (1) at least one group linked, either directly or via a linker molecule, to sulfide groups or carbohydrate moieties of the polypeptide,
- (2) at least one carbohydrate moiety, which is preferably oxidized, and /or
- (3) at least one free SH-group.

With respect to point (1) above, the modification of HAS will depend on the group linked to the polypeptide. The underlying mechanism are known in the art. An example is given in Example 4, 2.1.

5 With respect to points (2) and (3) above, several methods are known in the art to modify HAS. The basic principle underlying these methods is that either a reactive group of HAS is modified in order to be capable of reacting with the carbohydrate moiety or SH-group or a linker molecule is conjugated to HAS which contains a reactive group being capable of reacting with the carbohydrate moiety  
10 or SH-group.

In case of point (2), the modified HAS may be capable of reacting with oxidized carbohydrate moieties, preferably a terminal saccharide residue, more preferably galactose, or with a terminal sialic acid.

15 Several ways are known to modify HAS such that it is capable of reacting with an oxidized, preferably terminal saccharide residue. As mentioned above, this modification may be introduced regioselectively at the reducing end of the HES-chain. In this case, in a first step, the aldehyde group is oxidized to a lactone. The modifications include, but are not limited to the addition of hydrazide, amino (also hydroxylamino), semicarbazide or thiol functions to HAS, either directly or via a linker. These techniques are explained in further detail in Examples 2-4. Furthermore, the mechanisms per se are known in the art (see e.g. DE 196 28 705 A1; Hpoë et al., 1981, Carbohydrate Res., 91, 39; Fissekis et al., 1960, Journal of Me-  
20 dicinal and Pharmaceutical Chemistry, 2, 47; Frie, 1998, diploma thesis, Fachhochschule Hamburg, DE).

Within the present invention, the addition of a hydrazide or hydroxylamino function is preferred. In this case, by preferably conducting the reaction of step c) of  
30 the method of the present invention at a pH of 5.5, it is ensured that the modified HAS reacts selectively with the oxidized carbohydrate moiety of the polypeptide

without inter- or intramolecular polypeptide cross-linking by imine formation of lysine side chains with the oxidized saccharide residue.

In the case of point (3), also several ways are known to modify HAS such that it is capable of reacting with a free SH-group. Preferentially, this modification is introduced regioselectively at the reducing end of the HES-chain. The methods include, but are not limited to the addition of maleimide, disulfide or halogen acetamide functions to HAS. These techniques are explained in further detail in Examples 2-4

10

Further details about these techniques can be obtained from Chamov et al., 1992, J. Biol. Chem., 267, 15916; Thorpe et al., 1984, Eur. J. Biochem., 140, 63; Greenfield et al., 1990, Cancer Research, 50, 6600 as well as from the literature cited in Example 2, 1.3.

15

Further possible functions are listed in Table 1, providing a systematic overview over possible linker molecules. Furthermore, the mechanisms per se are known in the art.

20

Several linker molecules which are useful in the context of the present invention are known in the art or commercially available (e.g. from Pierce, available from Perbio Science Deutschland GmbH, Bonn, Germany).

In step c) of the method of the present invention, the polypeptide of step a) with the HAS of step b) is reacted, whereby an HAS-polypeptide is produced comprising one or more HAS molecules wherein the HAS is conjugated to the polypeptide via a carbohydrate moiety or via a thioether.

25

In principle, the detailed methods how to react the polypeptide with the modified HAS depend on the individual modification of the polypeptide and /or the HAS and are known in the art (see e.g. Rose, 1994, J. Am. Chem. Soc., 116, 30;

30

O'Shannessay and Wichek, 1990, Analytical Biochemistry, 191, 1; Thorpe et al., 1984, Eur. J. Biochem., 140, 63; Chamov et al., 1992, J. Biol. Chem., 267, 15916).

- 5 For the methods exemplified in the present invention, the details are given in Examples 2-4, especially 4.

Step c) may be performed in a reaction medium comprising at least 10 % per weight H<sub>2</sub>O.

10

The reaction medium in this preferred embodiment of the method of the invention comprises at least 10 % per weight water, preferred at least 50 %, more preferred at least 80 %, e.g. 90 % or up to 100 %. The degree of organic solvents is calculated respectively. Consequently, the reaction takes place in an aqueous phase.

- 15 The preferred reaction medium is water.

One advantage of this embodiment of the method of the invention is, that it is not necessary to use toxicologically critical solvents and that therefore it is not necessary to remove these solvents after the production process, in order to avoid the contamination with the solvent. Furthermore, it is not necessary to perform additional quality controls with respect to residual toxicologically critical solvents. It is preferred to use as organic solvents toxicologically not critical solvents like ethanol or propylenglycol.

- 20
- 25 Another advantage of the method of the invention is that irreversible or reversible structural changes are avoided which are induced by organic solvents. Consequently, polypeptides obtained according to the method of the invention are different from those prepared in organic solvents such as DMSO.

Furthermore, it has been surprisingly observed that the conjugation of HAS to drugs in an aqueous solution avoids side reactions. Consequently, this embodiment of the method of the invention leads to improved products with great purity.

- 5 In the context of the present invention, the term "hydroxyalkylstarch" is used to indicate starch derivatives which have been substituted by hydroxyalkylgroups. In this context, the alkyl group may be substituted. Preferably, the hydroxyalkyl contains 2-10 carbon atoms, more preferably 2-4 carbon atoms. "Hydroxyalkylstarch" therefore preferably comprises hydroxyethylstarch, hydroxypropylstarch and hydroxybutylstarch, wherein hydroxyethylstarch and hydroxypropylstarch are preferred.
- 10

The hydroxyalkylgroup(s) of HAS contain at least one OH-group.

- 15 Hydroxyethylstarch (HES) is most preferred for all embodiments of the present invention.

The expression "hydroxyalkylstarch" also includes derivatives wherein the alkyl group is mono- or polysubstituted. In this context, it is preferred that the alkyl group is substituted with an halogen, especially fluorine, or with an aryl group, provided that the HAS remains water soluble. Furthermore, the terminal hydroxy group of hydroxyalkyl may be esterified or etherified. In addition, the alkyl group of the hydroxyalkylstarch may be linear or branched.

20

- 25 Furthermore, instead of alkyl, also linear or branched substituted or unsubstituted alkylene groups may be used.

In the context of the present invention, hydroxyethylstarch may have a mean molecular weight (weight mean) of 1-300 kDa, wherein a mean molecular weight of 5-100 kDa is more preferred. Hydroxyethylstarch may further exhibit a molar

30

- 46 -

degree of substitution of 0.1 to 0.8 and a ratio between C<sub>2</sub>:C<sub>6</sub>-substitution in the range of 2-20, with respect to the hydroxyethylgroups.

The HAS-polypeptide produced by the method of the invention can be purified  
5 and characterized as follows:

Isolation of the HAS-polypeptide can be performed by using known procedures for the purification of natural and recombinant polypeptides (e.g. size exclusion chromatography, ion-exchange chromatography, RP-HPLC, hydroxyapatite  
10 chromatography, hydrophobic interaction chromatography, the procedure described in Example 20.8 or combinations thereof ).

The covalent attachment of HAS to the polypeptide can be verified by carbohydrate compositional analysis after hydrolysis of the modified protein.  
15

Demonstration of HAS modification at N-linked oligosaccharides of the polypeptide can be accomplished by removal of the HAS modified N-glycans and observation of the predicted shift to higher mobility in SDS-PAGE +/- Western Blotting analysis.  
20


HAS modification of the polypeptide at cysteine residues can be demonstrated by the failure to detect the corresponding proteolytic Cys-peptide in RP-HPLC and MALDI/TOF-MS in the proteolytic fragments of the HAS-modified product (Zhou et al., 1998, Application of capillary electrophoresis, liquid chromatography, electrospray-mass spectrometry and matrix-assisted laserdesorption/ionization - time of flight - mass spectrometry to the characterization of recombinant human erythropoietin, Electrophoresis, 19(13), 2348-55). The isolation of the HAS-containing fraction after proteolytic digestion of the Cys-modified polypeptide enables the verification in this fraction of the corresponding peptide  
25 by conventional amino acid compositional analysis.  
30

- 47 -

All embodiments disclosed above with respect of the HAS-polypeptide of the invention concerning properties of the polypeptide or HAS apply also to the method of the invention for the production of a HAS-polypeptide conjugate. Furthermore, all embodiments disclosed above with respect to HAS-EPO or the preparation thereof which relate to peptides in general or to HAS apply also to the method of the invention for the production of a HAS-polypeptide conjugate.

The invention further relates to a HAS-polypeptide, obtainable by the method of the invention. Preferably, this HAS-polypeptide has the features as defined for the above HAS-polypeptide of the invention.

According to a preferred embodiment of the present invention, the HAS used has the following formula (I)




wherein  $R_1$ ,  $R_2$  and  $R_3$  are independently hydrogen or a linear or branched hydroxyalkyl group. The term "hydroxyalkyl starch" as used in the present invention is not limited to compounds where the terminal carbohydrate moiety comprises hydroxyalkyl groups  $R_1$ ,  $R_2$ , and/or  $R_3$  as depicted, for the sake of brevity, in formula (I), but also refers to compounds in which at least one hydroxy group present anywhere, either in the terminal carbohydrate moiety and/or in the remaining part of the starch molecule, HAS', is substituted by a hydroxyalkyl group  $R_1$ ,  $R_2$ , or  $R_3$ . In this context, the alkyl group may be a linear or branched alkyl group which may be suitably substituted. Preferably, the hydroxyalkyl group contains 1 to 10 carbon atoms, more preferably from 1 to 6 carbon atoms, more preferably from 1 to 4 carbon atoms, and even more preferably 2-4 carbon atoms. "Hydroxyalkyl starch" therefore preferably comprises hydroxyethyl starch, hy-




droxypropyl starch and hydroxybutyl starch, wherein hydroxyethyl starch and hydroxypropyl starch are particularly preferred, hydroxyethyl starch being especially preferred.

- 5 HAS and preferably HES may be reacted with a crosslinking compound which reacts with HAS, preferably HES, and the polypeptide such as the polypeptides described above.

10 The reaction between HAS and the crosslinking compound may take place at the reducing end of HAS or at the oxidised reducing end of HAS. Therefore, HAS may be reacted having a structure according to formula (I)




and/or, in case the reducing end is oxidised, according to formula (IIa)




and/or according to formula (IIb)

- 49 -




If HAS according to formula (I) is reacted with a crosslinking compound, the reaction preferably takes place in an aqueous medium. If HAS according to formula (IIa) and/or (IIb) is reacted with a crosslinking compound, the reaction preferably takes place in a non-aqueous medium such as in a polar aprotic solvent or solvent mixture such as DMSO and/or in DMF.


If the HAS-polypeptide conjugate of the present invention is produced via reaction of a HAS derivative, comprising HAS and a crosslinking compound, with the oxidised carbohydrate moiety of the polypeptide, the crosslinking compound is preferably a compound





















- 50 -








If the HAS-polypeptide conjugate of the present invention is produced via reaction of a HAS derivative, comprising HAS and at least one crosslinking compound, with the thio group of the polypeptide, it is preferred to react HAS at its optionally oxidized reducing end with a first crosslinking compound which is preferably a compound



- 51 -





- 52 -




- and react the resulting HAS derivative with a second crosslinking compound which is capable of reacting with the HAS derivative and the thio group of the polypeptide. If, e.g., the HAS derivative comprises, as functional group which is reacted with the second crosslinking compound, the structure -NH-, as described
- 5 above in detail, the following types of second crosslinking compounds with functional groups F1 and F2 are, among others, preferred:

Type of compound (L)	F1	F2
C	Iodoalkyl	N-succinimide ester
D	Bromoalkyl	N-succinimide ester
E	Maleimido	N-succinimide ester
F	Pyridyldithio	N-succinimide ester
G	Vinylsulfone	N-succinimide ester

Especially preferred examples of the first crosslinking compound are




and




the compounds


- 53 -



being particularly preferred, and the following second crosslinking compounds




are preferred, the compound



being especially preferred.



5. Depending on the respective reaction conditions, the solvent or solvent mixture used and/or the residues R' and/or R'' of a compound R'-NH-R'' the HAS is reacted with in an aqueous medium, it is possible that the hydroxyalkyl starch derivative obtainable by the method or methods described above may have the following constitutions (IIIa):



- 54 -

Therefore, the present invention also relates to a hydroxyalkyl starch derivative as described above having a constitution according to formula (IIIa).

It is also possible that, e.g. in the case where R' is hydrogen that the hydroxyalkyl starch derivate obtainable by the method or methods described above may have the following constitutions (IIIa) or (IIIb) where (IIIa) and (IIIb) may be both present in the reaction mixture having a certain equilibrium distribution:



Therefore, the present invention also relates to a hydroxyalkyl starch derivative as described above having a constitution according to formula (IIIb).


Moreover, the present invention also relates to a hydroxyalkyl starch derivative as described above being present in a mixture of constitutions according to formulae (IIIa) and (IIIb).

Depending on the reaction conditions and/or the chemical nature of the compound R'-NH-R'' used for the reaction, the compounds according to formula (IIIa) may be present with the N atom in equatorial or axial position where also a mixture of both forms may be present having a certain equilibrium distribution.

- 55 -

Depending on the reaction conditions and/or the chemical nature of compound R'-NH-R'' used for the reaction, the compounds according to formula (IIIb) may be present with the C-N double bond in *E* or *Z* conformation where also a mixture of both forms may be present having a certain equilibrium distribution.

In some cases it may be desirable to stabilize the compound according to formula (IIIa). This is especially the case where the compound according to formula (IIIa) is produced and/or used in an aqueous solution. As stabilizing method, acylation of the compound according to formula (IIIa) is particularly preferred, especially in the case where R' is hydrogen. As acylation reagent, all suitable reagents may be used which result in the desired hydroxyalkyl starch derivative according to formula (IVa)



According to especially preferred embodiments of the present invention, the residue Ra being part of the acylation reagent is methyl. As acylation reagents, carboxylic acid anhydrides, carboxylic acid halides and carboxylic acid activated esters are preferably used.


Therefore, the present invention also relates to a hydroxyalkyl starch derivative obtainable by a method as described above wherein said derivative has a constitution according to formula (IVa).

The acylation is carried at a temperature in the range of from 0 to 30 °C, preferably in the range of from 2 to 20 °C and especially preferably in the range of from 4 to 10 °C.



- 56 -

In other cases it may be desirable to stabilize the compound according to formula (IIIb). This is especially the case where the compound according to formula (IIIb) is produced and/or used in an aqueous solution. As stabilizing method, reduction of the compound according to formula (IIIb) is particularly preferred, especially in the case where R' is hydrogen. As reduction reagent, all suitable reagents may be used which result in the desired hydroxyalkyl starch derivative according to formula (IVb)



According to especially preferred embodiments of the present invention, as reduction reagents boro hydrides such as  $\text{NaCNBH}_3$  or  $\text{NaBH}_4$  are used.

Therefore, the present invention also relates to a hydroxyalkyl starch derivate obtainable by a method as described above wherein said derivative has a constitution according to formula (IVb).

The reduction is carried at a temperature in the range of from 4 to 100 °C, preferably in the range of from 10 to 90 °C and especially preferably in the range of from 25 to 80 °C.

The present invention further relates to mixtures of compounds (IIIa) and (IIIb), (IVa) and (IVb), (IIIa) and (IVa), (IIIa) and (IVb), (IIIb) and (IVa), (IIIb) and (IVb), (IIIa) and (IIIb) and (IVa), (IIIa) and (IIIb) and (IVb), (IVa) and (IVb) and (IIIa), and (IVa) and (IVb) and (IIIb) wherein (IIIa) and/or (IVa) may be independently present in a conformation where the N atom in equatorial or axial posi-

- 57 -

tion and/or wherein (IIIb) may be present with the C-N double bond in *E* or *Z* conformation.

5 The invention further relates to a HAS-polypeptide according to the invention for use in a method for treatment of the human or animal body.

Furthermore, the present invention relates to a pharmaceutical composition comprising the HAS-polypeptide of the invention. In a preferred embodiment, the pharmaceutical composition comprises further at least one pharmaceutically acceptable diluent, adjuvant and/or carrier useful in erythropoietin therapy.

10

The invention further relates to the use of a HAS-polypeptide of the invention for the preparation of a medicament for the treatment of anemic disorders or hemato-poietic dysfunction disorders or diseases related hereto.

15

The invention is further illustrated by the following figures, tables and examples, which are in no way intended to restrict the scope of the present invention.

**Short description of the Figures****Figure 1**

5    Figure 1 shows an SDS page analysis of two HES-EPO conjugates

mw:	marker
Lane 1:	HES-EPO produced according to example protocol 8: EPO is conjugated to hydrazido-HES 12KD L
10    Lane 2:	HES-EPO produced according to example protocol 9 : EPO is conjugated to hydroxylamino HES 12 KD K
C:	control (unconjugated EPO); the upper band represents EPO dimer

**Figure 2**

15

Figure 2 demonstrates that the HES is conjugated to a carbohydrate moiety of a carbohydrate side chain by showing a digestion of HAS modified EPO forms with polypeptide N-glycosidase

20    Lane 1:	HES-EPO produced according to example protocol 8 after digestion with N-glycosidase
Lane 2:	HES-EPO produced according to example protocol 9 after digestion with N-glycosidase
Lane 3:	BRP EPO standard
25    Lane 4:	BRP EPO standard after digestion with N-glycosidase
mw:	marker (Bio-Rad SDS-PAGE Standards Low range Catalog No 161-0305, Bio-Rad Laboratories, Hercules, CA, USA)

**Figure 3**

Figure 3 shows an SDS page analysis of the HES-EPO conjugate, produced according to example 17.1.

5

Lane A: Protein marker Roti®-Mark PRESTAINED (Carl Roth GmbH+Co, Karlsruhe, D); molecular weights (in kD) of the protein marker from top to bottom: 245, 123, 77, 42, 30, 25.4, and 17.

Lane B: Crude product after conjugation according to example 17.1.

10 Lane C: EPO starting material.

**Figure 4**

Figure 4 shows an SDS page analysis of the HES-EPO conjugate, produced according to example 17.3.

15

Lane A: Crude product after conjugation according to example 17.3.

Lane B: EPO starting material.

20 Lane C: Protein marker Roti®-Mark PRESTAINED (Carl Roth GmbH+Co, Karlsruhe, D); molecular weights (in kD) of the protein marker from top to bottom: 245, 123, 77, 42, 30, 25.4, and 17.

**Figure 5**

25 Figure 5 shows an SDS page analysis of the HES-EPO conjugate, produced according to example 17.4 and 17.5.

30 Lane A: Protein marker Roti®-Mark PRESTAINED (Carl Roth GmbH+Co, Karlsruhe, D); molecular weights (in kD) of the protein marker from top to bottom: 245, 123, 77, 42, 30, 25.4, and 17.

Lane B: Crude product after conjugation according to example 17.4.

- 60 -

Lane C: Crude product after conjugation according to example 17.5.

Lane D: EPO starting material.

#### Figure 6

5

Figure 6 shows an SDS page analysis of HES-EPO conjugates, produced according to examples 19.1 and 19.4.

10 Lane A: Protein marker Roti®-Mark PRESTAINED (Carl Roth GmbH+Co, Karlsruhe, D); molecular weights (in kD) of the protein marker from top to bottom: 245, 123, 77, 42, 30, 25.4, and 17.

Lane B: Crude product after conjugation according to example 19.4.

Lane C: Crude product after conjugation according to example 19.1.

Lane D: EPO starting material.

15

#### Figure 7

Figure 7 shows an SDS page analysis of HES-EPO conjugates, produced according to examples 19.2, 19.3, 19.5, and 19.6.

20

Lane A: Protein marker Roti®-Mark PRESTAINED (Carl Roth GmbH+Co, Karlsruhe, D); molecular weights (in kD) of the protein marker from top to bottom: 245, 123, 77, 42, 30, 25.4, and 17.

25 Lane B: Crude product after conjugation according to example 19.6, based on example 13.3 b)

Lane C: Crude product after conjugation according to example 19.5, based on example 13.1 b).

Lane D: Crude product after conjugation according to example 19.6, based on example 13.3 a).

30 Lane E: Crude product after conjugation according to example 19.5, based on example 13.1 a).

- 61 -

- Lane F: Crude product after conjugation according to example 19.2.  
 Lane G: Crude product after conjugation according to example 19.3.  
 Lane K: EPO starting material.

# 5 Figure 8

Figure 8 shows an SDS page analysis of HES-EPO conjugates, produced according to examples 19.7, 19.8, 19.9, 19.10, 19.11, and 19.12.

- 10 Lane A: Protein marker Roti®-Mark PRESTAINED (Carl Roth GmbH+Co, Karlsruhe, D); molecular weights (in kD) of the protein marker from top to bottom: 245, 123, 77, 42, 30, 25.4, and 17.  
 Lane B: Crude product after conjugation according to example 19.11.  
 Lane C: Crude product after conjugation according to example 19.10.  
 15 Lane D: Crude product after conjugation according to example 19.7.  
 Lane E: Crude product after conjugation according to example 19.8.  
 Lane F: Crude product after conjugation according to example 19.12.  
 Lane G: EPO starting material.  
 Lane K: Crude product after conjugation according to example 19.9.

20

# Figure 9

- SDS-PAGE analyses of EPO-GT-1 subjected to mild acid treatment for 5 min. = lane 2; 10 min. = lane 3; 60 min. = lane 4 and untreated EPO = lane 1; the mobility shift of EPO after removal of N-glycans is shown (+PNGASE).

25

# Figure 10

- HPAEC-PAD pattern of oligosaccharides isolated from untreated EPO and from  
 30 EPO incubated for 5 min., 10 min. and 60 min. under mild acid hydrolysis conditions. Roman numbers I-V indicate the elution position of I = desialylated diantennary structure, II = trisialylated triantennary structures (two isomers), III =

- 62 -

tenary structure, II = trisialylated triantennary structures (two isomers), III = tetrasialylated tetraantennary structure + 2 N-acetylactosamine repeats, IV = tetrasialylated tetraantennary structure + 1 N-acetylactosamine repeat; V = tetrasialylated tetraantennary structure + without N-acetylactosamine repeat. The elution  
 5 area of oligosaccharides structures without, with 1-4 sialic acid is indicated by brackets.

### Figure 11

10 HPAEC-PAD of N-linked oligosaccharides after desialylation; the elution position of N-acetylneuraminic acid is shown; numbers 1-9 indicate the elution position of standard oligosaccharides: 1 = diantennary; 2 = triantennary (2-4 isomer), 3 = triantennary (2-6 isomer); 4 = tetraantennary; 5 = triantennary plus 1 repeat; 6 = tetraantennary plus 1 repeat; 7 = triantennary plus 2 repeats; 8 = tetraantennary  
 15 plus 2 repeats and 9 = tetraantennary plus 3 repeats.

### Figure 12

SDS-PAGE analysis of mild treated and untreated EPO which were subjected to  
 20 periodate oxidation of sialic acid residues. 1 = periodate oxidized without acid treatment; 2 = periodate oxidized 5 min. acid treatment; 3 = periodate oxidized and acid treatment 10 min.; 4 = periodate oxidized without acid treatment; 5 = BRP EPO standard without periodate and without acid treatment.

### 25 Figure 13

HPAEC-PAD pattern of native oligosaccharides isolated from untreated EPO and from EPO incubated for 5 min and 10 min under mild acid hydrolysis conditions and subsequent periodate treatment. The elution area of oligosaccharides structures without and with 1-4 sialic acid is indicated by brackets 1-5.  
 30

**Figure 14**

SDS-PAGE analysis of the time course of HES-modification of EPO-GT-1-A: 20  $\mu$ g aliquots of EPO-GT-1-A were reacted with hydroxylamine-modified HES derivative X for 30 min, 2, 4 and 17 hours. Lane 1 = 30 min reaction time; lane 2 = 2 hour reaction time; lane 3 = 4 hours reaction time; lane 4 = 17 hours reaction time; lane 5 = EPO-GT-1-A without HES-modification. Left figure shows the shift in mobility of EPO-GT-1-A with increasing incubation time in the presence of the with hydroxylamine-modified HES derivative (flow rate: 1 ml·min<sup>-1</sup>) X: Lane 1 = 30 min reaction time; lane 2 = 2 hours reaction time; lane 3 = 4 hours reaction time, lane 4 = 17 hours reaction time; lane 5 = EPO-GT-1-A with HES modification. The figure on the right shows analysis of the same samples after their treatment with N-glycosidase.

**Figure 15**

SDS-PAGE analysis of Q-Sepharose fractions of HES-EPO conjugates. Each 1% of the flow-through and 1% of the fraction eluting at high salt concentrations were concentrated in a Speed Vac concentrator and were loaded onto the gels in sample buffer. EPO protein was stained by Coomassie Blue. A = sample I; B = sample II; C = sample III; K = control EPO-GT-1; A1, B1, C1 and K1 indicated the flow-through fraction; A2, B2, C2 and K2 indicates the fraction eluted with high salt concentration.

**Figure 16a**

SDS-PAGE analysis of HES-modified EPO sample A2 (see Fig. 15), control EPO sample K2 and EPO-GT-1-A EPO preparation were digested in the presence of N-glycosidase in order to remove N-linked oligosaccharides. All EPO samples showed the mobility shift towards low molecular weight forms lacking or containing O-glycan. A lower ratio of the O-glycosylated and nonglycosylated protein



- 64 -

band was observed for the HES-modified EPO sample A2 after de-N-glycosylation and a diffuse protein band was detected around 30 KDa, presumably representing HES-modification at the sialic acid of O-glycan residue (see arrow marked by an asterisk).

5

**Figure 16b**

SDS-PAGE analysis after mild hydrolysis of HES-modified EPO sample A2 (see Fig. 15), control EPO sample K2 and EPO-GT-1A which were untreated or digested in the presence of N-glycosidase in order to remove N-linked oligosaccharides (see Figure 16a). Both high molecular weight form of A2 before and A after N.glycosidase treatment (see brackets with and without arrow) disappeared upon acid treatment of the samples. The BRP EPO standard which was run for comparison was not subjected to mild acid treatment.

15

**Figure 17**

HPAEC-PAD analysis of N-linked oligosaccharide material liberated from HES-modified sample A, from EPO-GT-1-A and from a control EPO sample incubated with unmodified HES (K). Roman numbers I-V indicate the elution position of I = disialylated diantennary structure, II = trisialylated triantennary structures (two isomers), III = tetrasialylated tetraantennary structure + 2 N-acetylglucosamine repeats, IV = tetrasialylated tetraantennary structure + 1 N-acetylglucosamine repeat, V = tetrasialylated tetraantennary structure + without N-acetylglucosamine repeat; brackets indicate the elution area of di-, tri- and tetrasialylated N-glycans as reported in the legends of Figs. 10 and 13.

20  
25**Figure 18**

HPAEC-PAD analysis of N-linked oligosaccharide material liberated from HES-modified sample A, from EPO-GT-1A and from a control EPO sample (K) incu-

30

bated with unmodified HES. The retention times of a mixture of standard oligosaccharides is shown: numbers 1-9 indicate the elution position of standard oligosaccharides: 1 = diantennary; 2 = triantennary (2-4 isomer); 3 = triantennary (2-6 isomer); 4 = tetraantennary; 5 = triantennary plus 1 repeat; 6 = tetraantennary plus 1 repeat; 7 = triantennary plus 2 repeats; 8 = tetraantennary plus 2 repeats and 9 = tetraantennary plus 3 repeats.

### Figures 19 to 25

Figures 19 to 25 represent MALDI/TOF mass spectra of the enzymatically liberated and chemically desialylated N-glycans isolated from HES-modified EPO and control EPO preparations. Major signals at  $m/z$  1809.7, 2174.8, 2539.9, 2905.0 and 3270.1 ( $[M+Na]^+$ ) correspond to di- to tetraantennary complex-type N-glycan structures with no, one or two N-acetylglucosamine repeats accompanied by weak signals due to loss of fucose or galactose which are due to acid hydrolysis conditions employed for the desialylation of samples for MS analysis.

### Figure 19

MALDI/TOF spectrum: desialylated oligosaccharides of HES-modified EPO A2.

### Figure 20

MALDI/TOF spectrum: desialylated oligosaccharides of EPO GT-1-A.

### Figure 21

MALDI/TOF spectrum: desialylated oligosaccharides of EPO K2.

### Figure 22

MALDI/TOF spectrum: desialylated oligosaccharides of EPO-GT-1.

**Figure 23**

- 5 MALDI/TOF spectrum: desialylated oligosaccharides of EPO-GT-1 subjected to acid hydrolysis for 5 min.

**Figure 24**

- 10 MALDI/TOF spectrum: desialylated oligosaccharides of EPO-GT-1 subjected to acid hydrolysis for 10 min.

**Figure 25**

- 15 MALDI/TOF spectrum: desialylated oligosaccharides of EPO-GT-1 subjected to acid hydrolysis for 60 min.

## Examples

### Example 1

#### 5 Production of recombinant EPO

##### A) Production in mammalian cells

Recombinant EPO was produced in CHO cells as follows

10

A plasmid harbouring the human EPO cDNA was cloned into the eukaryotic expression vector (pCR3 and named afterwards pCREPO). Site directed mutagenesis was performed using standard procedures as described (Grabenhorst, Nimtz, Costa et al., 1998, In vivo specificity of human alpha 1,3/4-fucosyltransferases  
15 III-VII in the biosynthesis of Lewis(x) and sialyl Lewis(x) motifs on complex-type N-glycans -Coexpression studies from BHK-21 cells together with human beta-trace protein, J. Biol. Chem., 273(47), 30985-30994).

CHO cells stably expressing human EPO or amino acid variants (e.g. Cys-  
20 29→Ser/Ala, or Cys-33→Ser/Ala , Ser-126→Ala etc.) thereof were generated with the calcium phosphate precipitation method and selected with G418-sulfate as described (Grabenhorst et al.). Three days after transfection, the cells were subcultivated 1:5 and selected in DMEM containing 10% FBS and 1.5 g/liter G418 sulfate.

25

Using this selection procedure, usually 100-500 clones survived and where propagated in selection medium for a further time period of 2-3 weeks. Cell culture supernatants of confluent growing monolayers were then analyzed for EPO expression levels by Western blot analysis and by IEF/Western Blot analysis.

30

- 68 -

EPO was produced from stable subclones in spinner flasks or in 2l perfusion reactors. Different glycoforms of EPO with different amounts of NeuAc (e.g. 2-8, 4-10, 8-12 NeuAc residues) were isolated according to published protocols using combinations various chromatographic procedures as described below.

5

#### Literature:

Grabenhorst, Conradt, 1999, The cytoplasmic, transmembrane, and stem regions of glycosyltransferases specify their in vivo functional sublocalization and stability in the Golgi., J Biol Chem., 274(51), 36107-16; Grabenhorst, Schlenke, Pohl, 10 Nimtz, Conradt, 1999, Genetic engineering of recombinant glycoproteins and the glycosylation pathway in mammalian host cells, Glycoconj J., 16(2), 81-97; Mueller, Schlenke, Nimtz, Conradt, Hauser, 1999, Recombinant glycoprotein product quality in proliferation-controlled BHK-21 cells, Biotechnology and bioengineering, 15 65(5), 529-536; Schlenke, Grabenhorst, Nimtz, Conradt, 1999, Construction and characterization of stably transfected BHK-21 cells with human-type sialylation characteristic, Cytotechnology, 30(1-3), 17-25.

#### B) Production in insect cells

20

Recombinant human EPO was produced from insect cell lines SF9 and SF 21 after infection of cells with recombinant baculovirus vector containing the human EPO cDNA under control of the polyhedrin promoter as described in the literature.

25

Cells grown in serum-free culture medium were infected at cell density of  $2 \times 10^6$  or  $1 \times 10^7$  cells per mL and EPO titers were determined every day in the cell culture supernatants. EPO was purified by Blue sepharose chromatography, ion-exchange chromatography on Q-Sepharose and finally RP-HPLC on C<sub>4</sub>-Phase.

30

- 69 -

Purity of the product was checked by SDS-PAGE and N-terminal sequencing .  
Detailed carbohydrate structural analysis (N- and O-glycosylation) was performed according to published procedures.

## 5 Literature:

- Grabenhorst, Hofer, Nimtz, Jager, Conradt, 1993, Biosynthesis and secretion of human interleukin 2 glycoprotein variants from baculovirus-infected Sf21 cells. Characterization of polypeptides and posttranslational modifications, Eur J Biochem., 215(1), 189-97; Quelle, Caslake, Burkert, Wojchowski, 1989, High-level expression and purification of a recombinant human erythropoietin produced using a baculovirus vector, Blood, 74(2), 652-7

## 15 Example 2


### Formation of reactive HES derivatives

#### 1. SH-reactive HES

20

##### 1.1 Reaction of EMCH with Oxo-HES12KD to form SH-reactive HES12KD

B



- 70 -

0.144 g (0.012 mmol) of Oxo-HES12KD (Fresenius German Patent DE 196 28 705 A1) were dissolved in 0.3 mL absolute dimethyl sulfoxide (DMSO) and were added dropwise under nitrogen to a mixture of 34 mg (0.15 mmol) EMCH (Perbio Science, Deutschland GmbH, Bonn, Germany) in 1.5 mL DMSO. After stirring for 19 h at 60°C the reaction mixture was added to 16 mL of a 1:1 mixture of ethanol and acetone. The precipitate was collected by centrifugation, redissolved in 3 mL DMSO and again precipitated as described. The SH-reactiv-HES12KD B was obtained by centrifugation and drying in vacuo. The conjugation reaction with Thio-EPO is described in Example 3, 2.2.

#### Alternatives:

In this reaction, all cross-linkers can be used, which exhibit a hydrazide- and a maleimide function, separated by a spacer. Further examples for molecules of that group, available from Perbio Science, Deutschland GmbH, Bonn, Germany, are shown in table 2; marked with an "A". Furthermore, another group of cross-linkers exhibiting an activated disulfide function instead of a maleimide function could also be used.

### 1.2 Halogenacetamide-derivatives of HES glycosylamines

#### a) Glycosylamine-formation <sup>1</sup>

A 1 mg sample of HES12KD was dissolved in 3 mL of saturated ammonium bicarbonate. Additional solid ammonium bicarbonate was then added to maintain saturation of the solution during incubation for 120 h at 30°C. The Amino-HES12KD C was desalted by direct lyophilization of the reaction mixture.

---

<sup>1</sup>Manger, Wong, Rademacher, Dwek, 1992, Biochemistry, 31, 10733-10740; Manger,

- 71 -

## b) Acylation of the glycosylamine C with chloroacetic acid anhydride

5 A 1 mg sample of Amino-HES12KD C was dissolved in 1 mL of 1 M sodium bicarbonate and cooled on ice. To this was added a crystal of solid chloroacetic acid anhydride (~5 mg), and the reaction mixture was allowed to warm to room temperature. The pH was monitored and additional base was added if the pH dropped below 7.0. After two hours at room temperature a second aliquot of base and anhydride was added. After six hours the product Chloroacetamide-HES D1 (X = Cl) was desalted by passage over  
10 a mixed bed Amberlite MB-3(H)(OH) ion exchange resins.

c) Acylation of the glycosylamine with bromoacetic anhydride<sup>2</sup>

15 Bromoacetic anhydride was prepared as described by Thomas.<sup>3</sup> A 1 mg sample of amino-HES12KD C was dissolved in 0.1 mL of dry DMF and cooled on ice and 5 mg bromoacetic anhydride was added. The reaction mixture was brought slowly to room temperature and the solution was stirred for 3 h. The reaction mixture was added to 1 mL of a 1:1 mixture of ethanol and acetone with -20 °C. The precipitate was collected by centrifugation, redissolved in 0.1 mL DMF and again precipitated as described.  
20 The Bromoacetamide-HES D2 (X = Br) was obtained by centrifugation and drying in vacuo. The conjugation reaction with Thio-EPO is described in Example 3, 1.2.

---


Rademacher, Dwek, 1992, *Biochemistry*, 31, 10724-10732

<sup>2</sup>Black, Kiss, Tull, Withers, 1993, *Carbohydr. Res.*, 250, 195

<sup>3</sup>Thomas, 1977, *Methodes Enzymol.*, 46, 362



- d) The corresponding Iodo-derivative **D3** ( $X = I$ ) was synthesised as described for **D2**. Instead bromoacetic anhydride N-succinimidyl iodoacetate was used and all steps were performed in the dark.



5

#### Alternatives:

For acylation of amino groups, other activated forms of halogen acidic acids can be used, e.g.

- -bromides or -chlorides
- 10 - esters, e.g. N-hydroxysuccinimide ester, esters with substituted phenoles (p-nitrophenole, pentafluorophenole, trichlorophenole etc)

Furthermore, all cross-linkers having an amino reactive group and a halogen acetyl function, separated by a spacer, could be used. An example thereof is SBAP. This molecule and others are available from Perbio Science Deutschland GmbH, Bonn, Germany. They are marked in table 2 with an "D". For the use as cross-linkers for the ligation of amino-HES with thio-EPO without isolation of the halogenacetamid-HES derivatives see remarks in example 3, 1.2.


### 20 1.3 Halogenacetamide-derivatives of Amino-HES <sup>E 1</sup>

- a) Reaction of 1,4-diaminobutane with Oxo-HES12KD to amino-HES12KD <sup>E 4</sup>

<sup>4</sup>S. Frie, Diplomarbeit, Fachhochschule Hamburg, 1998

- 73 -

1.44 g (0.12 mmol) of Oxo-HES12KD were dissolved in 3 mL dry dimethyl sulfoxide (DMSO) and were added dropwise under nitrogen to a mixture of 1.51 mL (15 mmol) 1,4-diaminobutane in 15 mL DMSO. After stirring for 19 h at 40°C the reaction mixture was added to 160 mL of a 1:1 mixture of ethanol and acetone. The precipitate Amino-HES12KD E was collected by centrifugation, redissolved in 40 mL of water and dialysed for 4 days against water (SnakeSkin dialysis tubing, 3.5 KD cut off, Perbio Science Deutschland GmbH, Bonn, Germany) and lyophilized.



b) Chloroacetamide-HES12KD F1 was prepared as described for Chloroacetamide-HES12KD D1 in 1.3 above.

c) Bromoacetamide-HES12KD F2 (X = Br) was prepared as described for Bromoacetamide-HES12KD D2 in 1.3 above. The conjugation reaction with Thio-EPO is described in Example 3, 1.2.

d) The corresponding Iodo-derivative F3 (X = I) was not isolated before its reaction with Thio-EPO. The experiment is described in Example 3, 1.1.

#### Alternatives:


See 1.2 above

## 2. CHO-Reactive HES

### 2.1 Hydrazide-HES


- 74 -

## a) Reaction of hydrazine with Oxo-HES12KD



1,44 g (0.12 mmol) of Oxo-HES12KD were dissolved in 3 mL absolute dimethyl sulfoxide (DMSO) and were added dropwise under nitrogen to a mixture of 0.47 mL (15 mmol) hydrazine in 15 mL DMSO. After stirring for 19 h at 40°C the reaction mixture was added to 160 mL of a 1:1 mixture of ethanol and acetone. The precipitated product J was collected by centrifugation, redissolved in 40 mL of water and dialysed for 2 days against a 0.5 % (v/v) triethylamine in water solution and for 2 days against water (SnakeSkin dialysis tubing, 3.5 KD cut off, Perbio Science Deutschland GmbH, Bonn, Germany) and lyophilized. The conjugation reaction with oxidised Glyco-EPO is described in Example 4, 2.2.

## b) Reaction of adipic dihydrazide with Oxo-HES12KD



1.74 g (15 mmol) adipic dihydrazide were dissolved in 20 mL absolute dimethyl sulfoxide (DMSO) at 65°C and 1,44 g (0.12 mmol) of Oxo-HES12KD, dissolved in 3 mL absolute DMSO were added dropwise under nitrogen. After stirring for 68 h at 60°C the reaction mixture was added to 200 mL of water. The solution containing L was dialysed for 2 days against a 0.5 % (v/v)

- 75 -

triethylamine in water solution and for 2 days against water (SnakeSkin dialysis tubing, 3.5 KD cut off, Perbio Science Deutschland GmbH, Bonn, Germany) and lyophilized. The conjugation reaction with oxidised Glyco-EPO is described in Example 4, 2.2.

5


#### Alternatives:

Furthermore, derivatives can be used, wherein 2 hydrazid groups are separated by any spacer.

### 10 3. Further Amino-HES12KD derivatives I and H<sup>1</sup>


Ammonolysis of **D** or **F** was performed separately by dissolving a 1 mg sample of each halogeneacetamide in 0.1 mL of saturated ammonium carbonate. Additional solid ammonium carbonate was then added to maintain saturation of the solution during incubation of 120 h at 30°C. The reaction mixture was added to 1 mL of a 1:1 mixture of ethanol and acetone with -20 °C. The precipitate was collected by centrifugation, redissolved in 0.05 mL water and again precipitated as described. The product aminoHES **H** or **I** was obtained by centrifugation and drying in vacuo. The conjugation reaction with oxidised Glyco-EPO is described in Example 4, 4.1.

20



### 4. Hydroxylamine-modified HES12KD K

- 76 -



O-[2-(2-aminoethoxy)-ethyl]-hydroxylamine was synthesized as described by Boturny et al in 2 steps from commercially available materials.<sup>5</sup> 1.44 g (0.12 mmol) of Oxo-HES12KD were dissolved in 3 mL absolute dimethyl sulfoxide (DMSO) and were added dropwise under nitrogen to a mixture of 2.04 g (15 mmol) O-[2-(2-aminoethoxy)-ethyl]-hydroxylamine in 15 mL DMSO. After stirring for 48 h at 65°C the reaction mixture was added to 160 mL of a 1:1 mixture of ethanol and acetone. The precipitated product K was collected by centrifugation, redissolved in 40 mL of water and dialysed for 4 days against water (SnakeSkin dialysis tubing, 3.5 KD cut off, Perbio Science Deutschland GmbH, Bonn, Germany) and lyophilized. The conjugation reaction with oxidised Glyco-EPO is described in Example 4, 3.1.

#### Alternatives:


- Furthermore, derivatives could be used, wherein the two hydroxylamine groups are separated by any spacer.

### **5. Thio-HES12KD**

#### **5.1 Addition to Oxo-HES12KD**

<sup>5</sup> Boturny, Boudali, Constant, Defrancq, Lhomme, 1997, *Tetrahedron*, 53, 5485

- 77 -

**M**

1,44 g (0.12 mmol) of Oxo-HES12KD were dissolved in 3 mL absolute dimethyl sulfoxide (DMSO) and were added to a mixture of 1.16 g (15 mmol) cysteamine in 15 mL DMSO under nitrogen dropwise. After stirring for 24 h at 40°C the reaction mixture was added to 160 mL of a 1:1 mixture of ethanol and acetone. The precipitated product **M** was collected by centrifugation, re-dissolved in 40 mL of water and dialysed for 2 days against a 0.5 % (v/v) triethylamine in water solution and for 2 days against water (SnakeSkin dialysis tubing, 3.5 KD cut off, Perbio Science Deutschland GmbH, Bonn, Germany) and lyophilized. The conjugation reaction with oxidised Glyco-EPO is described in Example 4, 2.1.

#### Alternatives:

Derivatives could be used, wherein the amino group and the thio-function are separated by any spacer. Furthermore, the amino group in the derivatives could be replaced by a hydrazine, a hydrazid or a hydroxylamine. The thio-function could be protected in the form of e.g. a disulfide or a trityl-derivative. However, in this case, a further deprotection step must be preformed before the conjugation, which would release a component being analogous to **M**.


## 20    5.2 Modifikation of Amino-HES12KD E, H or I

### a) Modification with SATA/SATP

- 78 -

1,44 g (0.12 mmol) of Amino-HES12KD E, H or I were dissolved in 3 mL absolute dimethyl sulfoxide (DMSO) and were added to a mixture of 139 mg (0.6 mmol) SATA in 5 mL DMSO under nitrogen dropwise. After stirring for 24 h at room temperature the reaction mixture was added to 160 mL of a 1:1 mixture of ethanol and acetone. The precipitated product N was collected by centrifugation, redissolved in 40 mL of water and dialysed for 2 days against water (SnakeSkin dialysis tubing, 3.5 KD cut off, Perbio Science Deutschland GmbH, Bonn, Germany) and lyophilized.

The deprotection was performed in a 50 mM sodium phosphate buffer, containing 25 mM EDTA and 0.5M hydroxylamine, pH7.5 for 2 hours at room temperature and the product O was purified by dialysis against a 0.1 M sodium acetate buffer pH 5.5, containing 1 mM EDTA. The deprotection reaction was performed immediately before the conjugation reaction which is described in Example 4, 2.1.



## b) Modification with SPDP

1,44 g (0.12 mmol) of Amino-HES12KD E, H or I were dissolved in 3 mL absolute dimethyl sulfoxide (DMSO) and were dropwise added to a mixture of 187 mg (0.6 mmol) SPDP in 5 mL DMSO under nitrogen. After stirring for 24 h at room temperature the reaction mixture was added to 160 mL of a 1:1 mixture of ethanol and acetone. The precipitated product P was collected by centrifugation, redissolved in 40 mL of water and dialysed for 2 days against water (SnakeSkin dialysis tubing, 3.5 KD cut off, Perbio Science Deutschland GmbH, Bonn, Germany) and lyophilized.

The deprotection was performed in a solution of 12 mg dithiothreitol (DTT) per 0.5 mL 100 mM sodiumacetate buffer, containing 100 mM sodium chloride at pH 4.5 for 30 min at room temperature and the product Q was purified by dialysis against a 0.1 M sodium acetate buffer pH 5.5, containing 1 mM EDTA. The deprotection reaction was performed immediately before the conjugation reaction which is described in Example 4, 2.1.

Alternatives:

For the conversion of amino- to thiol-groups, either in free form or protected, several reagents are available. After the modification, the products could be isolated. Alternatively, as accepted for the use of cross-linkers, they could be directly used for the conjugation reaction, preferably after a purification step. For the isolation and storage of thio-HES derivatives, the synthesis of thio-HES derivatives in a protected form may be useful. For this, all derivatives being analogous to SATA could be used, which have an active ester-function and a thioester-function, separated by any spacer. SATP, being a further member of this group, is found in table 2, marked with an "H". The derivatives being analogous to SPDP could have an active ester-function and a disulfide-function, separated by any spacer.



Further members of these groups are found in table 2, marked with an "F".  
Further analogous derivatives could have an active ester-function and a thiol-function, protected as a trityl derivative, separated by any spacer.

5

### **Example 3**

#### **Conjugation reactions with Thio-EPO**

- 10    **1. Reaction of Thio-EPO with a halogenacetamide-modified SH-reactive HES**

##### **1.1 Example Protocol 1**

- 15    Conjugation of ThioEPO to Amino-HES12KD (E, H or I) with a Cross-linker containing a NHS-active-ester and an iodoacetamide group, e.g. SIA.<sup>6</sup>

##### **Materials**

- 20    A. Borate buffer. Composition was 50 mM sodium borate, pH 8.3, 5 mM EDTA.  
B. PBS, phosphate buffered saline: 10 mM sodium phosphate, 150 mM NaCl, pH 7.4.  
C. AminoHES12KD E, H or I. Prepared at 1 mg/mL in borate buffer.  
25    D. Crosslinker stock solution: 14 mg SIA were dissolved in 1 mL DMSO  
E. D-Salt™ Dextran Desalting Columns, 2 x 5 mL bed volume (Perbio Science Deutschland GmbH, Bonn, Germany)  
F. Coomassie® Protein Assay Reagent (Perbio Science Deutschland GmbH, Bonn, Germany)

---

<sup>6</sup>Cumber, Forrester, Foxwell, Ross, Thorpe, 1985, *Methods Enzymol.*, 112, 207

- 81 -

G. ThioEPO solution: 5 mg/mL of ThioEPO 1 in borate buffer.

H. Microconcentrator: Microcon YM-3 (amicon, Milipore GmbH, Eschborn, Germany)

5      **Method**

100  $\mu$ L SIA solution was added to 400  $\mu$ L of the aminoHES12KD E solution and was allowed to react with agitation for 0.5 hours at room temperature. The excess crosslinker was removed by centrifuging the sample at 14000 x g for  
10      60 minutes using a microconcentrator. After centrifuging the sample was brought up to its original volume in borate buffer and this process was repeated two more times. The residual solution was added to 1 mL of ThioEPO solution and the reaction mixture was incubated for 16 hour at room temperature. Reactivity of the excess iodoacetamide was quenched at the end of the  
15      incubation period by the addition of cysteine to a final concentration of 10 mM. The reaction mixture was applied to a desalting column equilibrated with PBS buffer and the protein content of the fractions were monitored with a Coomassie protein assay reagent. All fractions containing the protein conjugate were pooled and the the conjugate was obtained by lyophilisation after  
20      dialysis against water over night.

Alternatives:

In this reaction, all cross-linkers could be used, which have a succinimide- or a sulfosuccinimide function and a iodoacetamide function separated by a  
25      spacer. Further examples are found in table 2. They are marked with a "C" and are avialable from Perbio Science Deutschland GmbH, Bonn, Germany.

**1.2 Example Protocol 2**

- 82 -

Conjugation of ThioEPO 1 to SH reactiveHES12KD bromoacetamide **D2**, **F2** or iodoacetamide **D3**.<sup>7</sup>

### Materials

5

A. Phosphate buffer. Composition was 100 mM sodium phosphate, pH 6.1, 5 mM EDTA.

B. PBS, phosphate buffered saline: 10 mM sodium phosphate, 150 mM NaCl, pH 7.4.

10 C. SH reactiveHES12KD bromoacetamide **D2**. Prepared at 10 mg/mL in phosphate buffer.

D. D-Salt™ Dextran Desalting Columns, 2 x 5 mL bed volume (Perbio Science Deutschland GmbH, Bonn, Germany)

15 E. Coomassie® Protein Assay Reagent (Perbio Science Deutschland GmbH, Bonn, Germany)

F. ThioEPO solution: 5 mg/mL of ThioEPO 1 in phosphate buffer.

### Method

20 1 mL SH reactiveHES12KD bromoacetamide **D2** solution and 1 mL of ThioEPO solution were combined and the reaction mixture was incubated for 48 hours at room temperature. Reactivity of the excess bromoacetamide was quenched at the end of the incubation period by the addition of cysteine to a final concentration of 10 mM. The reaction mixture was applied to a desalting  
25 column, equilibrated with PBS buffer. The protein content of the fractions were monitored with a Coomassie protein assay reagent, all fractions containing the protein conjugate were pooled and the the conjugate was obtained by lyophilisation after dialysis against water over night.

---

<sup>7</sup>de Valasco, Merkus, Anderton, Verheul, Lizzio, Van der Zee, van Eden, Hoffmann, Verhoef,

Alternatives:

Instead of the isolation of the SH reactive HES12KD-bromoacetamid **D2**, amino HES12KD (**E, H, I**) could be linked with a cross-linker via a succinimide- and a bromoacetamid function (see 1.1 above). SBAP is a member of this group of cross-linkers and is found in table 2, marked with a "D".

**2. Reaction of Thio-EPO with a maleimide-modified SH-reactive HES****2.1 Example Protocol 3**

Conjugation of ThioEPO to HES12KD with a cross-linker containing a hydrazide and a maleimide functional group, e.g.  $M_2C_2H$ .

**Materials**

- A.  $M_2C_2H$  stock: 10 mg/mL  $M_2C_2H$  in DMSO, prepared fresh
- B. HES12KD: 10 mg/mL in 0.1 M sodium acetate buffer, pH 5.5
- C. ThioEPO solution: 5 mg/mL of ThioEPO in phosphate/NaCl-buffer
- D. Phosphate/NaCl: 0.1 M sodium phosphate, 50 mM NaCl, pH 7.0
- E. Microconcentrator: Microcon YM-3 (Amicon, Milipore GmbH, Eschborn, Germany)
- F. Gel filtration column: for example, Sephadex® G-200 (1.5 x 45 cm)
- G. Coomassie® Protein Assay Reagent (Perbio Science Deutschland GmbH, Bonn, Germany)
- H. PBS, phosphate buffered saline: 10 mM sodium phosphate, 150 mM NaCl, pH 7.4.

**Method**

- 84 -

M<sub>2</sub>C<sub>2</sub>H solution was added to 400 µL of the HES12KD solution to a final concentration of 1 mM and was allowed to react with agitation for 2 hours at room temperature. The excess cross-linker was removed by centrifuging the sample at 14000 x g for 60 minutes using a microconcentrator. After centrifuging the sample was brought up to its original volume in phosphate/NaCl buffer and this process was repeated two more times. To the M<sub>2</sub>C<sub>2</sub>H-modified HES12KD 0.5 mL of ThioEPO solution was added and the reaction mixture was incubated for 2 hours at room temperature. Reactivity of the excess maleimides was quenched at the end of the incubation period by the addition of cysteine to a final concentration of 10 mM. The reaction mixture was applied to Sephadex® G-200 (1.5 x 45 cm) equilibrated with PBS buffer and 1 mL fractions were collected. The protein content of the fractions were monitored with a Coomassie protein assay reagent. All fractions containing the protein conjugate were pooled and the conjugate was obtained by lyophilisation after dialysis against water over night.

#### Procedural Notes

The hydrazone adduct is slightly less stable at extremes of pH. For applications that may involve treatment at low pH, we reduced the hydrazone by treatment with 30 mM sodium cyanoborohydride in PBS buffer to a hydrazine. For most applications, this extra step is unnecessary.

#### 2.2 Example Protocol 4

Conjugation of ThioEPO to Maleimido-HES12KD B.

#### Materials

A. Maleimido-HES12KD B: 10 mg/mL in 0.1 M sodium acetate buffer, pH 5.5

- 85 -

B. ThioEPO solution: 5 mg/mL of ThioEPO in phosphate/NaCl-buffer

C. Phosphate/NaCl: 0.1 M sodium phosphate, 50 mM NaCl, pH 7.0

D. Gel filtration column: for example, Sephadex® G-200 (1.5 x 45 cm)

5 E. Coomassie® Protein Assay Reagent (Perbio Science Deutschland GmbH,  
Bonn, Germany)

F. PBS, phosphate buffered saline: 10 mM sodium phosphate, 150 mM NaCl,  
pH 7.4.

### Method

10

1 mL SH-reactive-HES12KD B solution and 1 mL of ThioEPO 1 solution  
were combined and the reaction mixture was incubated for 2 hours at room  
temperature. Reactivity of the excess maleimides was quenched at the end of  
the incubation period by the addition of cysteine to a final concentration of 10  
15 mM. The reaction mixture was applied to Sephadex® G-200 (1.5 x 45 cm)  
equilibrated with PBS buffer and 1 mL fractions were collected. The protein  
content of the fractions were monitored with a Coomassie protein assay re-  
agent. All fractions containing the protein conjugate were pooled and the  
conjugate was obtained by lyophilisation after dialysis against water over  
20 night.

### 2.3 Example Protocol 12

25 Conjugation of ThioEPO to aminoHES12KD (E, H, I) with a Cross-linker  
containing a NHS-active-ester and a maleimide group, e.g. SMCC

### Materials

30 A: Microconcentrator: Microcon YM-10 (Amicon, Millipore GmbH, Eschborn,  
Germany).

B. PBS, phosphate buffered saline: 10 mM sodium phosphate, 150 mM NaCl,

pH 7.4.

C. AminoHES12KD E, H or I. Prepared at 10 mg/mL in PBS buffer.

D. SMCC solution: 1 mg SMCC were dissolved in 50  $\mu$ L DMSO

5 E. D-Salt™ Dextran Desalting Columns, 2 x 5 mL bed volume (Perbio Science Deutschland GmbH, Bonn, Germany)

F. Coomassie® Protein Assay Reagent (Perbio Science Deutschland GmbH, Bonn, Germany)

G. ThioEPO 1 solution: 5 mg/mL of ThioEPO 1 in PBS buffer.

## 10 Method

To 50  $\mu$ L SMCC solution 400  $\mu$ L of the aminoHES12KD E solution was added and the reaction mixture was allowed to react with agitation for 80 min at room temperature and for 10 min at 46°C. The excess crosslinker was removed by centrifugation of the reaction mixture through a microconcentrator at 14000 x g for 60 min. The volume was brought up to 450  $\mu$ L with PBS buffer and the process was repeated two more times. After the last centrifugation, the residual solution was brought up to 450  $\mu$ L with PBS and was added to 1 mL of ThioEPO solution and the reaction mixture was incubated for 16 hours at room temperature. Reactivity of the excess maleimide was quenched at the end of the incubation period by the addition of cysteine to a final concentration of 10 mM. The reaction mixture was applied to a desalting column equilibrated with PBS buffer. The protein content of the fractions were monitored with a Coomassie protein assay reagent, all fractions containing the protein conjugate were pooled and the conjugate was obtained by lyophilisation after dialysis against water over night.

15  
20  
25

### Alternatives:

In this reaction, all cross-linkers could be used which have a succinimide- or a sulfosuccinimide function and a maleimide-function, separated by a spacer.

30 Further examples for this group of molecules, available from Perbio Science

- 87 -

Deutschland GmbH, Bonn, Germany, are found in table, 2, marked with an "E". There is a further group of cross-linkers, which have instead of a maleimide function an activated disulfide function. These cross-linkers could also be used for the conjugation. However, the disulfide bond of the conjugate is cleavable under reductive conditions. Members of this group are marked in table 2 with a "F". A third group of cross-linkers uses instead of a maleimide function a vinylsulfon function as a SH-reactive group. A member of this group "SVSB" is marked in table 2 with a "G".

10

#### **Example 4**

#### **Conjugation reactions with oxidized EPO**

#### **1. Oxidation of Glyco-EPO**

#### **1.1 Oxidation of Glyco-EPO with sodium meta-periodate: Example Protocol**

5

20

#### **Materials**

A. Glyco-EPO solution: 10 mg/mL of Glyco-EPO in acetate buffer

B. Sodium meta-periodate solution: 10 mM or 100 mM sodium periodate in acetate buffer, prepared fresh. Keep in dark. Using these solutions, the final concentration of sodium periodate in the oxidation mixture is 1 mM or 10 mM, respectively.

25

C. acetate buffer: 0.1 M sodium acetate buffer, pH 5.5

D. Glycerol

E. Microconcentrator: Microcon YM-3 (amicon, Millipore GmbH, Eschborn, Germany)

30



## Method

All steps were performed in the dark.

5 To 1 mL of cold Glyco-EPO solution 0.1 mL of cold sodium meta-periodate solution were added and the the oxidation reaction was allowed to proceed for 1 hour in the dark. If the Glyco-EPO to be oxidized contained sialic acid residues, then the oxidation conditions were 1 mM sodium periodate, 0°C. Otherwise, 10 mM sodium periodate at room temperature was used. To stop the  
10 oxidation glycerol was added to a final concentration of 15 mM and incubated for 5 minutes at 0°C. The excess reagents and by-products were remove by centrifuging of the product at 14000 x g for 60 minutes using a microconcentrator. After centrifuging, sample was brought up to its original volume in the buffer used in the next modification step, e.g. in the acetate buffer. This process  
15 was repeated two more times.

### 1.2 Enzymatic oxidation of Glyco-EPO: Example Protocol 6

The enzymatic oxidation of EPO is described elsewhere (Chamow et al.,  
20 1992, J. Biol. Chem., 267, 15916-15922).

## 2. Conjugation with Hydrazine/Hydrazide-Derivatives

### 2.1 Example Protocol 7

25

Conjugation of oxidised Glyco-EPO to Thio-HES12KD M, O or Q with a Cross-linker containing a hydrazide and a maleimide functional group, e.g. M<sub>2</sub>C<sub>2</sub>H (Perbio Science, Deutschland GmbH, Bonn, Germany).

30

## Materials

- 89 -

- A.  $M_2C_2H$  stock: 10 mg/mL  $M_2C_2H$  in DMSO, prepared fresh
- B. Oxidised Glyco-EPO solution from 6.1.1: 5 mg/mL of Glyco-EPO in acetate buffer
- C. Thio-HES12KD M, O or Q: 10 mg/mL in phosphate/NaCl buffer
- 5 D. Acetate buffer: 0.1 M sodium acetate buffer, pH 5.5
- E. Phosphate/NaCl: 0.1 M sodium phosphate, 50 mM NaCl, pH 7.0
- F. Microconcentrator: Microcon YM-3 (amicon, Milipore GmbH, Eschborn, Germany)
- G. Gel filtration column: for example, Sephadex® G-200 (1.5 x 45 cm)
- 10 H. Coomassie® Protein Assay Reagent (Perbio Science Deutschland GmbH, Bonn, Germany)
- I. PBS, phosphate buffered saline: 10 mM sodium phosphate, 150 mM NaCl, pH 7.4

## 15 Method

$M_2C_2H$  stock solution was added to 1 mL of oxidized Glyco-EPO to a final concentration of 1 mM and was allowed to react with agitation for 2 hours at room temperature. The excess crosslinker was removed by centrifuging the sample at 14000 x g for 60 minutes using a microconcentrator. After centrifuging the sample was brought up to its original volume in phosphate/NaCl buffer and this process was repeated two more times. To the  $M_2C_2H$ -modified Glyco-EPO 1 mL of Thio-HES12KD M, O or Q solution was added and the reaction mixture was incubated for 16 hours at room temperature. Reactivity of the excess maleimides was quenched at the end of the incubation period by the addition of cysteine. The reaction mixture was applied to Sephadex® G-200 (1.5 x 45 cm) equilibrated with PBS and 1 mL fractions were collected. The protein content of the fractions were monitored with a Coomassie protein assay reagent, all fractions containing the protein conjugate were pooled and the conjugate was obtained by lyophilisation after dialysis against water over night.

20

25

30

### Procedural Notes

The hydrazone adduct is slightly less stable at extremes of pH. For applications that may involve treatment at low pH, we reduced the hydrazone by treatment with 30 mM sodium cyanoborohydride in PBS buffer to a hydrazine. For most applications, this extra step was unnecessary.

### 2.2 Example Protocol 8

Direct conjugation of oxidised Glyco-EPO to Hydrazido-HES12KD L or J.

#### Materials

- A. Oxidised Glyco-EPO solution from 6.1.1: 5 mg/mL of Glyco-EPO in acetate buffer
- B. Hydrazido-HES12KD L or J: 10 mg/mL in acetate buffer
- C. Acetate buffer: 0.1 M sodium acetate buffer, pH 5.5
- D. Gel filtration column: for example, Sephadex® G-200 (1.5 x 45 cm)
- E. Coomassie® Protein Assay Reagent (Perbio Science Deutschland GmbH, Bonn, Germany)
- F. PBS, phosphate buffered saline: 10 mM sodium phosphate, 150 mM NaCl, pH 7.4

#### Method

1 mL of Hydrazido-HES12KD L or J solution and 1 mL of oxidized Glyco-EPO solution were combined and the reaction mixture was allowed to react with agitation for 16 hours at room temperature. The reaction mixture was applied to Sephadex® G-200 (1.5 x 45 cm) equilibrated with PBS and 1 mL fractions were collected. The protein content of the fractions were monitored with a Coomassie protein assay reagent, all fractions containing the protein conju-

- 91 -

gate were pooled and the the conjugate was obtained by lyophilisation after dialysis against water over night. The result of the conjugation is shown in Figure 24. The observed molecular shift demonstrates that the conjugation was successful. The smear results from the heterogeneity of HES. Figure 25 demonstrates that HES is conjugated to a carbohydrate moiety of a carbohydrate side chain.

### Procedural Notes

The hydrazone adduct is slightly less stable at extremes of pH. For applications that may involve treatment at low pH, we reduced the hydrazone by treatment with 30 mM sodium cyanoborohydride in PBS buffer to a hydrazine. For most applications, this extra step was unnecessary.

### 3. Conjugation with Hydroxylamine-Derivatives<sup>8</sup>

#### 3.1 Example Protocol 9

##### Conjugation of oxidized Glyco-EPO to Hydroxylamino-HES12KD K

##### Materials

- A. Oxidised Glyco-EPO solution from 6.1.1: 5 mg/mL of Glyco-EPO in acetate buffer
- B. Hydroxylamino-HES12KD K: 10 mg/mL in acetate buffer
- C. Acetate buffer: 0.1 M sodium acetate buffer, pH 5.5
- D. Gel filtration column: for example, Sephadex® G-200 (1.5 x 45 cm)
- E. Coomassie® Protein Assay Reagent (Perbio Science Deutschland GmbH, Bonn, Germany)

---

<sup>8</sup>Rose, 1994, *Am. Chem. Soc.*, 116, 30

F. PBS, phosphate buffered saline: 10 mM sodium phosphate, 150 mM NaCl, pH 7.4

#### Method

5

1 mL of Hydroxylamino-HES12KD K solution and 1 mL of oxidized Glyco-EPO solution were combined and the reaction mixture was allowed to react with agitation for 16 hours at room temperature. The reaction mixture was applied to Sephadex® G-200 (1.5 x 45 cm) equilibrated with PBS and 1 mL fractions were collected. The protein content of the fractions were monitored with a Coomassie protein assay reagent, all fractions containing the protein conjugate were pooled and the conjugate was obtained by lyophilisation after dialysis against water over night. The result of the conjugation is shown in Figure 24. The observed molecular shift in lane 2 demonstrates that the conjugation was successful. The smear results from the heterogeneity of HES. Figure 25 demonstrates that HES is conjugated to a carbohydrate moiety of a carbohydrate side chain.

#### 20 Example 5

##### Characterisation of galactose oxidase treated EPO N-glycans

Recombinant EPO or partially desialylated EPO forms (generated by limited mild acid hydrolysis) were incubated with galactose oxidase in the presence of catalase at 37°C from 30 min - 4 hours at 37°C in 0.05 M Na-phosphate buffer pH 7.0. Progress of the reaction was monitored by removal of 50 µg aliquots of the EPO and subsequent treatment of the protein with polypeptide N-glycanase.

30 Liberated N-linked oligosaccharides (monitored by SDS-PAGE detection of the de-N-glycosylated polypeptide) were subjected to HPAEC-PAD mapping as de-

scribed ( Grabenhorst et al., 1999, Nimtz et al., 1993/1994; Schlenke et al., 1999) before and after removal of sialic acids. Quantitation of oxidised galactose residues in individual EPO oligosaccharides was performed by the typical shift observed in HPAEC-PAD and was also verified by MALDI/TOF MS of the oligosaccharide mixtures.

### Example 6

#### 10 Characterisation of HAS modified EPO

Separation of HAS modified EPO forms from nonreacted EPO and HAS-precursor molecules was achieved by gel filtration using e.g. Ultrogel AcA 44 / 54 or similar gel filtration media. Alternatively, nonreacted HAS was removed by immuno affinity isolation of EPO on a 4 mL column containing a monoclonal antibody coupled to Affigel (BioRad) and subsequent separation of unmodified EPO by gel filtration (e.g. using a matrix enabling the separation of globular proteins of a relative molecular mass between 20 kDa and 200 kDa ).

20 HAS modified EPOs were identified by SDS-PAGE analysis (using 12.5 or 10% acrylamide gels) through detection of their higher molecular weight compared to unmodified EPO upon staining of gels with Coomassie Brilliant Blue. The higher molecular weight of HAS modified EPO polypeptides was also identified by Western Blot analysis of samples using a polyclonal antibody raised against recombinant human EPO.

25 N-glycan modification of EPO forms was demonstrated by their successful removal from the EPO protein with polypeptide N-glycanase (recombinant N-glycosidase from Roche, Germany employing 25 units / mg EPO protein at 37°C for 16 hours); analysis by SDS-PAGE resulted in a typical shift of the EPO pro-

- 94 -

tein to a migration position of the N-glycosidase treated unmodified EPO of approximately 20 KDa.

Modification of the single desialylated and galactose oxidase treated EPO O-glycan at Ser 126 was demonstrated by SDS-PAGE migration of the de-N-glycosylated product by detection of its migration position compared to nonreacted de-N-glycosylated EPO. If required, modified EPO was fractionated by RP-HPLC on a C8-phase before SDS-PAGE analysis. HAS O-glycan modification of EPO was also analysed by  $\beta$ -elimination of the O-glycan and detection of the de-O-glycosylated form of EPO in Western blots using a polyclonal antibody raised against recombinant human EPO.

#### Example 7

##### Quantitation of EPO and modified EPO forms

EPO forms were quantitated by UV measurements as described in Ph.Eur (2000, Erythropoietini solutio concentrata, 1316, 780-785) and compared to the international BRP reference EPO standard. Alternatively, EPO concentrations were determined by a RP-HPLC assay using a RP-C4-column and absorption at 254 nm employing 20, 40, 80 and 120  $\mu$ g of the BRP standard EPO reference preparation for calibration.

#### Example 8

##### In-vitro biological activity of HES-modified recombinant human EPO:

Purified HES-modified EPO was tested for activity using the erythropoietin bioactivity assay as described by Krystal [Krystal, 1984, Exp. Hematol., 11, 649-660].

- 95 -

Anemia was induced in NMRI mice by treatment with phenylhydrazine hydrochloride and spleen cells were collected and used as described in [Fibi et al., 1991, Blood, 77, 1203 ff.]. Dilutions of EPO were incubated with  $3 \times 10^5$  cells/well in 96-well microtiter plates. After 24 hours at 37° C in a humidified atmosphere (5% CO<sub>2</sub>) cells were labelled for 4 hours with 1 µCi of <sup>3</sup>H-thymidine per well. Incorporated radioactivity was determined by liquid scintillation counting. The International reference EPO standard (BRP-standard) was used for comparison .

Alternatively, EPO bioactivity was measured by an in vitro assay using the EPO-sensitive cell line TF-1 (Kitamura et. al., [J. cell Phys., 140. 323-334]. Exponentially growing cells were washed free of growth factors and were incubated in the presence of serial dilutions of the EPO for further 48 hours. Proliferation of the cells was assessed by using the MTT reduction assay as described by Mosmann [Mosman, 1983, J.Immunol. Methods, 65, 55-63].

#### Example 9

##### In-vivo activity determination of EPO and HAS-modified EPO forms:

In vivo activity determinations were performed in normocythemic mice by measuring the increase of reticulocytes after 4 days after animals received the foreseen dose of EPO or modified EPO forms. Assays were performed using the BRP EPO standard which was calibrated against the WHO EPO standard in the polycythemic mouse assay. EPO samples were diluted in phosphate buffered saline containing 1 mg/ml of bovine serum albumin (Sigma).

0.5 ml of the EPO test solution in Dulbecco's buffered saline (corresponding to an EPO protein equivalent of a 100, 80, 40 or 20 IU/ml of the BRP standard EPO) were injected subcutaneously per animal. Blood samples were taken after 4 days



- 96 -

after injection and reticulocytes were stained with acridine orange; quantitation of reticulocytes was performed by flow-cytometry by counting a total of 30,000 blood cells within 5 hours after the blood sample was taken (see Ph. Eur, 2000, Erythropoietini solutio concentrata, 1316, pages 780-785) and European Pharmacopoeia (1996/2000, attachment 2002).

### Example 10

#### 10 In-vivo half-life Determinations

Rabbits were injected intravenously with specified amounts of unmodified or HAS-modified EPO forms. Blood samples were obtained at specified times, and serum was prepared. Serum erythropoietin levels were determined by *in vitro* bio-assay or by an EPO-specific commercial ELISA.

### Example 11

#### 20 In vivo pharmacokinetics

In mice: Each animal received 300 IU EPO/kg subcutaneously. Seven days after the post-treatment hematocrit of each animal was determined. A substantial increase in hematocrit was observed in all animals treated with modified EPO, an expected result in view of the relatively short half-life of untreated EPO. The mean change in hematocrit of the modified EPO-treated group was significantly different from that of the untreated EPO group and that of the control group.

In rabbits: Rabbits were treated with a single dose of unmodified or HAS-modified EPO corresponding to 200 or up to 800 ng/kg body weight. After 2, 6, 16, 24 and 48 hours blood samples were analyzed by using a commercial EPO-

- 97 -

specific ELISA for determination of plasma concentrations. Mean plasma EPO concentrations were determined and the average initial half-lives ( $\alpha$ -phase) and the terminal half-lives ( $\beta$ -phase) were calculated from the ELISA values as described: (Zettlmissl et al., 1989, J. Biol. Chem., 264, 21153-21159).

5

Literature:

Sytkowski, Lunn, Risinger, and Davis, 1999, An Erythropoietin Fusion Protein Comprised of Identical Repeating Domains Exhibits Enhanced Biological Properties, J. Biol. Chem., 274, 24773-24778.

10

**Example 12**

**Assessment of the in vitro biological activity of HES-modified recombinant human IL-2**


15

Modified IL2 was recovered by gel filtration on Ultrogel AcA 54. Aliquots of corresponding fraction were sterile filtrated and IL2 bioactivity was determined by using the IL2 dependent murine CTLL-2 cell line [Gillis, Ferm, On, and Smith, 1978, J. Immunol., 120, 2027-2032]. Activity was related to the international reference IL2 standard preparation.

20


**Example 13: Formation of hydroxyethyl starch derivatives by reductive amination of the non-oxidised reducing end**

**Example 13.1 Reaction of hydroxyethyl starch with 1,3-diamino-2-hydroxy propane**



- a) To a solution of 200 mg hydroxyethyl starch (HES18/0.4 (MW = 18,000 D, DS=0.4)) in 5 ml water, 0.83 mmol 1,3-diamino-2-hydroxy propane and 50 mg sodium cyanoborohydrate NaCNBH<sub>3</sub> were added. The resulting mixture was incubated at 80 °C for 17 h. The reaction mixture was added to 160 ml of a cold 1:1 mixture of acetone and ethanol (v/v). The precipitate was collected by centrifugation and dialysed for 4 d against water (SnakeSkin dialysis tubing, 3.5 KD cut off, Perbio Science Deutschland GmbH, Bonn, D), and lyophilized.
- b) Incubation of the mixture resulting from adding 0.83 mmol 1,3-diamino-2-hydroxy propane and 50 mg sodium cyanoborohydrate NaCNBH<sub>3</sub> to the solution of 200 mg hydroxyethyl starch was also possible and carried out at 25 °C for 3 d.

**Example 13.2 Reaction of hydroxyethyl starch with 1,2-dihydroxy-3-amino propane**



- a) To a solution of 200 mg hydroxyethyl starch (HES18/0.4 (MW = 18,000 D, DS=0.4)) in 5 ml water, 0.83 mmol 1,2-dihydroxy-3-amino propane and 50 mg sodium cyanoborohydrate NaCNBH<sub>3</sub> were added. The resulting mixture


- 99 -

was incubated at 80 °C for 17 h. The reaction mixture was added to 160 ml of a cold 1:1 mixture of acetone and ethanol (v/v). The precipitate was collected by centrifugation and dialysed for 4 d against water (SnakeSkin dialysis tubing, 3.5 KD cut off, Perbio Science Deutschland GmbH, Bonn, D), and lyophilized.

The reaction of 1,2-dihydroxy-3-amino propane with HES was confirmed indirectly by quantification of formaldehyde, resulting from the oxidative cleavage of the 1,2-diole in the reaction product by periodate as described by G. Avigad, Anal. Biochem. 134 (1983) 449-504.

- b) Incubation of the mixture resulting from adding 0.83 mmol 1,2-dihydroxy-3-amino propane and 50 mg sodium cyanoborohydrate  $\text{NaCNBH}_3$  to the solution of 200 mg hydroxyethyl starch was also possible and carried out at 25 °C for 3 d.

**Example 13.3 Reaction of hydroxyethyl starch with 1,4-diamino butane**




- a) To a solution of 200 mg hydroxyethyl starch (HES18/0.4 (MW = 18,000 D, DS=0.4)) in 5 ml water, 0.83 mmol 1,4-diamino butane and 50 mg sodium cyanoborohydrate  $\text{NaCNBH}_3$  were added. The resulting mixture was incubated at 80 °C for 17 h. The reaction mixture was added to 160 ml of a cold 1:1 mixture of acetone and ethanol (v/v). The precipitate was collected by centrifugation and dialysed for 4 d against water (SnakeSkin dialysis tubing, 3.5 KD cut off, Perbio Science Deutschland GmbH, Bonn, D), and lyophilized.
- b) Incubation of the mixture resulting from adding 0.83 mmol 1,4-diamino butane and 50 mg sodium cyanoborohydrate  $\text{NaCNBH}_3$  to the solution of

- 100 -

200 mg hydroxyethyl starch was also possible and carried out at 25 °C for 3 d.

**Example 13.4** Reaction of hydroxyethyl starch with 1-mercapto-2-amino ethane




- a) To a solution of 200 mg hydroxyethyl starch (HES18/0.4 (MW = 18,000 D, DS=0.4)) in 5 ml water, 0.83 mmol 1-mercapto-2-amino ethane and 50 mg sodium cyanoborohydrate NaCNBH<sub>3</sub> were added. The resulting mixture was incubated at 80 °C for 17 h. The reaction mixture was added to 160 ml of a cold 1:1 mixture of acetone and ethanol (v/v). The precipitate was collected by centrifugation and dialysed for 4 d against water (SnakeSkin dialysis tubing, 3.5 KD cut off, Perbio Science Deutschland GmbH, Bonn, D), and lyophilized.

- b) Incubation of the mixture resulting from adding 0.83 mmol 1-mercapto-2-amino ethane and 50 mg sodium cyanoborohydrate NaCNBH<sub>3</sub> to the solution of 200 mg hydroxyethyl starch was also possible and carried out at 25 °C for 3 d.

**Example 14:** Formation of hydroxyethyl starch derivatives by conjugation with the non-oxidised reducing end


**Example 14.1:** Reaction of hydroxyethyl starch with carbohydrazide



- 101 -

0.96 g of HES18/0.4 (MW = 18,000 D, DS=0.4) were dissolved in 8 ml aqueous 0.1 M sodium acetate buffer, pH 5.2, and 8 mmol carbohydrazide (Sigma Aldrich, Taufkirchen, D) were added. After stirring for 18 h at 25 °C, the reaction mixture was added to 160 ml of a cold 1:1 mixture of acetone and ethanol (v/v). The precipitated product was collected by centrifugation, re-dissolved in 40 ml water, and dialysed for 3 d against water (SnakeSkin dialysis tubing, 3.5 KD cut off, Perbio Science Deutschland GmbH, Bonn, D), and lyophilized.

**Example 14.2: Reaction of hydroxyethyl starch with adipic dihydrazide**




10

0.96 g of HES18/0.4 (MW = 18,000 D, DS=0.4) were dissolved in 8 ml aqueous 0.1 M sodium acetate buffer, pH 5.2, and 8 mmol adipic dihydrazide (Lancaster Synthesis, Frankfurt/Main, D) were added. After stirring for 18 h at 25 °C, the reaction mixture was added to 160 ml of a cold 1:1 mixture of acetone and ethanol (v/v). The precipitated product was collected by centrifugation, re-dissolved in 40 ml water, and dialysed for 3 d against water (SnakeSkin dialysis tubing, 3.5 KD cut off, Perbio Science Deutschland GmbH, Bonn, D), and lyophilized.

15


**Example 14.3: Reaction of hydroxyethyl starch with 1,4-phenylene-bis-3-thiosemicarbazide**



0.96 g of HES18/0.4 (MW = 18,000 D, DS=0.4) were dissolved in 8 ml aqueous 0.1 M sodium acetate buffer, pH 5.2, and 8 mmol 1,4-phenylene-bis-3-

thiosemicarbazide (Lancaster Synthesis, Frankfurt/Main, D) were added. After stirring for 18 h at 25 °C, 8 ml water was added to the reaction mixture, and the suspension was centrifugated for 15 min at 4,500 rpm. The clear supernatant was decanted and subsequently added to 160 ml of a cold 1:1 mixture of acetone and ethanol (v/v). The precipitated product was collected by centrifugation, re-dissolved in 40 ml water, and centrifugated for 15 min at 4,500 rpm. The clear supernatant was dialysed for 3 d against water (SnakeSkin dialysis tubing, 3.5 KD cut off, Perbio Science Deutschland GmbH, Bonn, D), and lyophilized.

**Example 14.4: Reaction of hydroxyethyl starch with O-[2-(2-aminooxy-ethoxy)-ethyl]-hydroxyl amine**




O-[2-(2-aminooxy-ethoxy)-ethyl]-hydroxyl amine was synthesized as described in Boturyn et al. Tetrahedron 53 (1997) p. 5485-5492 in 2 steps from commercially available materials.

0.96 g of HES18/0.4 (MW = 18,000 D, DS=0.4) were dissolved in 8 ml aqueous 0.1 M sodium acetate buffer, pH 5.2, and 8 mmol O-[2-(2-aminooxy-ethoxy)-ethyl]-hydroxyl amine were added. After stirring for 18 h at 25 °C, the reaction mixture was added to 160 ml of a cold 1:1 mixture of acetone and ethanol (v/v). The precipitated product was collected by centrifugation, re-dissolved in 40 ml water, and dialysed for 3 d against water (SnakeSkin dialysis tubing, 3.5 KD cut off, Perbio Science Deutschland GmbH, Bonn, D), and lyophilized.

**Example 15 Formation of hydroxyethyl starch derivatives by reaction with the oxidised reducing end**

**Example 15.1 Reaction of hydroxyethyl starch with carbohydrazide**


- 103 -



0.12 mmol Oxo-HES 10/0.4 (MW = 10,000 D, DS=0.4, prepared according to DE 196 28 705 A1) were dissolved in 3 ml absolute dimethyl sulfoxide (DMSO) and added dropwise under nitrogen to a mixture of 15 mmol of carbonylhydrazide (Sigma Aldrich, Taufkirchen, D) in 15 ml DMSO. After stirring for 88 h at 65 °C, the reaction mixture was added to 160 ml of a cold 1:1 mixture of acetone and ethanol (v/v). The precipitate was collected by centrifugation and was dialysed for 4 d against water (SnakeSkin dialysis tubing, 3.5 KD cut off, Perbio Science Deutschland GmbH, Bonn, D) and lyophilized.

10

**Example 15.2 Reaction of hydroxyethyl starch with 1,4-phenylene-bis-3-thiosemicarbazide**




0.12 mmol Oxo-HES 10/0.4 (MW = 10,000 D, DS=0.4, prepared according to DE 196 28 705 A1) were dissolved in 3 ml absolute dimethyl sulfoxide (DMSO) and added dropwise under nitrogen to a mixture of 15 mmol of 1,4-phenylene-bis-3-thiosemicarbazide (Lancaster Synthesis, Frankfurt/Main, D) in 15 ml DMSO. After stirring for 88 h at 65 °C, the reaction mixture was added to 160 ml of a cold 1:1 mixture of acetone and ethanol (v/v). The precipitate was collected by centrifugation and was dialysed for 4 d against water (SnakeSkin dialysis tubing, 3.5 KD cut off, Perbio Science Deutschland GmbH, Bonn, D) and lyophilized.

20

**Example 15.3 Reaction of hydroxyethyl starch with hydrazine**




- 104 -



1,44 g (0.12 mmol) of Oxo-HES 10/0.4 (MW = 10,000 D, DS=0.4, prepared according to DE 196 28 705 A1) were dissolved in 3 ml absolute dimethyl sulfoxide (DMSO) and were added dropwise under nitrogen to a mixture of 0.47 ml (15 mmol) hydrazine in 15 ml DMSO. After stirring for 19 h at 40°C the reaction mixture was added to 160 ml of a 1:1 mixture of ethanol and acetone (v/v). The precipitated product was collected by centrifugation, redissolved in 40 mL of water and dialysed for 2 days against a 0.5 % (v/v) triethylamine in water solution and for 2 days against water (SnakeSkin dialysis tubing, 3.5 KD cut off, Perbio Science Deutschland GmbH, Bonn, Germany) and lyophilized.

**Example 15.4 Reaction of hydroxyethyl starch with hydroxylamine**




O-[2-(2-aminoxy-ethoxy)-ethyl]-hydroxylamine was synthesized as described by Boturn et al in 2 steps from commercially available materials (Boturn, Boudali, Constant, Defrancq, Lhomme, 1997, *Tetrahedron*, 53, 5485).

1.44 g (0.12 mmol) of Oxo-HES 10/0.4 (MW = 10,000 D, DS=0.4, prepared according to DE 196 28 705 A1) were dissolved in 3 ml absolute dimethyl sulfoxide (DMSO) and were added dropwise under nitrogen to a mixture of 2.04 g (15 mmol) O-[2-(2-aminoxy-ethoxy)-ethyl]-hydroxylamine in 15 ml DMSO. After stirring for 48 h at 65°C the reaction mixture was added to 160 ml of a 1:1 mixture of ethanol and acetone (v/v). The precipitated product was collected by centrifugation, redissolved in 40 ml of water and dialysed for 4 days against water (SnakeSkin dialysis tubing, 3.5 KD cut off, Perbio Science Deutschland GmbH, Bonn, Germany) and lyophilized.

**Example 15.5 Reaction of hydroxyethyl starch with adepic dihydrazide**


- 105 -



1.74 g (15 mmol) sebacic dihydrazide were dissolved in 20 ml absolute dimethyl sulfoxide (DMSO) at 65°C and 1.44 g (0.12 mmol) of Oxo-HES 10/0.4 (MW = 10,000 D, DS=0.4, prepared according to DE 196 28 705 A1), dissolved in 3 ml absolute DMSO were added dropwise under nitrogen. After stirring for 68 h at 60°C the reaction mixture was added to 200 ml of water. The solution containing the reaction product was dialysed for 2 days against a 0.5 % (v/v) triethylamine in water solution and for 2 days against water (SnakeSkin dialysis tubing, 3.5 KD cut off, Perbio Science Deutschland GmbH, Bonn, Germany) and lyophilized.

10

#### Example 15.6 Reaction of hydroxyethyl starch with 1,4-diamino butane



1.44 g (0.12 mmol) of Oxo-HES 10/0.4 (MW = 10,000 D, DS=0.4, prepared according to DE 196 28 705 A1) were dissolved in 3 ml dry dimethyl sulfoxide (DMSO) and were added dropwise under nitrogen to a mixture of 1.51 ml (15 mmol) 1,4-diaminobutane in 15 ml DMSO. After stirring for 19 h at 40°C the reaction mixture was added to 160 ml of a 1:1 mixture of ethanol and acetone (v/v). The precipitate Amino-HES10KD/0.4 was collected by centrifugation, redissolved in 40 ml of water and dialysed for 4 days against water (SnakeSkin dialysis tubing, 3.5 KD cut off, Perbio Science Deutschland GmbH, Bonn, Germany) and lyophilized.

20

#### Example 16 Oxidation of erythropoietin

25

- 106 -

Oxidized erythropoietin was produced as described in Example 20. As oxidized erythropoietin, EPO-GT-1-A as described in Example 20.11(c) was used (EPO-GT-1 without acid hydrolysis, treated with mild periodate oxidation).

5

**Example 17: Conjugation of hydroxyethyl starch derivatives with oxidized erythropoietin of example 4**

**Example 17.1 Reaction of oxidized erythropoietin with the reaction product of example 14.1**

10

Oxidized EPO (1.055 µg/µl) in 20 mM PBS buffer was adjusted to pH 5.3 with 5 M sodium acetate buffer, pH 5.2. To 19 µl of the EPO solution, 18 µl of a solution of the HES derivate as produced according to example 14.1 (MW 18 kD; 18.7 µg/µl in 0.1 M sodium acetate buffer, pH 5.2) was added, and the mixture was incubated for 16 h at 25 °C. After lyophilisation, the crude product was analyzed by SDS-Page with NuPAGE 10% Bis-Tris Gels/MOPS buffer (Invitrogen, Carlsbad, CA, USA) as described in the instructions given by Invitrogen. The gel is stained with Roti-Blue Coomassie staining reagent (Roth, Karlsruhe, D) overnight.

20

The experimental result is shown in Fig. 3. A successful conjugation is indicated by the migration of the protein band to higher molecular weights. The increased bandwidth is due to the molecular weight distribution of the HES derivatives used and the number of HES derivatives linked to the protein.

25

**Example 17.2 Reaction of oxidized erythropoietin with the reaction product of example 14.3**

Oxidized EPO (1.055 µg/µl) in 20 mM PBS buffer was adjusted to pH 5.3 with 5 M sodium acetate buffer, pH 5.2. To 19 µl of the EPO solution, 18 µl of a solution

30

of the HES derivate as produced according to example 14.3 (MW 18 kD; 18.7 µg/µl in 0.1 M sodium acetate buffer, pH 5.2) was added, and the mixture was incubated for 16 h at 25 °C. After lyophilisation, the crude product was analyzed by SDS-Page with NuPAGE 10% Bis-Tris Gels/MOPS buffer (Invitrogen, Carls-  
bad, CA, USA) as described in the instructions given by Invitrogen.

**Example 17.3    Reaction of oxidized erythropoietin with the reaction product of example 14.4**

Oxidized EPO (1.055 µg/µl) in 20 mM PBS buffer was adjusted to pH 5.3 with 5 M sodium acetate buffer, pH 5.2. To 19 µl of the EPO solution, 18 µl of a solution of the HES derivate as produced according to example 14.4 (MW 18 kD; 18.7 µg/µl in 0.1 M sodium acetate buffer, pH 5.2) was added, and the mixture was incubated for 16 h at 25 °C. After lyophilisation, the crude product was analyzed by SDS-Page with NuPAGE 10% Bis-Tris Gels/MOPS buffer (Invitrogen, Carls-  
bad, CA, USA) as described in the instructions given by Invitrogen. The gel is stained with Roti-Blue Coomassie staining reagent (Roth, Karlsruhe, D) over-  
night.

The experimental result is shown in Fig. 4. A successful conjugation is indicated by the migration of the protein band to higher molecular weights. The increased bandwidth is due to the molecular weight distribution of the HES derivatives used and the number of HES derivatives linked to the protein.

**Example 17.4    Reaction of oxidized erythropoietin with the reaction product of example 15.1**

Oxidized EPO (1.055 µg/µl) in 20 mM PBS buffer was adjusted to pH 5.3 with 5 M sodium acetate buffer, pH 5.2. To 19 µl of the EPO solution, 18 µl of a solution of the HES derivate as produced according to example 15.1 (MW 10 kD; 18.7 µg/µl in 0.1 M sodium acetate buffer, pH 5.2) was added, and the mixture was

- 108 -

incubated for 16 h at 25 °C. After lyophilisation, the crude product was analyzed by SDS-Page with NuPAGE 10% Bis-Tris Gels/MOPS buffer (Invitrogen, Carlsbad, CA, USA) as described in the instructions given by Invitrogen. The gel is stained with Roti-Blue Coomassie staining reagent (Roth, Karlsruhe, D) overnight.

The experimental result is shown in Fig. 5. A successful conjugation is indicated by the migration of the protein band to higher molecular weights. The increased bandwidth is due to the molecular weight distribution of the HES derivatives used and the number of HES derivatives linked to the protein.

**Example 17.5    Reaction of oxidized erythropoietin with the reaction product of example 15.2**

Oxidized EPO (1.055 µg/µl) in 20 mM PBS buffer was adjusted to pH 5.3 with 5 M sodium acetate buffer, pH 5.2. To 19 µl of the EPO solution, 18 µl of a solution of the HES derivate as produced according to example 15.1 (MW 10 kD; 18.7 µg/µl in 0.1 M sodium acetate buffer, pH 5.2) was added, and the mixture was incubated for 16 h at 25 °C. After lyophilisation, the crude product was analyzed by SDS-Page with NuPAGE 10% Bis-Tris Gels/MOPS buffer (Invitrogen, Carlsbad, CA, USA) as described in the instructions given by Invitrogen. The gel is stained with Roti-Blue Coomassie staining reagent (Roth, Karlsruhe, D) overnight.

The experimental result is shown in Fig. 5. successful conjugation is indicated by the migration of the protein band to higher molecular weights. The increased bandwidth is due to the molecular weight distribution of the HES derivatives used and the number of HES derivatives linked to the protein.


**Example 18    Formation of Thio-EPO by reduction of erythropoietin**

- 109 -

241.5 µg erythropoietin (EPO-GT-1, see Example 20) in 500 µl of a 0.1 M sodium borate buffer, 5 mM EDTA, 10 mM DTT (Lancaster, Morcambe, UK), pH 8.3, were incubated for 1 h at 37 °C. The DTT was removed by centrifugal filtration with a VIVASPIN 0.5 ml concentrator, 10 KD MWCO (VIVASCIENCE, Hannover, D) at 13,000 rpm, subsequent washing 3 times with the borate buffer and twice with a phosphate buffer (0.1 M, 9.15 M NaCl, 50 mM EDTA, pH 7.2).

10 **Example 19: Conjugation of hydroxyethyl starch derivatives with thio-erythropoietin using a crosslinking compound**

In each of the following examples, N-(alpha-maleimidoacetoxy) succinimide ester (AMAS)



15 was used as crosslinking compound.

**Example 19.1 Reaction of thio-erythropoietin with the reaction product of example 14.1 and the crosslinking compound**

20 To 50 nmol HES derivate as produced according to example 14.1 and dissolved in 200 µl of a 0.1 M sodium phosphate buffer (0.1 M, 9.15 M NaCl, 50 mM EDTA, pH 7.2), 10 µl of a solution of 2.5 µmol AMAS (Sigma Aldrich, Taufkirchen, D) in DMSO were added. The clear solution was incubated for 80 min at 25 °C and 20 min at 40 °C. Remaining AMAS was removed by centrifugal filtration with a  
25 VIVASPIN 0.5 ml concentrator, 5 KD MWCO (VIVASCIENCE, Hannover, D) at 13,000 rpm, washing 4 times and 30 min with the phosphate buffer.

- 110 -

To the residual solution, 15 µg of ThioEPO as produced according to example 18 (1 µg/µl in phosphate buffer) were added, and the mixture was incubated for 16 h at 25 °C. After lyophilisation, the crude product was analysed by SDS-Page with  
5 NuPAGE 10% Bis-Tris Gels/MOPS buffer (Invitrogen, Carlsbad, USA) as described in the instructions given by Invitrogen. The gel is stained with Roti-Blue Coomassie staining reagent (Roth, Karlsruhe, D) overnight.

The experimental result is shown in Fig. 6. A successful conjugation is indicated  
10 by the migration of the protein band to higher molecular weights. The increased bandwidth is due to the molecular weight distribution of the HES derivatives used and the number of HES derivatives linked to the protein.

**Example 19.2 Reaction of thio-erythropoietin with the reaction product of  
15 example 14.2 and the crosslinking compound**

To 50 nmol HES derivate as produced according to example 14.2 and dissolved in 200 µl of a 0.1 M sodium phosphate buffer (0.1 M, 9.15 M NaCl, 50 mM EDTA, pH 7.2), 10 µl of a solution of 2.5 µmol AMAS (Sigma Aldrich, Taufkirchen, D)  
20 in DMSO were added. The clear solution was incubated for 80 min at 25 °C and 20 min at 40 °C. Remaining AMAS was removed by centrifugal filtration with a VIVASPIN 0.5 ml concentrator, 5 KD MWCO (VIVASCIENCE, Hannover, D) at 13,000 rpm, washing 4 times and 30 min with the phosphate buffer.

25 To the residual solution, 15 µg of ThioEPO as produced according to example 18 (1 µg/µl in phosphate buffer) were added, and the mixture was incubated for 16 h at 25 °C. After lyophilisation, the crude product was analysed by SDS-Page with NuPAGE 10% Bis-Tris Gels/MOPS buffer (Invitrogen, Carlsbad, USA) as described in the instructions given by Invitrogen. The gel is stained with Roti-Blue  
30 Coomassie staining reagent (Roth, Karlsruhe, D) overnight.

- 111 -

The experimental result is shown in Fig 7. A successful conjugation is indicated by the migration of the protein band to higher molecular weights. The increased bandwidth is due to the molecular weight distribution of the HES derivatives used and the number of HES derivatives linked to the protein.

5

**Example 19.3    Reaction of thio-erythropoietin with the reaction product of example 14.3 and the crosslinking compound**

To 50 nmol HES derivate as produced according to example 14.3 and dissolved in  
10 200 µl of a 0.1 M sodium phosphate buffer (0.1 M, 9.15 M NaCl, 50 mM EDTA, pH 7.2), 10 µl of a solution of 2.5 µmol AMAS (Sigma Aldrich, Taufkirchen, D) in DMSO were added. The clear solution was incubated for 80 min at 25 °C and 20 min at 40 °C. Remaining AMAS was removed by centrifugal filtration with a VIVASPIN 0.5 ml concentrator, 5 KD MWCO (VIVASCIENCE, Hannover, D)  
15 at 13,000 rpm, washing 4 times and 30 min with the phosphate buffer.

To the residual solution, 15 µg of ThioEPO as produced according to example 18 (1 µg/µl in phosphate buffer) were added, and the mixture was incubated for 16 h at 25 °C. After lyophilisation, the crude product was analysed by SDS-Page with  
20 NuPAGE 10% Bis-Tris Gels/MOPS buffer (Invitrogen, Carlsbad, USA) as described in the instructions given by Invitrogen. The gel is stained with Roti-Blue Coomassie staining reagent (Roth, Karlsruhe, D) overnight.

The experimental result is shown in Fig. 7. A successful conjugation is indicated  
25 by the migration of the protein band to higher molecular weights. The increased bandwidth is due to the molecular weight distribution of the HES derivatives used and the number of HES derivatives linked to the protein.

**Example 19.4    Reaction of thio-erythropoietin with the reaction product of example 14.4 and the crosslinking compound**

30



- 112 -

To 50 nmol HES derivate as produced according to example 14.4 and dissolved in 200 µl of a 0.1 M sodium phosphate buffer (0.1 M, 9.15 M NaCl, 50 mM EDTA, pH 7.2), 10 µl of a solution of 2.5 µmol AMAS (Sigma Aldrich, Taufkirchen, D) in DMSO were added. The clear solution was incubated for 80 min at 25 °C and  
5 20 min at 40 °C. Remaining AMAS was removed by centrifugal filtration with a VIVASPIN 0.5 ml concentrator, 5 KD MWCO (VIVASCIENCE, Hannover, D) at 13,000 rpm, washing 4 times and 30 min with the phosphate buffer.

To the residual solution, 15 µg of ThioEPO as produced according to example 18  
10 (1 µg/µl in phosphate buffer) were added, and the mixture was incubated for 16 h at 25 °C. After lyophilisation, the crude product was analysed by SDS-Page with NuPAGE 10% Bis-Tris Gels/MOPS buffer (Invitrogen, Carlsbad, USA) as described in the instructions given by Invitrogen. The gel is stained with Roti-Blue Coomassie staining reagent (Roth, Karlsruhe, D) overnight.

15 The experimental result is shown in Fig 6. A successful conjugation is indicated by the migration of the protein band to higher molecular weights. The increased bandwidth is due to the molecular weight distribution of the HES derivatives used and the number of HES derivatives linked to the protein.

20

**Example 19.5 Reaction of thio-erythropoietin with the reaction product of example 13.1 and the crosslinking compound**

To 50 nmol HES derivate as produced according to example 13.1, at incubation  
25 conditions of 80 °C and 17 h as well as of 25 °C and 3 d, and dissolved in 200 µl of a 0.1 M sodium phosphate buffer (0.1 M, 9.15 M NaCl, 50 mM EDTA, pH 7.2), 10 µl of a solution of 2.5 µmol AMAS (Sigma Aldrich, Taufkirchen, D) in DMSO were added. The clear solution was incubated for 80 min at 25 °C and 20 min at 40 °C. Remaining AMAS was removed by centrifugal filtration with a  
30 VIVASPIN 0.5 ml concentrator, 5 KD MWCO (VIVASCIENCE, Hannover, D) at 13,000 rpm, washing 4 times and 30 min with the phosphate buffer.

To the residual solution, 15 µg of ThioEPO as produced according to example 18 (1 µg/µl in phosphate buffer) were added, and the mixture was incubated for 16 h at 25 °C. After lyophilisation, the crude product was analysed by SDS-Page with  
5 NuPAGE 10% Bis-Tris Gels/MOPS buffer (Invitrogen, Carlsbad, USA) as described in the instructions given by Invitrogen. The gel is stained with Roti-Blue Coomassie staining reagent (Roth, Karlsruhe, D) overnight.

The experimental result is shown in Fig. 7. A successful conjugation is indicated  
10 by the migration of the protein band to higher molecular weights. The increased bandwidth is due to the molecular weight distribution of the HES derivatives used and the number of HES derivatives linked to the protein.

**Example 19.6 Reaction of thio-erythropoietin with the reaction product of  
15 example 13.3 and the crosslinking compound**

To 50 nmol HES derivate as produced according to example 13.3, at incubation conditions of 80 °C and 17 h as well as of 25 °C and 3 d, and dissolved in 200 µl of a 0.1 M sodium phosphate buffer (0.1 M, 9.15 M NaCl, 50 mM EDTA, pH  
20 7.2), 10 µl of a solution of 2.5 µmol AMAS (Sigma Aldrich, Taufkirchen, D) in DMSO were added. The clear solution was incubated for 80 min at 25 °C and 20 min at 40 °C. Remaining AMAS was removed by centrifugal filtration with a VIVASPIN 0.5 ml concentrator, 5 KD MWCO (VIVASCIENCE, Hannover, D) at 13,000 rpm, washing 4 times and 30 min with the phosphate buffer.

25 To the residual solution, 15 µg of ThioEPO as produced according to example 18 (1 µg/µl in phosphate buffer) were added, and the mixture was incubated for 16 h at 25 °C. After lyophilisation, the crude product was analysed by SDS-Page with NuPAGE 10% Bis-Tris Gels/MOPS buffer (Invitrogen, Carlsbad, USA) as described in the instructions given by Invitrogen. The gel is stained with Roti-Blue  
30 Coomassie staining reagent (Roth, Karlsruhe, D) overnight.

The experimental result is shown in Fig 7. A successful conjugation is indicated by the migration of the protein band to higher molecular weights. The increased bandwidth is due to the molecular weight distribution of the HES derivatives used and the number of HES derivatives linked to the protein.

**Example 19.7 Reaction of thio-erythropoietin with the reaction product of example 15.1 and the crosslinking compound**

To 50 nmol HES derivate, produced according to Example 15.1 and dissolved in 200 µl phosphate buffer (0.1 M, 9.15 M NaCl, 50 mM EDTA, pH 7.2), 10 µl of a solution of 2.5 µmol AMAS (Sigma Aldrich, Taufkirchen, D) in DMSO was added, and the clear solution was incubated for 80 min at 25 °C and 20 min at 40 °C. The AMAS was removed by centrifugal filtration with a VIVASPIN 0.5 ml concentrator, 5 KD MWCO (VIVASCIENCE, Hannover, Germany) at 13,000 rpm and washing 4 times for 30 min with the phosphate buffer.

To the residual solution, 15 µg Thio-EPO as produced according to example 18 (1 µg/µl in phosphate buffer) were added, and the mixture was incubated for 16 h at 25 °C. After lyophilisation, the crude product was analysed by SDS-Page with NuPAGE 10 % Bis-Tris Gels/MOPS buffer (Invitrogen, Carlsbad, CA, USA) as described in the instructions given by Invitrogen. The gel is stained with Roti-Blue Coomassie staining reagent (Roth, Karlsruhe, D) overnight.

The experimental result is shown in Fig 8. A successful conjugation is indicated by the migration of the protein band to higher molecular weights. The increased bandwidth is due to the molecular weight distribution of the HES derivatives used and the number of HES derivatives linked to the protein.

**Example 19.8 Reaction of thio-erythropoietin with the reaction product of example 15.2 and the crosslinking compound**

- 115 -

To 50 nmol HES derivate, produced according to Example 15.2 and dissolved in 200 µl phosphate buffer (0.1 M, 9.15 M NaCl, 50 mM EDTA, pH 7.2), 10 µl of a solution of 2.5 µmol AMAS (Sigma Aldrich, Taufkirchen, D) in DMSO was added, and the clear solution was incubated for 80 min at 25 °C and 20 min at 40 °C. The AMAS was removed by centrifugal filtration with a VIVASPIN 0.5 ml concentrator, 5 KD MWCO (VIVASCIENCE, Hannover, Germany) at 13,000 rpm and washing 4 times for 30 min with the phosphate buffer.

To the residual solution, 15 µg Thio-EPO as produced according to example 18 (1 µg/µl in phosphate buffer) were added, and the mixture was incubated for 16 h at 25 °C. After lyophilisation, the crude product was analysed by SDS-Page with NuPAGE 10 % Bis-Tris Gels/MOPS buffer (Invitrogen, Carlsbad, CA, USA) as described in the instructions given by Invitrogen. The gel is stained with Roti-Blue Coomassie staining reagent (Roth, Karlsruhe, D) overnight.

The experimental result is shown in Fig 8. A successful conjugation is indicated by the migration of the protein band to higher molecular weights. The increased bandwidth is due to the molecular weight distribution of the HES derivatives used and the number of HES derivatives linked to the protein.

**Example 19.9    Reaction of thio-erythropoietin with the reaction product of example 15.3 and the crosslinking compound**

To 50 nmol HES derivate, produced according to Example 15.3 and dissolved in 200 µl phosphate buffer (0.1 M, 9.15 M NaCl, 50 mM EDTA, pH 7.2), 10 µl of a solution of 2.5 µmol AMAS (Sigma Aldrich, Taufkirchen, D) in DMSO was added, and the clear solution was incubated for 80 min at 25 °C and 20 min at 40 °C. The AMAS was removed by centrifugal filtration with a VIVASPIN 0.5 ml concentrator, 5 KD MWCO (VIVASCIENCE, Hannover, Germany) at 13,000 rpm and washing 4 times for 30 min with the phosphate buffer.

To the residual solution, 15 µg Thio-EPO as produced according to example 18 (1 µg/µl in phosphate buffer) were added, and the mixture was incubated for 16 h at 25 °C. After lyophilisation, the crude product was analysed by SDS-Page with  
5 NuPAGE 10 % Bis-Tris Gels/MOPS buffer (Invitrogen, Carlsbad, CA, USA) as described in the instructions given by Invitrogen. The gel is stained with Roti-Blue Coomassie staining reagent (Roth, Karlsruhe, D) overnight.

The experimental result is shown in Fig 8. A successful conjugation is indicated  
10 by the migration of the protein band to higher molecular weights. The increased bandwidth is due to the molecular weight distribution of the HES derivatives used and the number of HES derivatives linked to the protein.

**Example 19.10 Reaction of thio-erythropoietin with the reaction product of  
15 example 15.4 and the crosslinking compound**

To 50 nmol HES derivate, produced according to Example 15.4 and dissolved in 200 µl phosphate buffer (0.1 M, 9.15 M NaCl, 50 mM EDTA, pH 7.2), 10 µl of a solution of 2.5 µmol AMAS (Sigma Aldrich, Taufkirchen, D) in DMSO was  
20 added, and the clear solution was incubated for 80 min at 25 °C and 20 min at 40 °C. The AMAS was removed by centrifugal filtration with a VIVASPIN 0.5 ml concentrator, 5 KD MWCO (VIVASCIENCE, Hannover, Germany) at 13,000 rpm and washing 4 times for 30 min with the phosphate buffer.

25 To the residual solution, 15 µg Thio-EPO as produced according to example 18 (1 µg/µl in phosphate buffer) were added, and the mixture was incubated for 16 h at 25 °C. After lyophilisation, the crude product was analysed by SDS-Page with NuPAGE 10 % Bis-Tris Gels/MOPS buffer (Invitrogen, Carlsbad, CA, USA) as described in the instructions given by Invitrogen. The gel is stained with Roti-  
30 Blue Coomassie staining reagent (Roth, Karlsruhe, D) overnight.

- 117 -

The experimental result is shown in Fig 8. A successful conjugation is indicated by the migration of the protein band to higher molecular weights. The increased bandwidth is due to the molecular weight distribution of the HES derivatives used and the number of HES derivatives linked to the protein.

5

**Example 19.11 Reaction of thio-erythropoietin with the reaction product of example 15.5 and the crosslinking compound**

To 50 nmol HES derivate, produced according to Example 15.5 and dissolved in  
10 200 µl phosphate buffer (0.1 M, 9.15 M NaCl, 50 mM EDTA, pH 7.2), 10 µl of a solution of 2.5 µmol AMAS (Sigma Aldrich, Taufkirchen, D) in DMSO was added, and the clear solution was incubated for 80 min at 25 °C and 20 min at 40 °C. The AMAS was removed by centrifugal filtration with a VIVASPIN 0.5 ml concentrator, 5 KD MWCO (VIVASCIENCE, Hannover, Germany) at 13,000  
15 rpm and washing 4 times for 30 min with the phosphate buffer.

To the residual solution, 15 µg Thio-EPO as produced according to example 18 (1 µg/µl in phosphate buffer) were added, and the mixture was incubated for 16 h at 25 °C. After lyophilisation, the crude product was analysed by SDS-Page with  
20 NuPAGE 10 % Bis-Tris Gels/MOPS buffer (Invitrogen, Carlsbad, CA, USA) as described in the instructions given by Invitrogen. The gel is stained with Roti-Blue Coomassie staining reagent (Roth, Karlsruhe, D) overnight.

The experimental result is shown in Fig 8. A successful conjugation is indicated  
25 by the migration of the protein band to higher molecular weights. The increased bandwidth is due to the molecular weight distribution of the HES derivatives used and the number of HES derivatives linked to the protein.

**Example 19.12 Reaction of thio-erythropoietin with the reaction product of example 15.6 and the crosslinking compound**

30

- 118 -

To 50 nmol HES derivate, produced according to Example 15.6 and dissolved in 200 µl phosphate buffer (0.1 M, 9.15 M NaCl, 50 mM EDTA, pH 7.2), 10 µl of a solution of 2.5 µmol AMAS (Sigma Aldrich, Taufkirchen, D) in DMSO was added, and the clear solution was incubated for 80 min at 25 °C and 20 min at 40 °C. The AMAS was removed by centrifugal filtration with a VIVASPIN 0.5 ml concentrator, 5 KD MWCO (VIVASCIENCE, Hannover, Germany) at 13,000 rpm and washing 4 times for 30 min with the phosphate buffer.

To the residual solution, 15 µg Thio-EPO as produced according to example 18 (1 µg/µl in phosphate buffer) were added, and the mixture was incubated for 16 h at 25 °C. After lyophilisation, the crude product was analysed by SDS-Page with NuPAGE 10-% Bis-Tris Gels/MOPS buffer (Invitrogen, Carlsbad, CA, USA) as described in the instructions given by Invitrogen. The gel is stained with Roti-Blue Coomassie staining reagent (Roth, Karlsruhe, D) overnight.

The experimental result is shown in Fig 8. A successful conjugation is indicated by the migration of the protein band to higher molecular weights. The increased bandwidth is due to the molecular weight distribution of the HES derivatives used and the number of HES derivatives linked to the protein.

#### **Example 20      Preparative production of HES-EPO conjugates**

##### **Summary**

HES-EPO conjugates were synthesized by coupling of HES derivatives (average mw of 18,000 Dalton; hydroxyethyl substitution degree of 0.4) to the partially (mild periodate) oxidized sialic acid residues on the oligosaccharide chains of recombinant human EPO. Based on carbohydrate structural analysis the modifications introduced did not affect the structural integrity of the core oligosaccharide chains since MALDI/TOF-MS of the mild acid treated HES-modified glycans

- 119 -

revealed intact neutral N-acetylglucosamine-type chains which were indistinguishable from those observed in unmodified EPO product. The results obtained indicate that at least 3 modified HES-residues are attached per EPO molecule in the case of the EPO preparation which was subjected to modification without prior partial sialic acid removal. An EPO variant lacking about 50% of the sialic acid residues of the former protein showed a similar apparent high molecular weight mobility in SDS-PAGE (60-110 KDa vs 40 KDa for the BRP EPO standard). The HES modified EPO is stable under standard ion-exchange chromatography conditions at room temperature at pH 3-10.

10

The EPO-bioassay in the normocythaemic mouse system indicates that the HES-modified EPO has 2.5-3.0 fold higher specific activity (IU/mg) in this assay when compared to the International BRP EPO reference standard based on protein determination using the UV absorption value from the European Pharmacopeia and an RP-HPLC EPO protein determination method calibrated against the BRP EPO standard preparation.

15

#### **Example 20.1    Materials and methods**

##### **20    (a)    Liberation of N-linked oligosaccharides by digestion with N-glycosidase**

Samples were incubated with 25 units (according to manufacturer's specification, Roche Diagnostics, Germany) of recombinant PNGase F over night at 37°C.

25    Complete digestion was monitored by the specific mobility shift of the protein in SDS-PAGE. The released N-glycans were separated from the polypeptide by addition of 3 volumes of cold 100% ethanol and incubation at -20°C for at least 2 hours (Schroeter S et al., 1999). The precipitated protein was removed by centrifugation for 10 minutes at 4°C at 13000 rpm. The pellet was then subjected to two additional washes with 500 µl of ice-cold 75% ethanol. The oligosaccharides in the pooled supernatants were dried in a vacuum centrifuge (Speed Vac concen-

30



- 120 -

trator, Savant Instruments Inc., USA). The glycan samples were desalted using Hypercarb cartridges (25 mg or 100 mg of HyperCarb) as follows prior to use: the columns were washed with 3 x 500  $\mu$ l of 80% acetonitrile (v/v) in 0.1% TFA followed by washes with 3 x 500  $\mu$ l of water. The samples were diluted with water to a final volume of 300  $\mu$ l – 600  $\mu$ l before loading onto the cartridge which then was rigorously washed with water. Oligosaccharides were eluted with 1.2 ml (25 mg cartridges; 1.8 ml in the case of 100 mg cartridges) 25% acetonitrile in water containing 0.1% trifluoroacetic acid (v/v). The eluted oligosaccharides were neutralized with 2 M  $\text{NH}_4\text{OH}$  and were dried in a Speed Vac concentrator. In some cases desalting of N-glycosidase released oligosaccharides was performed by adsorption of the digestion mixture from samples < 100  $\mu$ g of total (glyco)protein onto 100 mg Hypercarb cartridges.

(b) Analysis of oligosaccharides by matrix-assisted laser desorption/ionization time-of-flight mass-spectrometry (MALDI/TOF/TOF-MS)

A Bruker ULTRAFLEX time-of-flight (TOF/TOF) instrument was used: native desialylated oligosaccharides were analyzed using 2,5-dihydroxybenzoic acid as UV-absorbing material in the positive as well as in the negative ion mode using the reflectron in both cases. For MS-MS analyses, selected parent ions were subjected to laser induced dissociation (LID) and the resulting fragment ions separated by the second TOF stage (LIFT) of the instrument. Sample solutions of 1  $\mu$ l and an approximate concentration of 1-10  $\text{pmol}\cdot\mu\text{l}^{-1}$  were mixed with equal amounts of the respective matrix. This mixture was spotted onto a stainless steel target and dried at room temperature before analysis.

**Example 20.2 Preparation and characterization of recombinant human EPO (EPO-GT-1)**

EPO was expressed from recombinant CHO cells as described (Mueller PP et al., 1999, Dorner AJ et al., 1984) and the preparations were characterized according to

methods described in the Eur. Phar. (*Ph. Eur.* 4, *Monography 01/2002:1316: Erythropoietin concentrated solution*). The final product had a sialic acid content of 12 nMol (+/- 1.5 nMol) per nMol of protein. The structures of N-linked oligosaccharides were determined by HPAEC-PAD and by MALDI/TOF-MS as described (Nimtz et al., 1999, Grabenhorst, 1999). The EPO preparations that were obtained contained di-, tri- and tetrasialylated oligosaccharides (2-12%, 15-28% and 60-80%, respectively, sulphated and pentasialylated chains were present in small amounts). The overall glycosylation characteristics of EPO preparations were similar to that of the international BRP EPO standard preparation.

The isoelectric focusing pattern of the recombinant EPO was comparable to that of the international BRP Reference EPO standard preparation showing the corresponding isoforms. 25% of the EPO protein lacked O-glycosylation at Ser<sub>126</sub> of the polypeptide chain.

#### **Example 8.3 Preparation of partially desialylated EPO forms**

EPO GT-1 protein (2.84 mg/ml) was heated to 80°C in 20 mM Na-phosphate buffer pH 7.0 and then 100 µl of 1 N H<sub>2</sub>SO<sub>4</sub> was added per 1 ml of the EPO solution; incubation was continued for 5 min, 10 min and 60 min, respectively, yielding EPO preparations of different degree of sialylation. Quantitation of oligosaccharides with 0-4 sialic acids was performed after liberation of oligosaccharides with polypeptide N-glycosidase and isolation of N-linked chains was performed by desalting using Hypercarb cartridges (25 mg HyperSep Hypercarb; Thermo-Hypersil-Keystone, UK). EPO preparations were neutralized by addition of 1 N NaOH and were frozen in liquid N<sub>2</sub> and were stored at -20°C until further use.

#### **Example 20.4 Periodate oxidation of sialylated EPO forms**

To 10 mg of untreated or mild acid treated EPO dissolved in 3.5 ml of 20 mM Na-phosphate buffer pH 7.0 was added 1.5 ml of 0.1 M Na-acetate buffer pH 5.5 and

- 122 -

- the mixture was cooled to 0°C in an ice-bath; 500 µl of 10 mM Na-periodate was added and the reaction mixture was kept in the dark for 60 min at 0°C. Then 10 µl of glycerol was added and incubation was continued for further 10 min in the dark. The partially oxidized EPO forms were separated from reagents by desalting using VIVASPIN concentrators (10,000 MWCO, PES Vivascience AG, Han-
- 5     nover, Germany) according to manufacturer's recommendation at 3000 rpm in a laboratory centrifuge equipped with a fixed angle rotor. After freezing in liquid nitrogen the EPO preparations were stored in a final volume of 4 ml at -20°C.
- 10    100 µg aliquots of the partially oxidized EPO preparation were subjected to N-glycosidase treatment and oligosaccharides were isolated using Hypercarb cartridges as described. Oligosaccharides were desialylated by mild acid treatment and were analyzed by HPAEC-PAD and their retention times were compared to those of authentic standard oligosaccharides as described (Nimtz et al., 1990 and
- 15    1993).

#### **Example 20.5   Reduction of EPO disulfides with dithioerythritol**

- 5 mg of EPO-GT-1 was incubated in 5 ml of 0.1 M Tris/HCl buffer pH 8.1 in the presence of 30 mM dithioerythritol (DTT) at 37°C for 60 minutes; removal of DTT was achieved by using a Vivaspin concentrator at 4 °C, 4 cycles of buffer exchange. The final reduced EPO preparation was frozen in liquid nitrogen and stored at -20°C in 50 mM Na-acetate buffer pH 5.5.
- 20

#### **25   Example 20.6   EPO protein determination**

- Quantitative determination of EPO protein was performed by measuring UV absorption at 280 nm according to the Eur. Phar. (European Pharmacopeia 4, Monography 01/2002: 1316: erythropoietin concentrated solution) in a cuvette with 1
- 30    cm path length. In addition, EPO was quantitated by applying a RP-HPLC method using a RP-C4 column (Vydac Protein C4, Cat.# 214TP5410, Grace Vydac, Ca,

- 123 -

US); the HPLC method was calibrated using the erythropoietin BRP 1 reference standard (European Pharmacopeia, Conseil de l'Europe B.P. 907-F67029, Strasbourg Cedex 1).

5    **Example 20.7    Oxidation of desialylated EPO with galactose oxidase**

4.485 mg of completely desialylated EPO was incubated in 20 mM Na-phosphate buffer pH 6.8 in the presence of 16  $\mu$ l catalase (6214 units/200 ml) and 80  $\mu$ l of galactose oxidase (2250 units/ml from *Dactylium dendroides* (Sigma-Aldrich,  
10    Steinheim, Germany); incubation at 37°C was over night; 2 times 20  $\mu$ l of galactose oxidase was added after 4 hours and after 8 hours after starting of the incubation.

15    **Example 20.8    Preparation of EPO samples for bioassays**

*Purification of EPO from incubations of periodate- or galactose-oxidase-oxidized EPO protein preparations with activated HES*

Purification of EPO samples (removal of unreacted HES derivatives) was carried  
20    out at room temperature. The EPO incubation mixtures (approximately 5 mg of EPO protein) were diluted 1:10 with buffer A (20 mM N-morpholine propane sulfonic acid [MOPS/NaOH] in H<sub>2</sub>O bidest, pH 8.0) and were applied to a column containing 3 ml Q-Sepharose HP (Pharmacia Code no. 17-1014-03, Lot no. 220211) equilibrated with 10 column volumes (CV) of buffer A by using a flow  
25    rate of 0.5 ml/min. The column was washed with 6-8 CV of buffer A (flow rate = 0.8 ml/min) and elution was performed by using buffer B (20 mM morpholine ethane sulfonic acid [MES/NaOH], 0.5 M NaCl in H<sub>2</sub>O bidest, pH 6.5) at a flow rate of 0.5 ml/min. EPO was detected by UV absorption at 280 nm and eluted in about 6 ml. The column was regenerated by using 3 CV of buffer C (20 mM  
30    MES, 1.5 M NaCl in H<sub>2</sub>O adjusted to pH 6.5) and was re-equilibrated by using 10 CV of buffer A (flow rate = 0.7 ml/min).

- 124 -

Buffer exchange of EPO eluates obtained from the Q-Sepharose step was performed using Vivaspin concentrators and phosphate buffered saline (PBS) with each 3 centrifugation cycles per sample; samples were adjusted to 2 ml with PBS and were stored at -20°C.

Only <25% of the partially desialylated and subsequently mild periodate oxidized EPO forms that were subjected to HES-modification were obtained from the Q-Sepharose eluate since under the conditions employed the basic EPO forms did not bind Q-Sepharose and were found in the flow-through together with nonreacted HES derivatives.

**Example 20.9    High-pH anion-exchange chromatography with pulsed amperometric detection (HPAEC-PAD)**

Purified native and desialylated oligosaccharides were analyzed by high-pH anion-exchange (HPAE) chromatography using a Dionex BioLC system (Dionex, USA) equipped with a CarboPac PA1 column (0.4 x 25 cm) in combination with a pulsed amperometric detector (PAD) (Schröter et al., 1999; Nimtz et al., 1999). Detector potentials (E) and pulse durations (T) were: E1: +50 mV, T1: 480 ms; E2: +500 mV, T2: 120 ms; E3: -500 mV, T3: 60 ms, and the output range was 500-1500 nA. The oligosaccharides were then injected onto the CarboPac PA1 column which was equilibrated with 100% solvent A. For desialylated oligosaccharides elution (flow rate: 1 ml·min<sup>-1</sup>) was performed by applying a linear gradient (0-20%) of solvent B over a period of 40 min followed by a linear increase from 20-100% solvent B over 5 min. Solvent A was 0.2 M NaOH in bidistilled H<sub>2</sub>O, solvent B consisted of 0.6 M NaOAc in solvent A. For native oligosaccharides the column was equilibrated with 100% solvent C (0.1 M NaOH in bidistilled H<sub>2</sub>O) and elution (flow rate: 1 ml·min<sup>-1</sup>) was performed by applying a linear gradient (0-35%) of solvent D over a period of 48 min followed by a linear in-

- 125 -

crease from 35-100% solvent D over 10 min. Solvent D consisted of 0.6 M NaAc in solvent C.

**Example 20.10 Monosaccharide compositional analysis of N-glycans, HES-modified N-glycans and EPO protein by GC-MS**

Monosaccharides were analyzed as the corresponding methyl glycosides after methanolysis, *N*-reacetylation and trimethylsilylation by GC/MS [Chaplin, M.F. (1982) A rapid and sensitive method for the analysis of carbohydrate. *Anal. Biochem.* 123, 336-341]. The analyses were performed on a Finnigan GCQ ion trap mass spectrometer (Finnigan MAT corp., San Jose, CA) running in the positive ion EI mode equipped with a 30 m DB5 capillary column. Temperature program: 2 min isotherm at 80°C, then 10 degrees min<sup>-1</sup> to 300°C.

Monosaccharides were identified by their retention time and characteristic fragmentation pattern. The uncorrected results of electronic peak integration were used for quantification. Monosaccharides yielding more than one peak due to anomericity and/or the presence of furanoid and pyranoid forms were quantified by adding all major peaks. 0.5 µg of myo-inositol was used as an internal standard compound.

**Example 20.11 Results**

**Example 20.11(a) Characterization of N-glycans of mild acid treated (partially desialylated) EPO-GT-1**

EPO-GT-1 preparations subjected to mild acid treatment for 5, 10 or 60 min. were analyzed by SDS-PAGE before and after liberation of N-linked oligosaccharides by incubation with N-glycosidase as shown in Figure 9. N-linked oligosaccharides were subjected to HPAEC-PAD oligosaccharide mapping (Figure 10). The untreated EPO-GT-1 contained >90% of N-linked oligosaccharides with 3 or 4 sialic

acid residues whereas after 5 min. of incubation in the presence of mild acid <40% of carbohydrate chains had 3 or 4 sialic acid residues. HPAEC-PAD of the desialylated N-glycans revealed that the ratio of neutral oligosaccharides that were detected for the untreated EPO-GT-1 and remained stable in the preparations subjected to acid treatment for 5, 10 or 60 min. MALDI/TOF-MS of the desialylated glycans revealed that <90% of the proximal fucose was present after mild acid treatment of the protein.

#### **Example 20.11(b) Characterization of periodate treated EPO-GT-1**

10

SDS-PAGE mobility of mild periodate treated EPO forms that were previously subjected to a 5 and 10 minute treatment with acid or were not treated are compared in Figure 12. The conditions used for periodate oxidation of sialic acids did not change the SDS-PAGE pattern of EPO preparations (compare Fig. 9). Oxidation of sialic acids resulted in a shift of oligosaccharides in HPAEC-PAD analysis to earlier elution times (compare Figure 10 and 13).

#### **Example 20.11(c) Characterization of HES-modified EPO derivatives**

##### **20 (aa) Time course of HES modification of EPO-GT-1-A with hydroxylamine-modified HES derivative X, produced according to Example 14.4**

400  $\mu$ g of hydroxylamine-modified HES derivative X was added to 20  $\mu$ g of EPO-GT-1-A (mild periodate oxidized EPO, not acid hydrolyzed prior to mild periodate oxidation) in 20  $\mu$ L of 0.5 M NaOAc buffer pH 5.5 and the reaction was stopped after 30 min, 2, 4, and 17 hours, respectively, by freezing samples in liquid nitrogen. Subsequently samples were stored at -20°C until further analysis.

SDS-PAGE sample buffer was added and the samples were heated to 90°C and applied onto SDS-gels. As shown in Figure 14, increasing incubation times resulted in an increased shift towards higher molecular weight of the protein. After

30

- 127 -

17 hours of incubation in the presence of the hydroxylamine-modified HES derivative **X** a diffuse Coomassie stained protein band was detected migrating in an area between 60 and 11 KDa, based on the position of molecular weight standards (see left part of Fig. 14). Upon treatment with N-glycosidase most of the protein was shifted towards the position of de-*N*-glycosylated EPO (see Fig. 14, right gel; 5 arrow A indicates migration position of N-glycosidase, arrow B indicates migration position of de-*N*-glycosylated EPO; the diffuse protein band visible in the region between the 28 KDa and 36 KDa molecular weight standards presumably represents EPO-forms which are modified by HES and the O-glycosylation site of the molecule. In view of the specificity of N-glycosidase we conclude from this 10 result that in fact HES-modification occurs at the periodate oxidized sialic acid residues of glycans of the EPO protein.

#### (bb) Characterization of HES-EPO conjugates

15 HES-EPO conjugates **I** (originating from EPO-GT-1 after mild periodate oxidation, i.e. from EPO-GT-1-A), **II** (resulting from EPO-GT-1 subjected to 5 min acid hydrolysis and mild periodate oxidation), **III** (resulting from EPO-GT-1 subjected to 10 min acid hydrolysis and mild periodate oxidation) were synthesized as described before. A control incubation (**K**) was included containing unmodified 20 EPO-GT-1 under the same buffer conditions to which an equivalent amount of unmodified HES was added. The incubation mixtures were subjected to further purification for subsequent biochemical analysis of the HES-EPO derivatives.

25 Incubations HES-EPO conjugates **I**, **II** and **III** as well as the control incubation **K** were subjected to a Q-Sepharose purification step as described under "Material and Methods" (**Example 20.8**) in order to remove the excess of nonreacted HES-reagent which was expected in flow through of the ion-exchange column. Due to the high amounts of basic EPO forms contained in previously acid treated samples 30 **II** and **III** we expected considerable amounts of modified EPO product from these incubations in the flow through. As is shown in Figure 15, almost all of the EPO



- 128 -

material from samples I was retained by Q-Sepharose column whereas only approximately 20-30% of the samples III and II was recovered in the fraction eluting with high salt concentration. All of the protein material from the incubations with HES derivative X, both in the flow-through and the fractions eluting with high salt, had apparent higher molecular weight in SDS-PAGE when compared to the control EPO.

In order to characterize in more detail the HES-modified EPO sample A and K (see Figure 13) were compared to periodate oxidized form EPO-GT-1-A. The samples were subjected to N-glycosidase treatment and as is depicted in Figures 16a and 16b the release of N-glycans resulted in the two low molecular weight bands at the position of the O-glycosylated and nonglycosylated EPO forms of the standard EPO preparation. In the case of sample A a further band migrating at the position of the 28 KDa mw standard was detected suggesting HES-modification at the O-glycan of this EPO variant (cf. Example 20.11(c)(aa)). This band (and also the heavily HES-modified high mw form of N-glycosylated EPO, see Figs. 16a and 16b) disappeared after subjecting the samples to mild hydrolysis which is in agreement with the view that HES modification was achieved at the periodate oxidised sialic acid residues of erythropoietin.

Aliquots of the N-glycosidase incubation mixtures were hydrolyzed using conditions enabling the complete removal of sialic acids residues (and also the sialic acid linked HES derivative) from oligosaccharides; after neutralization, the mixtures were then absorbed onto small Hypercarb columns for their desalting. The columns were washed rigorously with water followed by elution of bound neutral oligosaccharides with 40% acetonitrile in H<sub>2</sub>O containing 0.1% of trifluoroacetic acid. The resulting oligosaccharides were subjected to MALDI/TOF-MS. The spectra of the desialylated oligosaccharide fractions from sample A, EPO-GT-1-A and sample K showed identical masses for complex type oligosaccharides at  $m/z$  = 1810 Da (diantennary), 2175 = triantennary, 2540 = tetraantennary, 2906 = tetraantennary plus 1 N-acetylactosamine repeat and 3271 = tetraantennary plus 2

- 129 -

N-acetylglucosamine repeats; small signals corresponding to lack of fucose (-146) and galactose (minus 162) were detected which are attributable to the acid hydrolysis conditions applied for sialic acid removal (see MALDI-Figures 19, 20 and 21).

5

In a parallel experiment the N-glycosidase digestion mixture was absorbed onto 1 ml RP-C18 cartridge (without prior acid hydrolysis of oligosaccharides) and elution was performed with 5% acetonitrile in water containing 0.1% TFA; under these conditions the EPO protein was completely retained onto the RP-material and oligosaccharides were washed off from the column with 5% acetonitrile in H<sub>2</sub>O containing 0.1% TFA. The de-N-glycosylated EPO protein was eluted with 70% acetonitrile in H<sub>2</sub>O containing 0.1% TFA. The oligosaccharide fractions from the RP-C18 step of N-glycosidase-treated sample A, EPO GT-1-A and sample K were neutralized and subjected to desalting using Hypercarb cartridges as described before. The isolated oligosaccharides were subjected to HPAEC-PAD mapping before (see Figures 17) and after mild acid treatment under conditions which enabled quantitative removal of sialic acids from glycans (see Figures 18).

The HPAEC-PAD profile for the native material obtained from the HES-modified sample A showed only neglectable signals for oligosaccharides whereas EPO GT-1-A-derived oligosaccharides exhibited the same glycan profile as the one shown in Fig. 13 (sample named EPO-GT-1 after mild periodate treatment). The elution profile of oligosaccharides obtained from the control EPO sample (K) yielded the expected pattern (compare profile in Figure 10). For comparison, the native oligosaccharide profile of the international BRP-EPO standard is included for comparison and as reference standard.

After mild acid hydrolysis, all oligosaccharide preparations showed an identical elution profile of neutral oligosaccharide structures (see Figures 18) with the expected qualitative and quantitative composition of di-, tri- and tetraantennary complex-type carbohydrate chains as described in the methods section for the EPO

30

- 130 -

preparation which was used as a starting material in the present study. This result demonstrates that the HES-modification of the EPO sample results in a covalent linkage of the HES derivative which is detached from the EPO-protein by N-glycosidase and is acid-labile since it is removed from the N-glycans using mild acid treatment conditions known to desialylate carbohydrates (see Figures 16a+b).

**(cc) Monosaccharide compositional analysis of HES-EPO and HES-EPO N-glycans by GC-MS**

In order to further confirm HES-modification of EPO at the N-glycans of the molecule, EPO samples were digested with N-glycosidase and the EPO protein was adsorbed onto RP-C18 cartridges whereas oligosaccharide material was washed off as described above. As shown in Table 3, glucose and hydroxyethylated glucose derivatives were detected only in the EPO protein which was subjected to HES-modification at cysteine residues and in oligosaccharide fractions of EPO sample A2.

**Example 20.11(d) In-vivo assay of the biological activity of HES-modified EPO**

The EPO-bioassay in the normocythaemic mouse system indicates was performed according to the procedures described in the European Pharmacopeia; the laboratory that carried out the EPO assay was using the International BRP EPO reference standard preparation. For the HES-modified EPO A2 preparation a mean value for the specific activity of 294,600 units per mg EPO of protein was determined indicating an approximately 3-fold higher specific activity when compared to the International BRP EPO reference standard preparation that was included in the samples sent for activity assays.

The results of the study are summarized in Table 4.







**References for examples 13 to 20:**

- Nimtz M, Noll G, Paques EP, Conradt HS.  
Carbohydrate structures of a human tissue plasminogen activator expressed in  
5 recombinant Chinese hamster ovary cells.  
FEBS Lett. 1990 Oct. 1; 271(1-2):14-8
- Dorner AJ, Wasley LC, Kaufman RJ.  
Increased synthesis of secreted proteins induces expression of glucose-regulated  
10 proteins in butyrate-treated Chinese hamster ovary cells.  
J Biol Chem. 1989 Dec 5; 264 (34):20602-7
- Mueller PP, Schlenke P, Nimtz M, Conradt HS, Hauser H  
Recombinant glycoprotein quality in proliferation-controlled BHK-21 cells.  
15 Biotechnol Bioeng. 1999 Dec 5; 65(5):529-36
- Nimtz M, Martin W, Wray V, Kloppel KD, Augustin J, Conradt HS.  
Structures of sialylated oligosaccharides of human erythropoietin expressed in  
recombinant BHK-21 cells.  
20 Eur J Biochem. 1993 Apr. 1; 213(1):39-56
- Hermentin P, Witzel R, Vliegthart JF, Kamerling JP, Nimtz M, Conradt HS.  
A strategy for the mapping of N-glycans by high-ph anion-exchange chromatog-  
raphy with pulsed amperometric detection.  
25 Anal Biochem. 1992 Jun; 203(2):281-9
- Schroter S, Derr P, Conradt HS, Nimtz M, Hale G, Kirchhoff C.  
Male specific modification of human CD52.  
J Biol Chem. 1999 Oct. 15; 274(42):29862-73







Table 1

Linker-type	Functional group 1: Reaction with polypeptide, especially EPO	Functional group 2: Reaction with HES
A	Hydrazide (aldehyde-reactive)	Maleimido (SH-reactive)
B	Hydrazide (aldehyde-reactive)	Pyridyldithio (SH-reactive)
C	Iodoalkyl (SH-reactive)	N-succinimide ester (amine-reactive)
D	Bromoalkyl (SH-reactive)	N-succinimide ester (amine-reactive)
E	Maleimido (SH-reactive)	N-succinimide ester (amine-reactive)
F	Pyridyldithio (SH-reactive)	N-succinimide ester (amine-reactive)
G	Vinylsulfone (SH-reactive)	N-succinimide ester (amine-reactive)







Table 2

Abreviation	Chemical Name	Type	
AMAS	N-( $\alpha$ -Maleimidoacetoxy) succinimide ester	E	
BMPH	N-( $\beta$ -Maleimidopropionic acid) hydrazide·TFA	A	
BMPS	N-( $\beta$ -Maleimidopropoxy) succinimide ester	E	
EMCH	N-( $\epsilon$ -Maleimidocaproic acid) hydrazide	A	
EMCS	N-( $\epsilon$ -Maleimidocaproyloxy) succinimide ester	E	
GMBS	N- $\gamma$ -Maleimidobutyryloxy-succinimide ester	E	







-134-

Abbreviation	Chemical Name	Type	
KMUH	N-(κ-Maleimidoundecanoic acid) hydrazide	A	
LC-SMCC	Succinimidyl 4-(N-maleimidomethyl) cyclohexane-1-carboxy-(6-amido-caproate)	E	
LC-SPDP	Succinimidyl 6-(3'-[2-pyridyl-dithio]propionamido) hexanoate	F	
MBS	m-Maleimidobenzoyl-N-hydroxysuccinimide ester	E	
M <sub>2</sub> C <sub>2</sub> H	4-(N-Maleimidomethyl)-cyclohexane-1-carboxyl-hydrazide·HCl·1/2 dioxane	A	
MPBH	4-(4-N-Maleimidophenyl)-butyric acid hydrazide·HCl	A	







- 135 -

Abreviation	Chemical Name	Type	
SATA	N-Succinimidyl S-acetylthio-acetate	H	
SATP	N-Succinimidyl S-acetylthio-propionate	H	
SBAP	Succinimidyl 3-(bromoacetamido) propionate	D	
SIA	N-Succinimidyl iodoacetate	C	
SIAB	N-Succinimidyl(4-iodoacetyl)aminobenzoate	C	
SMCC	Succinimidyl 4-(N-maleimidomethyl) cyclohexane-1-carboxylate	E	





Abreviation	Chemical Name	Type	
SMPB	Succinimidyl 4-(p-maleimidophenyl)butyrate	E	
SMPH	Succinimidyl-6-(β-maleimidopropionamido)hexanoate	E	
SMPT	4-Succinimidyl-6-(β-maleimidopropionamido)pyridylidithio)toluene	F	
SPDP	N-Succinimidyl 3-(2-pyridylidithio)propionate	F	
Sulfo-EMCS	N-(ε-Maleimidocaproyloxy) sulfosuccinimide ester	E	
Sulfo-GMBS	N-γ-Maleimido butyloxy-sulfosuccinimide ester	E	

-137-

Abreviation	Chemical Name	Type	
Sulfo-KMUS	N-( $\kappa$ -Maleimidoundecanoyloxy)-sulfosuccinimide ester	E	
Sulfo-LC-SPDP	Sulfosuccinimidyl 6-(3'-[2-pyridyl-dithio]propionamido) hexanoate	F	
Sulfo-MBS	m-Maleimidobenzoyl-N-hydroxysulfosuccinimide ester	E	
Sulfo-SIAB	Sulfosuccinimidyl(4-iodoacetyl)aminobenzoate	C	
Sulfo-SMCC	Sulfosuccinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate	E	
Sulfo-SMPB	Sulfosuccinimidyl 4-(p-maleimidophenyl)butyrate	E	

-138-

Abreviation	Chemical Name	Type	
Sulfo-LC-SMPT	Suflosuccinimidyl 6-( $\alpha$ -methyl- $\alpha$ -[2-pyridyldithiol]-toluamido)hexanoate	F	
SVSB	N-Succinimidyl-(4-vinylsulfonyl)benzoate	G	

- 139 -

**Table 3**  
**Monosaccharide compositional analysis of glycans from HES-modified EPO**  
**and control samples**

<b>**Mono-saccharide</b>	<b>I. Glycans from A2</b>	<b>II. Glycans from EPO-GT- 1A</b>	<b>III. Glycans from K2</b>	<b>III. Glycans from A2</b>	<b>IV. Glycans from EPO- GT-1A</b>	<b>V. Glycans from K2</b>	<b>VI. Cystein modified EPO pro- tein*</b>
fucose	1,935	3,924	2,602	2,246	4,461	2,601	2,181
mannose	6,028	11,020	9,198	6,379	11,668	6,117	6,260
galactose	8,886	19,935	14,427	10,570	16,911	11,555	10,386
glucose	17,968	—	—	21,193	trace	trace	33,021
GlcNAc	7,839	21,310	14,440	11,360	15,953	10,503	10,498
GlcHe1	5,583	—	—	5,926	—	—	14,857
GlcHe2	1,380	—	—	1,552	—	—	3,775
NeuNAc	5,461	822	4,504	3,895	4,871	13,562	13,003
inositol	1,230	2,310	1,620	2,050	1,320	1,134	1,087

\* the equivalent of Cys-HES-modified EPO protein was subjected to compositional analysis; the EPO protein was isolated from the HES-incubation mixture by chromatography on a Q-Sepharose column as described above and was desalted by centrifugation using a Vivaspin 5 separation device.

\*\* Monosaccharide determinations were performed from single GC runs of the pertrimethylsilylated methylglycosides; the electronical integration values of peaks are given without correction for losses during the derivatisation procedure and recoveries of each compound.

5

**Table 4**

<b>Sample No.</b>	<b>Sample description</b>	<b>Calculated specific activity of EPO sample (based on A280 nm and RP-HPLC determination)</b>
850247	1. HES-modified EPO A2	344,000 U/mg
850248	2. EPO-GT-1-A	82,268 U/mg
850249	3. Control EPO K2	121,410 U/mg
850250	4. BRP EPO standard	86,702 U/mg
850251	1. diluted with 4 volume of PBS	309,129 U/mg
850252	2. diluted with 4 volume of PBS	94,500 U/mg
850253	3. diluted with 4 volume of PBS	114,100 U/mg
850254	4. diluted with 4 volume of PBS	81,200 U/mg
850255	1. diluted with 4 volume of PBS	230,720 U/mg

Claims

5

1. A hydroxyalkylstarch (HAS)-erythropoietin (EPO)-conjugate (HAS-EPO), comprising one or more HAS molecules, wherein each HAS is conjugated to the EPO via

10

- a) a carbohydrate moiety; or
- b) a thioether.

2. The HAS-EPO of claim 1, wherein the EPO has the amino acid sequence of human EPO.

15

3. The HAS-EPO of any of claims 1 or 2, wherein the EPO comprises one or more carbohydrate side chains attached to the EPO via N- and/ or O-linked glycosylation.

20

4. The HAS-EPO of claim 3, wherein the carbohydrate side chains have been attached to the EPO during production in mammalian, especially human, insect or yeast cells.

25

5. The HAS-EPO of any of claims 1 to 4, wherein HAS is conjugated to the EPO via a linker molecule.

30

6. The HAS-EPO of any of claims 3 to 5, wherein HAS is conjugated to the EPO via a carbohydrate moiety which is part of the carbohydrate side chains and which is preferably oxidized.

- 141 -

7. The HAS-EPO of claim 6, wherein HAS is conjugated to a galactose or sialic acid residue of the carbohydrate side chains.
8. The HAS-EPO of any of claims 1 to 7, wherein the S atom in the thioether is derived from a naturally-occurring cysteine or from an added cysteine.
9. The HAS-EPO of claim 8, wherein the EPO has the amino acid sequence of human EPO and the naturally occurring cysteines are cysteine 29 and/ or 33.
10. The HAS-EPO of claim 9, wherein HAS is conjugated to cysteine 29 and cysteine 33 is replaced by another amino acid.
11. The HAS-EPO of claim 9, wherein HAS is conjugated to cysteine 33 and cysteine 29 is replaced by another amino acid.
12. The HAS-EPO of any of claims 8 to 11, wherein the added cysteine has been added by replacing a naturally occurring amino acid by a cysteine.
13. The HAS-EPO of claim 12, wherein the EPO is human EPO and the replaced amino acid residue is serine 126.
14. The HAS-EPO of any of claims 1 to 13, comprising 1-12, preferably 1-6 or 1-3, most preferred 1-4 HAS molecules per EPO molecule.
15. The HAS-EPO of any of claims 1 to 14, wherein the HAS is selected from the group consisting of hydroxyethylstarch, hydroxypropylstarch and hydroxybutylstarch.
16. The HAS-EPO of claim 15, wherein the HAS is hydroxyethylstarch (HES).

- 142 -

17. The HAS-EPO of claim 16, wherein the HES has a molecular weight of 1 to 300 kDa, preferably 5 to 100 kDa.
18. The HAS-EPO of any of claims 16 or 17, wherein the HES exhibits a molar degree of substitution of 0.1 to 0.8 and a ratio between C<sub>2</sub>:C<sub>6</sub>-substitution in the range of 2-20, with respect to the hydroxyethylgroups.
19. A method for the production of a hydroxyalkylstarch (HAS)-erythropoietin (EPO)-conjugate (HAS-EPO), comprising the steps of:
- providing EPO being capable of reacting with modified HAS,
  - providing modified HAS being capable of reacting with the EPO of step a), and
  - reacting the EPO of step a) with the HAS of step b), whereby an HAS-EPO is produced comprising one or more HAS molecules, wherein each HAS is conjugated to the EPO via
    - a carbohydrate moiety; or
    - a thioether.
20. The method of claim 19, wherein the EPO has the amino acid sequence of human EPO.
21. The method of any of claims 19 or 20, wherein the EPO is recombinantly produced.
22. The method of any of claims 19 to 21, wherein the EPO comprises one or more carbohydrate side chains attached to the EPO via N- and/ or O-linked glycosylation.

23. The method of claim 22, wherein the carbohydrate side chains have been attached to the EPO during production in mammalian, especially human, insect or yeast cells.
- 5 24. The method of any of claims 22 or 23, wherein the HAS is conjugated to the EPO via a carbohydrate moiety which is part of the carbohydrate side chains.
- 10 25. The method of claim 24, wherein in step a) the EPO is modified by oxidizing at least one carbohydrate moiety, preferably at least one terminal saccharide unit, more preferably galactose, of the one or more carbohydrate side chains of the EPO.
- 15 26. The method of claim 25, wherein the terminal saccharide unit is oxidized after partial or complete (enzymatic and/ or chemical) removal of the terminal sialic acid.
- 20 27. The method of claims 25 or 26, wherein in step c) the modified HAS is conjugated to the oxidized terminal saccharide unit.
28. The method of any of claims 19 to 27, wherein the EPO comprises at least one free SH-group.
- 25 29. The method of claim 28, wherein the free SH-group is part of a naturally-occurring cysteine or of an added cysteine.
- 30 30. The method of claim 29, wherein the EPO has the amino acid sequence of human EPO and the naturally occurring cysteines are cysteine 29 and/ or 33.
31. The method of claim 30, wherein cysteine 33 is replaced by another amino acid and in step c) the modified HAS is conjugated to cysteine 29.



32. The method of claim 30, wherein cysteine 29 is replaced by another amino acid and in step c) the modified HAS is conjugated to cysteine 33.
- 5 33. The method of any of claims 29 to 32, wherein the added cysteine has been added by replacing a naturally occurring amino acid by a cysteine.
34. The method of claim 33, wherein the EPO is human EPO and the replaced amino acid residue is serine 126.
- 10 35. The method of any of claims 33 or 34, wherein in step c) the modified HAS is conjugated to the added cysteine.
36. The method of any of claims 19 to 35, wherein the HAS is modified such  
15 that it comprises a free hydrazide, hydroxylamine, thiol or semicarbazide function if the HAS is conjugated to the oxidized carbohydrate moieties or a free maleimide, disulfide or halogen acetamide function if the HAS is to be conjugated to the SH-group.
- 20 37. The method of any of claims 19 to 36, wherein step c) is performed in a reaction medium comprising at least 10 % per weight H<sub>2</sub>O.
38. The method of any of claims 19 to 37, wherein the HAS is conjugated to the EPO via a linker molecule.
- 25 39. The method of any of claims 19 to 38, wherein the HAS is, hydroxyethylstarch, hydroxypropylstarch or hydroxybutylstarch, preferably hydroxyethylstarch (HES).
- 30 40. The method of claim 39, wherein the HES has the properties as defined in any of claims 17 or 18.

41. A HAS-EPO, obtainable by the method of any of claims 19 to 40.
42. The HAS-EPO of claim 41, having the features as defined in any of claims 1  
5 to 18.
43. A HAS-EPO according to any of claims 1 to 18, 41 or 42 for use in a  
method for treatment of the human or animal body.
- 10 44. A pharmaceutical composition comprising the HAS-EPO according to any  
of claims 1 to 18, 41 or 42.
45. The pharmaceutical composition of claim 44, further comprising at least one  
pharmaceutically acceptable carrier.
- 15 46. Use of a HAS-EPO according to any of claims 1 to 18, 41 or 42 for the  
preparation of a medicament for the treatment of anemic disorders or hema-  
topoietic dysfunction disorders.
- 20 47. A hydroxyalkylstarch (HAS)-polypeptide-conjugate (HAS-polypeptide),  
comprising one or more HAS molecules, wherein each HAS is conjugated  
to the polypeptide via
- 25 c) a carbohydrate moiety; or  
d) a thioether.
48. The HAS-polypeptide of claim 47, wherein the polypeptide is of human  
origin.
- 30 49. The HAS-polypeptide of any of claims 47 or 48, wherein the polypeptide is  
selected from the group comprising erythropoietin, interleukins, especially

- 146 -

interleukin-2, IFN- $\beta$ , IFN-alpha, CSF, interleukin 6 and therapeutic antibodies.

50. The HAS-polypeptide of any of claims 47 to 49, wherein the polypeptide  
5 comprises one or more carbohydrate side chains attached to the polypeptide  
via N- and/ or O-linked glycosylation.
51. The HAS-polypeptide of claim 50, wherein the carbohydrate side chains  
10 have been attached to the polypeptide during production in mammalian, es-  
pecially human, insect or yeast cells.
52. The HAS-polypeptide of any of claims 47 to 51, wherein the HAS is conju-  
gated to the polypeptide via a linker molecule.
- 15 53. The HAS-polypeptide of any of claims 49 to 52, wherein the HAS is conju-  
gated to the polypeptide via a carbohydrate moiety which is part of the car-  
bohydrate side chains and which is preferably oxidized.
54. The HAS-polypeptide of claim 53, wherein the HAS is conjugated to a ga-  
20 lactose residue of the carbohydrate side chains.
55. The HAS-polypeptide of any of claims 47 to 54, wherein the S atom in the  
thioether is derived from a naturally-occurring cysteine or from an added  
cysteine.
- 25 56. The HAS-polypeptide of claim 55, wherein the added cysteine has been  
added by replacing a naturally occurring amino acid by a cysteine.
57. The HAS-polypeptide of any of claims 47 to 56, comprising 1-12, prefera-  
30 bly 1-6 or 1-3, most preferred 1-4 HAS molecules per polypeptide molecule.

- 147 -

58. The HAS-polypeptide of any of claims 47 to 57, wherein the HAS is selected from the group consisting of hydroxyethylstarch, hydroxypropylstarch and hydroxybutylstarch.
- 5 59. The HAS-polypeptide of claim 58, wherein the HAS is hydroxyethylstarch (HES).
60. The HAS-polypeptide of claim 59, wherein the HES has a molecular weight of 1 to 300 kDa, preferably 5 to 100 kDa.
- 10 61. The HAS-polypeptide of any of claims 59 or 60, wherein the HES exhibits a molar degree of substitution of 0.1 to 0.8 and a ratio between C<sub>2</sub>:C<sub>6</sub>-substitution in the range of 2-20, with respect to the hydroxyethylgroups.
- 15 62. A method for the production of a hydroxyalkylstarch (HAS)-polypeptide-conjugate (HAS-polypeptide), comprising the steps of:
- d) providing a polypeptide being capable of reacting with modified HAS,
- e) providing modified HAS being capable of reacting with the polypeptide of step a), and
- 20 f) reacting the polypeptide of step a) with the HAS of step b), whereby HAS-polypeptide is produced comprising one or more HAS molecules, wherein each HAS is conjugated to the polypeptide via
- i) a carbohydrate moiety; or
- 25 ii) a thioether.
63. The method of claim 62, wherein the polypeptide is of human origin.
64. The method of any of claims 62 or 63, wherein the polypeptide is selected from the group comprising erythropoietin, interleukins, especially interleukin-2, IFN- $\beta$ , IFN- $\alpha$ , CSF, interleukin 6 and therapeutic antibodies
- 30

- 148 -

65. The method of any of claims 62 to 64, wherein the polypeptide is recombinantly produced.
- 5 66. The method of any of claims 62 to 65, wherein the polypeptide comprises one or more carbohydrate side chains attached to the polypeptide via N- and/ or O-linked glycosylation.
67. The method of claim 66, wherein the carbohydrate side chains have been  
10 attached to the polypeptide during production in mammalian, especially human, insect or yeast cells.
68. The method of any of claims 66 or 67, wherein the HAS is conjugated to the polypeptide via a carbohydrate moiety which is part of the carbohydrate side  
15 chains.
69. The method of claim 68, wherein in step a) the polypeptide is modified by oxidizing at least one carbohydrate moiety, preferably at least one terminal saccharide unit, more preferably galactose, of the one or more carbohydrate  
20 side chains of the polypeptide.
70. The method of claim 69, wherein the terminal saccharide unit is oxidized after partial or complete (enzymatic and/ or chemical) removal of the terminal sialic acid.  
25
71. The method of claims 69 or 70, wherein in step c) the modified HAS is conjugated to the oxidized terminal saccharide unit.
72. The method of any of claims 62 to 71, wherein the polypeptide comprises at  
30 least one free SH-group.


- 149 -

73. The method of claim 72, wherein the free SH-group is part of a naturally-occurring cysteine or of an added cysteine.
74. The method of any of claims 62 to 73, wherein the added cysteine has been added by replacing a naturally occurring amino acid by a cysteine.
75. The method of any of claims 73 or 74, wherein in step c) the modified HAS is conjugated to the added cysteine.
76. The method of any of claims 62 to 75, wherein the HAS is modified such that it comprises a free hydrazide, hydroxylamine, thiol or semicarbazide function if the HAS is conjugated to the oxidized carbohydrate moieties or a free maleimide, disulfide or halogen acetamide function if the HAS is to be conjugated to the SH-group.
77. The method of any of claims 62 to 76, wherein step c) is performed in a reaction medium comprising at least 10 % per weight H<sub>2</sub>O.
78. The method of any of claims 62 to 78, wherein the HAS is conjugated to the polypeptide via a linker molecule.
79. The method of any of claims 62 to 78, wherein the HAS is hydroxyethylstarch, hydroxypropylstarch or hydroxybutylstarch, preferably hydroxyethylstarch (HES).
80. The method of claim 79, wherein the HAS has the properties as defined in any of claims 60 or 61.
81. A HAS-polypeptide, obtainable by the method of any of claims 62 to 80.

- 150 -

82. The HAS-polypeptide of claim 41, having the features as defined in any of claims 47 to 61.
- 5 83. A HAS-polypeptide according to any of claims 47 to 61, 81 or 82 for use in a method for treatment of the human or animal body.
84. A pharmaceutical composition comprising the HAS-polypeptide according to any of claims 47 to 61, 81 or 82.
- 10 85. The pharmaceutical composition of claim 84, further comprising at least one pharmaceutically acceptable carrier.

**Fig. 1**




5


10



**Fig. 2**



**Fig. 3**



**Fig. 4**




Fig. 5




Fig. 6





Fig. 7



Fig. 8



- 9 / 26 -

**Fig. 9**






Fig. 10




Fig. 11




Fig. 12







Fig. 13




EPO GT-1 no acid treatment;  
+ mild periodate ox



EPO GT-1 5 min H<sup>+</sup> and mild periodate ox



EPO GT-1 10 min H<sup>+</sup> and mild periodate ox



EPO GT-1 no acid and no periodate treatment

Fig. 14




Fig. 15






Fig. 16a




Samples before and after digestion with N-glycosidase

- 17/26 -

Fig. 16b

Samples were treated with mild acid before SDS-PAGE analysis



O-glycosylated EPO

non-glycosylated EPO



Fig. 17




Fig. 18




Fig. 19

5




Fig. 20




Fig. 21




Fig. 22

5




Fig. 23




Fig. 24







Fig. 25



# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP 03/08858

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07K14/505 C07K17/10 C08B31/00 C07K17/06 C12N15/12  
A61K38/18 C07K14/55 C07K14/54 C07K14/56 C07K14/565  
C07K14/53

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K C08B A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, MEDLINE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>WO 94 28024 A (ENZON INC) 8 December 1994 (1994-12-08) cited in the application page 1, line 12 - line 15 page 3, line 5 - line 13 page 4, line 4 - line 23 page 3, line 17 - line 27 page 5, line 35 - line 37 page 6, line 10 - line 15 page 6, line 21 - line 25 page 7, line 18 - line 25 page 9, line 16 - line 27 page 15; table page 10, line 33 - line 36</p> <p style="text-align: center;">-/-</p>	1-85

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

27 October 2003

Date of mailing of the international search report

17/11/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Mauhin, V

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/08858

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DE 196 28 705 A (FRESENIUS AG). 15 January 1998 (1998-01-15) cited in the application column 4, line 58 - line 65	47-85
Y	column 6, line 28 - line 32 column 4, line 52 - line 54 column 6, line 9 - line 17 ---	1-85
X	LARIONOVA NATHALIA I ET AL: "Conjugation of the Bowman-Birk soybean proteinase inhibitor with hydroxyethylstarch." APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY, vol. 62, no. 2-3, 1997, pages 175-182, XP001122297 ISSN: 0273-2289 the whole document ---	47-85
A	US 5 281 698 A (NITECKI DANUTE E) 25 January 1994 (1994-01-25) the whole document ---	
A	EP 0 809 996 A (HOFFMANN LA ROCHE) 3 December 1997 (1997-12-03) the whole document ---	
A	US 4 847 325 A (MORELAND MARGARET ET AL) 11 July 1989 (1989-07-11) the whole document -----	

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/EP 03/08858

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☒ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

**FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210**

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-46, 47-85 (all partially)

Hasylated erythropoietin

2. Claims: 47-85 (all partially)

Hasylated Interleukin-2 and Interleukin-6

3. Claims: 47-85 (all partially)

Hasylated therapeutic antibodies

4. Claims: 47-85 (all partially)

Hasylated CSF

5. Claims: 47-85 (all partially)

Hasylated therapeutic antibodies

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 03/08858

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9428024	A	08-12-1994	AU 7097094 A WO 9428024 A1	20-12-1994 08-12-1994
DE 19628705	A	15-01-1998	DE 19628705 A1 AT 209931 T AU 710879 B2 AU 3541197 A BR 9710865 A CA 2258947 A1 DE 59705678 D1 DK 912197 T3 WO 9801158 A2 EP 0912197 A2 ES 2166551 T3 JP 2000514434 T PT 912197 T US 6083909 A	15-01-1998 15-12-2001 30-09-1999 02-02-1998 11-01-2000 15-01-1998 17-01-2002 18-03-2002 15-01-1998 06-05-1999 16-04-2002 31-10-2000 31-05-2002 04-07-2000
US 5281698	A	25-01-1994	NONE	
EP 0809996	A	03-12-1997	AT 235920 T AU 725195 B2 AU 2372397 A BG 62273 B1 BG 101540 A BR 9703421 A CA 2203480 A1 CN 1167777 A , B CZ 9701679 A3 DE 69720320 D1 DE 809996 T1 DK 809996 T3 EP 0809996 A2 ES 2110386 T1 GR 97300063 T1 HR 970298 A1 HU 9700959 A2 JP 2980569 B2 JP 10067800 A KR 254097 B1 NO 972480 A NZ 314903 A PL 320251 A1 PT 809996 T RU 2180595 C2 SG 55314 A1 SI 809996 T1 SK 67397 A3 TJ 97000465 A , B TR 9700358 A2 TW 517067 B ZA 9704583 A	15-04-2003 05-10-2000 04-12-1997 30-07-1999 27-02-1998 15-09-1998 30-11-1997 17-12-1997 17-12-1997 08-05-2003 09-04-1998 21-07-2003 03-12-1997 16-02-1998 30-01-1998 30-04-1998 02-03-1998 22-11-1999 10-03-1998 01-05-2000 01-12-1997 28-10-1998 08-12-1997 30-06-2003 20-03-2002 21-12-1998 31-08-2003 10-12-1997 25-12-1998 21-12-1997 11-01-2003 17-11-1998
US 4847325	A	11-07-1989	AT 102050 T AU 3180789 A CA 1340297 C DE 68913520 D1 DE 68913520 T2	15-03-1994 11-08-1989 29-12-1998 07-04-1994 25-08-1994

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 03/08858

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4847325	A	EP 0402378 A1	19-12-1990
		IE 64887 B1	20-09-1995
		IL 89001 A	12-04-1994
		JP 3503759 T	22-08-1991
		JP 3280016 B2	30-04-2002
		NO 8906546 A1	27-07-1989
		US 5153265 A	06-10-1992

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☒ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☒ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**